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 I 
Summary 
Lymph node-like follicles called ectopic lymphoid-like structures (ELS) often develop in 
inflamed tissues affected by autoimmunity and cancer. ELS range from co-localised T 
and B cell aggregates to highly segregated structures displaying germinal centre 
reactions. As such, ELS can prime local immune responses and influence chronic 
disease progression. To understand how interleukin (IL)-27 regulates ELS during 
inflammatory arthritis, studies established an RNA-sequencing and bioinformatic 
pipeline to characterise joint inflammation in IL-27 receptor (IL-27R)-deficient mice that 
develop synovial ELS. Molecular pathway analysis revealed that IL-27 shapes the 
inflammatory response through suppressing genes involved in leukocyte activation, 
effector T cell function and chemotaxis. Gene set enrichment analysis identified a 
prominent pathogenic T helper (Th)17 signature in ELS-rich synovitis, which was 
confirmed by increased infiltration of IL-17-producing T helper cells in the joints of 
IL-27R-deficient mice. The significance of the Th17/IL-17 axis on ELS development was 
also investigated in inflammation-associated gastric cancer. The spontaneous 
development of gastric tumours in gp130Y757F:Y757F mice coincided with the formation of 
extra-tumoural ELS in the gastric submucosa. Here, ELS displayed T and B cell 
segregation, reactive germinal centres, and their formation coincided with the temporal 
induction of homeostatic chemokines. Interestingly, genetic ablation of IL-17 in 
gp130Y757F:Y757F mice revealed that the early formation of lymphoid aggregates did not 
require IL-17. Rather, IL-17 was needed for the formation of mature ELS that comprised 
follicular dendritic cells and germinal centres. In clinical disease, while an ELS gene 
signature was associated with advanced gastric cancer, it did not indicate a favourable 
prognosis. The gp130Y757F:Y757F mice represent a new model for the study of ELS in 
cancer and an opportunity to test novel drugs that may target ELS. The cross-disease 
roles revealed for the Th17 programme in regulating ELS makes an attractive target for 
the immunomodulation of ELS-rich arthritis and cancer.  
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Chapter 1. General Introduction 
  
 2 
1.1 The immune system 
The immune system is a collective network of lymphoid organs and specialised 
leukocytes that is regulated by various proteins (e.g. cytokines, antibodies, complement 
factors), bioactive lipids (e.g. leukotrienes, prostaglandins) and carbohydrate moieties 
[1]. It provides defence against infectious agents (e.g. bacteria, viruses, fungi, parasites) 
and injury by distinguishing between ‘self’ and ‘non-self’. However, dysregulation of this 
response can result in allergy and autoimmune disease [2]. The immune response is 
divided into two arms determined by the speed and specificity of the response, although 
there is much communication between them. These are termed innate and adaptive 
immunity. 
1.1.1 Innate immunity 
The inflammatory process is initiated through recognition of invading pathogens by 
pattern recognition receptors (PRRs) from the innate compartment. These recognise 
pathogen-associated molecular patterns (PAMPs) on invading pathogens and as such 
have co-evolved with microbes to protect against infection. PRRs also recognise danger-
associated molecular patterns (DAMPs) induced in response to endogenous stress. The 
best known PRRs are Toll like receptors (TLRs) which can recognise a diverse range of 
PAMPs. Others include macrophage scavenger receptors, nucleotide-binding 
oligomerisation domain-like receptors (NLRs) that recognise intracellular pathogens, 
C-type lectin receptors (e.g. Dectin-1 and Clec-2) and AIM2-like receptors, as well as 
secreted PRRs such as C-reactive protein and mannose binding lectin [3]. Recognition 
of PAMPs and DAMPs by PRRs triggers cellular responses that promote anti-microbial 
and pro-inflammatory activities, such as phagocytosis, opsonisation, secretion of 
cytokines and chemokines and inflammasome activation. The inflammasome is a 
multimeric protein complex that assembles following recognition of PAMPs or DAMPs. 
The oligomerisation of pro-caspase-1 activates its protease activity that cleaves 
precursor cytokines (e.g. pro-IL-1b and pro-IL-18) to support host defence and 
inflammation [4]. Together, these activities alter the expression of adhesion molecules 
and recruitment of immune cells in order to progress the inflammatory response [3]. 
Importantly, innate cells such as dendritic cells can traffic to secondary lymphoid organs, 
such as the spleen and lymph node, and present antigens on MHC molecules to T cells 
in order to prime the adaptive response [5].  
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1.1.2 Adaptive immunity 
Adaptive immunity generates responses against specific antigens and provides long 
term protection through the generation of immunological memory. The generation of 
unique receptors occurs early in development in the bone marrow and thymus for B and 
T cells respectively. For B cells, this is the B cell receptor (BCR) and T cells have the T 
cell receptor (TCR) [6]. The TCR is typically composed of an a- and b-chain, though 
some TCRs consist of a g- and d-chain and are expressed by gd T cells, which sit at the 
interface of innate and adaptive immunity. The BCR is a membrane bound IgM, hence 
is formed of heavy and light chains. The large repertoire of receptors is acquired through 
genetic recombination of variable, diverse and joining, V(D)J, gene clusters by enzymes 
encoded by the recombination activating genes, RAG-1 and RAG-2 [7, 8]. Since this is 
a random process, cells that recognise self-antigens are removed by negative selection 
before they enter the circulation [9].  
1.1.3 Activation of adaptive responses 
Antigens are presented to lymphocytes in secondary lymphoid organs by antigen 
presenting cells (APCs), such as dendritic cells. If a TCR or BCR recognises the antigen 
it is induced to proliferate and promote antigen-specific responses. T cells require both 
TCR activation and interaction of co-stimulatory molecules in order to differentiate into 
either effector or memory cells [10]. Co-receptors for T cell activation are CD80 (B7.1), 
CD86 (B7.2) and CD40, expressed on APCs, that bind CD28 and CD40 ligand (CD40L) 
on T cells respectively [11]. Co-receptors are upregulated on APCs following recognition 
of pathogens by PRRs [12].  
The inflammatory environment and the nature of the pathogenic insult have a profound 
effect on the functional characteristics of lymphocytes. This can result in the activation 
and differentiation of naive T cells into effector T cell populations with defined cytokine 
signatures (Figure 1.1). For example, interleukin (IL)-12 promotes immunity against 
intracellular parasites by promoting the differentiation of naïve CD4+ T cells into T helper 
(Th)1 cells that express T-bet and produce interferon (IFN)g [13]. During helminth 
infection IL-4 predominates which induces the expression of GATA3 and drives the 
differentiation of naïve CD4+ T cells into Th2 cells, which secrete IL-4, IL-5 and IL-13 
[14]. Th17 cells are induced in response to TGFb, IL-6, IL-21, IL-23 and IL-1b to provide 
immunity against extracellular bacteria and fungi [15]. TGFb and IL-6 are required for 
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early Th17 differentiation, whereas IL-23 is required for full effector function and 
maintenance of a Th17 phenotype [15, 16]. The master transcriptional regulator of Th17 
cells, retinoic acid receptor-related orphan receptor gamma-T (RORgt) is induced in 
response to STAT3 activation and leads to the expression of IL-17A, IL-17F and IL-22. 
Along with Th17 cells, gd T cells, natural killer (NK) cells, group 3 innate lymphoid cells 
(ILC3s), neutrophils and eosinophils are also capable of producing IL-17 [17-20]. The 
cognate receptor for IL-17 comprises an IL-17RA and IL-17RC heterodimer, which is 
expressed ubiquitously with particularly high levels in haematopoietic cells [21, 22]. T 
follicular helper (Tfh) cells support the generation of high-affinity antibodies by B cells. 
Tfh cell differentiation is dependent on IL-6 and IL-21, which induce the expression of 
Bcl-6. Tfh cells upregulate the expression of CXCR5 which directs their recruitment to B 
cell zones within lymphoid organs [23]. Regulatory T (Treg) cells limit effector T cell 
responses and support immune tolerance and maintain homeostasis. Natural Treg 
(nTreg) cells are released from the thymus as a distinct lineage, but inducible Treg 
(iTreg) cells can also differentiate upon TCR activation in response to TGFb [24].  
Activation of B cells occurs in germinal centres and requires signals from Tfh cells. This 
results in expression of activation-induced cytidine deaminase (AID) which promotes 
class-switching and somatic hypermutation in order to increase the affinity and diversity 
of antibodies [25, 26]. Somatic hypermutation generates point mutations within the 
antigen-binding site in order to increase affinity. Class-switching involves the changing 
of the constant region of the heavy chain in order to generate antibodies with different 
effector functions. There are five antibody isotypes – IgM, IgD, IgG, IgA and IgE. IgG 
antibodies are further divided into IgG1, IgG2, IgG3 and IgG4. The effector functions of 
antibodies include, neutralisation, activation of complement and activation of phagocytes 
by binding of antibody constant regions to Fc receptors. Activated B cells differentiate 
into antibody-secreting plasma cells or memory B cells [27].  
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Figure 1.1 - T helper cell differentiation. Following activation of naïve CD4+ T cells by 
antigen presenting cells the local cytokine environment polarises them into different 
effector T cell subsets – T helper (Th)1, Th2, Th17, T follicular helper (Tfh) and regulatory 
T (Treg) cells. Each effector cell has a distinct master transcriptional regulator that 
determines its differentiation, expression of cell surface receptors and secretion of 
effector molecules. In response to different pathogens different effector T cell subsets 
are generated.  
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1.1.4 Inflammation 
The symptoms of inflammation include heat (calor), redness (rubor), pain (dolor) and 
swelling (oedema) which arise from the accumulation of immune cells, secreted proteins 
and fluids at the site of infection or injury. Inflammation involves the organised 
recruitment of leukocytes and release of effector molecules in order to clear the infection. 
However aberrant regulation of this process can lead to chronic inflammation and tissue 
damage. 
1.1.5 Resolution of Inflammation 
Following clearance of the pathogen the inflammatory response has to cease in order to 
prevent tissue damage and injury. This is mediated through a balance of pro- and 
anti-inflammatory mediators that ensure appropriate regulation of leukocyte recruitment 
and apoptotic clearance, and the restoration of normal tissue architecture [28]. These 
mediators act to decrease vascular permeability, prevent the entry of neutrophils to sites 
of inflammation, and promote the infiltration of monocytes required for wound healing 
[29, 30]. They also stimulate macrophages to engulf apoptotic neutrophils, which 
reprograms them to adopt an anti-inflammatory phenotype resulting in the release of 
anti-inflammatory mediators and egress from inflamed tissue [31, 32]. Thus, these 
signals promote resolution of inflammation and tissue repair in order to restore tissue 
homeostasis. 
1.1.6 Chronic Inflammation 
Dysregulation of the inflammatory process through persistent, recurrent or unresolved 
inflammation can result in chronic inflammation [33]. For example, recognition of 
self-antigens leads to the development of chronic autoimmune diseases [34]. 
Additionally, it is now appreciated that chronic inflammation plays a role in many 
diseases including cancer, neurodegenerative disorders, type 2 diabetes and 
cardiovascular diseases. In these conditions, dysregulated and persistent inflammation 
leads to tissue damage and loss-of-function [33].  
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1.2 Cytokines and Chemokines 
The inflammatory response is a complex process that must be tightly controlled by a host 
of extracellular protein and lipid mediators. These include, cytokines, chemokines, 
eicosanoids (e.g. prostaglandins) and leukotrienes. The following sections will briefly 
introduce cytokines and chemokines before focusing on the IL-6 family cytokines, IL-6 
and IL-27.  
1.2.1 Cytokines 
Cytokines are small proteins released by both immune and stromal cells that participate 
in inflammatory processes by binding to specific receptors found on target cells. This can 
be on the cell that produced them (autocrine signalling), cells in close contact (juxtacrine 
signalling), adjacent cells (paracrine signalling), or act like hormones by entering the 
circulation to effect distant cells (endocrine signalling). The binding of cytokines to their 
cognate receptor activates diverse intracellular signalling cascades. For example, the 
binding of tumor necrosis factor-a (TNFa) to its receptor activates the NF-kB and 
mitogen activated protein kinase (MAPK) cascades [35], whereas IL-6 binding to its 
receptor predominantly activates the janus-activated kinase (JAK) and signal 
transducers and activator of transcription (STAT) pathway [36]. Through activation of 
these pathways, cytokines control cellular proliferation, differentiation and survival.  
While their action can be highly disease and context specific, cytokines have been 
broadly classed as either pro- or anti-inflammatory. Typical pro-inflammatory cytokines 
include TNFa and IL-1b, that are produced early in the inflammatory response by cells 
such as macrophages to elicit numerous effects. For example, IL-1b induces the acute 
phase response, has a stimulatory effect on CD4+ T cells and can support the 
differentiation of Th17 cells [37]. In contrast, cytokines such as IL-10 have potent 
anti-inflammatory effects. The suppressive effect of Treg cells on the inflammatory 
response is linked with their production of IL-10 [38]. Further to this, some cytokines are 
pleiotropic, thus can elicit both pro- and anti-inflammatory effects depending on the 
context in which they are acting. For example, IL-6 can inhibit the production of 
pro-inflammatory cytokines, chemokines and the microbicidal activities of macrophages 
to promote resolution of innate immune responses, yet IL-6 is also an important survival 
and commitment factor for T cells [36]. Hence, cytokines elicit diverse responses that 
regulate the inflammatory response.  
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1.2.2 Chemokines 
Cytokines that act as chemoattractants are termed chemokines. Named from the Greek 
‘kinos’ meaning movement, chemokines recruit leukocytes to the site of infection or injury 
along a concentration gradient. They are small (8-12 kDa) proteins that are typically 
characterised by the presence of four highly conserved cysteine residues that allow 
disulphide bridging important for their structural shape. The positioning of the N-terminal 
cysteine residues subdivides chemokines into four subfamilies. The CC chemokines 
have two adjacent N-terminal cysteines, while the cysteine residues in the CXC 
subfamily are separated by a single amino acid. These two subfamilies, comprising 
CCL1-28 and CXCL1-17 respectively, represent the majority of known chemokines. 
Additionally, there are the C subfamily (CL1 and CL2), which contain only a single 
N-terminal cysteine residue and the CX3C chemokine Fractalkine (CX3CL1), where the 
cysteines are separated by three amino acids. Nomenclature assigns chemokines to 
their subfamily based on positioning and number of cysteine residues followed by a 
number. An L or R is then added to designate either ligand or receptor respectively [39-
41].  
Chemokines signal by binding to seven transmembrane spanning G-protein coupled 
receptors on target cells. Binding induces changes in the cytoskeleton and lipid 
membrane resulting in movement along a chemokine gradient [42]. Chemokines can 
also interact with glycosaminoglycans present on the endothelial cell surface, which 
facilitates establishing a chemotactic gradient in injured or inflamed tissues. Whilst the 
chemotaxis of leukocytes to the site of infection or injury is the main role of chemokines 
they are also involved in processes that aid this. For example, chemokines increase the 
expression of lymphocyte function-associated antigen (LFA-1) an integrin involved in the 
tethering and diapedesis through the endothelium [43]. A subset of the CXC subfamily 
of chemokines that contain the motif, ELR (Glu-Leu-Arg), are neutrophil 
chemoattractants and are also found to be involved in angiogenesis [44, 45]. Importantly, 
homeostatic chemokines also play a role in the spatial organisation of lymphoid tissues. 
Here, the CCR7 ligands, CCL19 and CCL21, recruit and retain T cells in the T cell zone 
and CXCL13 binds its receptor CXCR5 on B cells to recruit them into the B cell follicle 
[46]. The development of lymphoid tissue will be discussed in detail in section 1.4.  
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1.3 The IL-6 family 
The IL-6 family of cytokines all share a common 130 kDa signal transducing co-receptor 
called gp130. Members of this family include IL-6, IL-11, IL-27, oncostatin-M, ciliary 
neurotrophic factor, leukaemia inhibitory factor and cardiotrophin-1 [47]. The following 
sections will review the roles that IL-6 and IL-27 play in inflammation and disease. 
1.3.1 IL-6 and the IL-6 receptor complex 
IL-6 is a pleiotropic cytokine first identified for its ability to promote the activation of T 
cells, differentiation of B cells and regulate the acute phase response [48-53]. However, 
it is now appreciated that IL-6 has hormone-like roles beyond regulation of the immune 
response. For example, IL-6 is associated with mitochondrial activities, lipid metabolism, 
insulin resistance, the neuroendocrine system and neuropsychological behaviour [54-
58]. Almost all immune cells and stromal cells are capable of producing IL-6 in response 
to various stimuli. Typically, IL-6 is secreted in response to IL-1b and TNFa, but 
expression is also induced by TLRs and other cytokines [36]. The receptor complex for 
IL-6 is composed of an IL-6 receptor-a subunit, that binds IL-6, in partnership with a 
signal-transducing co-receptor, gp130. Signalling through this method is termed 
‘classical signalling’. While gp130 is universally expressed, the IL-6 receptor is restricted 
to hepatocytes, leukocytes and megakaryocytes (Figure 1.2) [59, 60]. Whilst naïve, 
effector memory and central memory T cells all express IL-6 receptor, their response to 
IL-6 differs depending on whether they have previously experienced TCR activation [61]. 
A soluble form of the IL-6 receptor also exists through either the differential splicing of 
the Il6ra gene to produce a protein lacking the membrane anchor domain, or by 
proteolytic cleavage of membrane bound IL-6 receptor by adamylsin and disintegrin-
associated metalloproteinases (ADAM)-17 and ADAM-10 [62]. Proteolytic cleavage of 
the IL-6 receptor therefore results in a reduction in cell surface levels of the receptor 
upon T cell activation [63]. Thus, this mode of signalling broadens the cell types that can 
respond to IL-6. This is termed IL-6 ‘trans-signalling’ (Figure 1.2). It has been proposed 
that these distinct signalling mechanisms regulate different processes, with classical 
signalling predominantly involved in homeostasis and acute phase responses [36], while 
trans-signalling is associated with inflammatory activation of tissue, leukocyte 
recruitment and T cell function [64, 65].  
Binding of IL-6 to the IL-6 receptor complex through either classical or trans-signalling 
promotes intracellular signalling cascades. Recruitment of SH2 domain containing 
tyrosine protein phosphatase (SHP2) activates the MAPK cascade and 
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phosphoinositide-3-kinase (PI3K)-protein kinase B (PKB; also known as AKT) pathway 
[66]. IL-6 can also activate SRC tyrosine kinases to promote the YAP-NOTCH pathway 
associated with tissue regeneration [67]. However, the activities of IL-6 in leukocytes is 
predominantly linked to the activation of the JAK-STAT pathway. 
1.3.2 JAK-STAT signalling pathway 
Binding of IL-6 to the IL-6 receptor complex promotes signalling by the JAK-STAT 
pathway. Binding results in association of JAKs (e.g. JAK1, JAK2, Tyk2) which 
phosphorylate tyrosine residues on the intracellular domain of gp130 [68]. This promotes 
the binding of STAT transcription factors to gp130 – namely STAT1 and STAT3, though 
IL-6 predominantly activates STAT3 (Figure 1.2). Subsequent phosphorylation of STAT 
proteins by receptor-associated JAKs promotes STAT dimerization, and their 
translocation to the nucleus where they initiate transcription. This process is tightly 
regulated by inhibitory mechanisms, for example, suppressors of cytokine signalling 
(SOCS)1 and SOCS3 which act through negative feedback to supress STAT1 and 
STAT3 activity respectively [68]. The importance of regulating STAT signalling 
downstream of IL-6 family cytokines is highlighted in mice that express a mutant form of 
gp130 that is unable to bind SOCS3. These mice develop exacerbated inflammation and 
cancer associated with hyperactivation of STAT3 [69-72].  
1.3.3 IL-6 in inflammation 
The pleiotropic properties of IL-6 are best illustrated by its contrasting roles in the 
resolution of inflammation and in the maintenance of chronic inflammation. For example, 
IL-6 regulation of neutrophil accumulation and apoptosis controls transition to a 
sustained population of mononuclear cells. Here, infiltrating neutrophils shed IL-6 
receptor enabling IL-6 ‘trans-signalling’ in resident stromal cells, which alters chemokine 
expression profiles. This causes inhibition of neutrophil chemoattractants, CXCL1 and 
CXCL8 and expression of monocyte chemoattractants, CCL2 and CCL8, as well as 
regulating expression of adhesion molecules such as ICAM-1 and VCAM-1. Further to 
this, IL-6 also mediates neutrophil apoptosis [73]. It follows that Il6-/- mice develop 
heightened and prolonged neutrophil accumulation [74, 75]. IL-6 also has a role in wound 
healing. This is associated with its ability to inhibit pro-inflammatory cytokine release and 
microbial activities of macrophages [76, 77]. Hence these mechanisms of IL-6 action 
prevent tissue damage and drive the correct progression of the inflammatory response.  
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In contrast, IL-6 has a role in driving chronic inflammation, which may be best associated 
with its ability to shape adaptive immunity (Figure 1.3). The initial characterisation of IL-6 
as B-cell stimulatory factor 2 highlights the role it plays in B cell differentiation and 
antibody production. This may be linked to the ability of IL-6 to induce Bcl-6 and IL-21, 
promoting the commitment to Tfh cells, which support B cell responses and 
class-switching [78-80]. While IL-6 has varying effects on the differentiation of T cell 
lineages, through the regulation of anti-apoptotic factors, Bcl-2 and Bcl-xL, it acts as an 
important survival factor for these cells [81]. However, IL-6 is required for the 
differentiation of Th17 cells. Here, IL-6 activation of STAT3 results in the expression of 
RORgt and expansion of Th17 cells that secrete IL-17A as their signature cytokine [15, 
82-84]. Additionally, IL-6 inhibits the functions of Treg cells and at sites of inflammation 
can reprogramme them to adopt effector characteristics [85, 86]. For example, in 
collagen-induced arthritis, synovial fibroblast derived IL-6 converted FoxP3+ T cells into 
Th17-like cells, that produced IL-17A and RANKL, and contributed to disease 
progression [87]. It follows that IL-6 is a hallmark of chronic inflammatory diseases. For 
example, Il6-/- mice show protection in experimental models of chronic inflammatory 
conditions, including inflammatory arthritis [88, 89] and experimental autoimmune 
encephalomyelitis (EAE) [90]. Thus, IL-6 has diverse pro- and anti-inflammatory roles as 
well as hormone-like properties. 
1.3.4 IL-27 and the IL-27 receptor complex 
IL-27 is a heterodimeric cytokine composed of an IL27p28 subunit and Epstein-Barr 
virus-induced gene 3 (EBI3) subunit. EBI3 also partners with the IL12p35 subunit to form 
IL-35 and low affinity interactions of IL27p28 with soluble IL-6R and cytokine-like factor 1 
have been reported, however the physiological relevance of these remain to be fully 
determined [91]. Myeloid cells such as macrophages, monocytes and dendritic cells are 
the major sources of IL-27 [91]. However, during malaria infection IL-27 producing CD4+ 
T cells were recently identified [92]. Activation of TLRs and signalling by type I and II 
interferons promotes the expression of IL-27. Like all IL-6 family cytokines, IL-27 signals 
through binding its cognate receptor, IL-27 receptor-a (IL-27R, also known as TCCR or 
WSX-1), in partnership with the signal-transducing co-receptor, gp130. The expression 
of IL-27R is largely restricted to lymphocytes, monocytes and osteoclasts (Figure 1.2). 
IL-27R is expressed on all CD4+ T helper cell subsets, as IL-27 has broad roles in 
directing T cell effector characteristics (see section 1.3.5), and the activation of CD4+ T 
cells leads to the upregulation of IL-27R surface expression [91]. Similar to IL-6, IL-27 
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predominantly signals through STAT1 and STAT3. However, IL-27 induces a group of 
immunoregulatory genes through activation of STAT1 (Figure 1.2) [93]. Thus, although 
IL-27 shares the same gp130 co-receptor it can often oppose the action of IL-6 (Figure 
1.3). 
1.3.5 IL-27 in inflammation 
Using mouse models of infection, IL-27 was initially described as a pro-inflammatory 
cytokine due to its ability to promote IFNg secretion by T helper cells. Here, IL-27 
promoted the expression of STAT1, T-bet, IL12Rb2 and IFNg to support Th1 cells [94-
98]. Early studies also showed that IL-27 promoted the growth and survival of T cells [94, 
99]. However, this pro-inflammatory description for IL-27 was later challenged when 
infection of Il27ra-/- mice with Toxoplasma gondii led to a lethal CD4+ T cell response with 
elevated levels of IFNg [100]. Further studies in models of infection, autoimmunity and 
inflammation revealed IL-27 to be a potent negative regulator of IL-2 and an inhibitor of 
adaptive immune responses [101-105]. For example, IL-27 promotes the production of 
IL-10 from T cells [103, 106, 107], and supports the development of immunosuppressive 
CXCR3+ Treg populations [102]. IL-27 also suppresses effector T helper responses. In 
this context, it often antagonises the actions of IL-6. For example, IL-6 supports the 
development of Th17 cells [15, 82-84], however IL-27 inhibits Th17 cell function by 
supressing expression of RORgt, the master transcriptional regulator for Th17 
development [105, 108]. IL-27 also inhibits Th2 responses by antagonising expression 
of GATA3, the master transcriptional regulator of Th2 responses [98, 109-111]. In this 
regard, Il27ra-/- mice showed enhanced resistance to helminth infection associated with 
increased production of Th2 cytokines, IL-4, IL-5 and IL-13 [111]. Similarly, exaggerated 
T helper responses in Il27ra-/- mice have been linked with enhanced viral and fungal 
clearance [112, 113]. The expression of co-inhibitory receptors, PD-L1 and CTLA-4, on 
T cells is also upregulated by IL-27, further restricting T cell responses [114, 115]. Thus, 
in chronic inflammatory conditions, IL-27 mainly has anti-inflammatory effects that often 
oppose the actions of IL-6 (Figure 1.3).  
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Figure 1.2 - The IL-6 and IL-27 receptor complexes. The composition of the IL-6 and 
IL-27 receptor complexes, the cell types expressing the receptors and the STAT 
transcription factors are shown. The preferential activation of STATs by IL-6 and IL-27 is 
indicated in bold. RBCs, red blood cells. Adapted from Jones et al. 2018. 
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Figure 1.3 - The immunomodulatory actions of IL-6 and IL-27 in adaptive immunity. 
IL-6 and IL-27 often have opposing actions on adaptive immunity. IL-27 supports the 
expression of co-inhibitory receptors programmed death ligand 1 (PD-L1), programmed 
death 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA4) on T cells. IL-27 also 
supports the development of IL-10 producing T-bet+CXCR3+ Treg cells, whereas IL-6 
inhibits Treg cells. IL-27 also inhibits IL-6 driven Th17 differentiation. However, IL-6 and 
IL-27 can both promote IL-21 production in Tfh cells, support IFNg producing Th1 cells 
and induce IL-10 expression in effector T cells. Adapted from Jones et al. 2018 and 
Yoshida and Hunter 2015.  
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1.4 Ectopic Lymphoid-like Structures 
Secondary lymphoid organs (SLOs), such as the spleen and lymph nodes, have a highly 
organised structure that allows communication and interaction of immune cells for the 
generation of antigen specific responses, an essential component of the adaptive 
immune response [116]. However, antigen specific responses may also be generated at 
sites distinct from SLOs. The first evidence of this comes from studies of the immune 
response in organisms that lack lymph nodes [117]. It is now becoming evident that in 
tissues affected by non-resolving inflammation, for example in cancer, infection and 
autoimmunity, infiltrating leukocytes can often form organised lymphoid aggregates 
within the inflamed tissue that promote adaptive immune responses [118]. These 
structures can exist as simple aggregates of T and B cells or more organised structures 
that resemble SLOs. Therefore, they are referred to as ectopic lymphoid-like structures 
(ELS; also called tertiary lymphoid structures, TLS). How and why these structures 
develop at these sites is currently unknown. To understand the mechanisms responsible 
for the development of ELS, researchers have relied on information derived from the 
development of SLO. In the sections below the development of SLOs is outlined and 
differences between the development of SLOs and ELS are highlighted.  
1.4.1 Secondary Lymphoid Organogenesis 
SLO development is initiated during embryogenesis through the interaction of 
haematopoietic derived lymphoid tissue inducer (LTi) cells with stromal lymphoid tissue 
organiser (LTo) cells [119]. LTi cells are characterised as CD45+CD4+CD3- cells with the 
transcription factors RORgt and Id2 required for their development. LTi cells also express 
CXCR5 and IL-7R, and accumulate at pre-determined sites of lymph node development 
due to local production of IL-7 and CXCL13, the ligand for CXCR5, by stromal cells in 
response to retinoic acid signals released by neurons and ILC3s [120, 121]. IL-7 and 
RANKL expressed by LTo cells support the differentiation and survival of LTi cells and 
upregulate lymphotoxin (LT) ab on the surface of LTi cells [122-124]. The interaction of 
LTab with LTb receptor (LTbR) found on LTo cells activates the canonical and 
non-canonical NF-kB pathways leading to expression of CXCL13, CCL19 and CCL21 
as well as survival factors such as BAFF and adhesion molecules such as ICAM-1, 
VCAM-1 and MAdCAM-1 [125]. This leads to the recruitment of more LTi cells, which 
initiates a positive feedback loop through binding of homeostatic chemokines to their 
receptors which leads to upregulation of LTab and enlargement of the developing LN 
[126]. LTi cells enter the developing LN as they express the integrin a4b7, the ligand for 
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MAdCAM-1 expressed on all embryonic blood vessels [127]. After birth, there is a switch 
in vascular addressin expression by HEVs; MAdCAM-1 is downregulated and PNAd is 
upregulated [128]. PNAd acts as a ligand for L-selectin to allow the recruitment of naïve 
T and B cells and expansion of the LN [129]. To further support SLO development, LTo 
cells can also differentiate into follicular dendritic cells (FDCs) found in B cell follicles and 
germinal centres, fibroblastic reticular cells (FRCs) found in the T cell zones and marginal 
reticular cells (MRCs) found at the edge of follicles. FRCs express CCL19 and CCL21 to 
attract CCR7+ T cells and produce podoplanin and extracellular matrix components 
which form a scaffold for the organisation of T cells [130, 131]. FRCs have recently been 
shown to support interactions between APCs and T cells, promote antigen-specific 
immune tolerance and restrict the expansion of newly generated naïve T cells [132]. 
FDCs express CXCL13 and CD21 to recruit and organise CXCR5+ B cells and BAFF, a 
B cell survival and proliferation factor [133, 134]. A new stromal cell subset called 
versatile stromal cells that reside in the T cell zone has also been identified [135]. Indeed, 
the complexity of stromal cell subsets within LNs has recently been elucidated through 
the use of single-cell RNA sequencing which identified nine distinct clusters [136]. Hence 
SLOs display a highly organised structure comprising of segregated T cell and B cell 
zones, germinal centres, HEVs and stromal cell networks (Figure 1.4A).  
Therefore, according to the characteristics of SLO, it has been proposed that the minimal 
requirements to form ELS include: (i) organised T and B cell zones; (ii) PNAd+ HEVs for 
the extravasation of L-selectin+ immune cells; (iii) expression of homeostatic chemokines 
(CCL19, CCL21 and CXCL13) required for lymphoid organ organisation; and (iv) stromal 
cell networks such as FDC networks for germinal centres reactions. Where the 
requirements for ELS are not met they are better described as lymphoid aggregates 
[137].  
1.4.2 Mediators of ELS development 
While ELS share many of the features of SLOs, it is emerging that there are key 
differences. Firstly, in terms of structure, ELS are not encapsulated. They are also 
inducible structures that form in response to inflammatory stimuli at sites of inflammation 
rather than at pre-determined locations based on developmental signals [138]. However, 
ELS can only form in permissive tissues and an association has been made with mucosal 
epithelium. For example, overexpression of CCL21 induces the formation of ELS in the 
pancreas but not in the skin [139]. Interestingly, despite the lack of epithelium, ELS can 
form in synovium of patients with RA [118]. Thus, certain tissues are more permissive to 
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ELS formation than others. It is also emerging that the initiation cues required for ELS 
development differ from secondary lymphoid organogenesis. Whilst LTi cells are central 
to the initiation of SLO development, ELS can form in the absence of LTi cells. Here, 
ELS can still form in mice deficient in RORgt and the transcriptional repressor Id2, despite 
the lack of LTi cells [140-142]. This has led to the notion that resident stromal tissue cells 
or infiltrating inflammatory cells can initiate the development of ELS at sites of disease 
(Figure 1.4B).  
Th17 cells, including cytokines linked with Th17 effector responses, have recently been 
associated with tissue inflammation featuring ELS. In this regard, a direct role in 
promoting ELS formation was demonstrated through the adoptive transfer of in vitro 
generated Th17 cells into mice with EAE [143]. Additionally, the Th17 cell effector 
cytokines, IL-17A and IL-22, have been linked to the development of inducible bronchus-
associated lymphoid tissue (iBALT) [142, 144] and the development of ELS in salivary 
glands following local challenge with adenovirus [145]. Interestingly, gd T cells are also 
capable of producing IL-17A and IL-22. During the development of iBALT in response to 
Pseudomonas aeruginosa infection the main source of IL-17 was from gd T cells [144]. 
Following adenovirus delivery, IL-22 regulation of ELS development in the salivary gland 
was initially associated with IL-22 expression in gd T cells. However, this was replaced 
by a prominent ab T cell response [145]. Interleukin-21, derived from either Th17 or Tfh 
cells, has also been implicated with ELS development. Here, elevated levels were 
observed in synovial tissue in a murine model of inflammatory arthritis and in inflamed 
salivary glands that featured ELS [146, 147]. Furthermore, expression of Tfh markers, 
including Bcl-6 and CXCR5, have been linked with ELS development in an experimental 
uveitis model [148]. 
Innate cells have also been linked with ELS development. For example, LPS-induced 
iBALT was associated with increased levels of neutrophils within the lung. Interestingly, 
neutrophil depletion, using an anti-Ly6G antibody, reduced iBALT formation [149]. 
Mirroring the central role played by LTi cells in SLO development during ontogeny, adult 
LTi cells have also been implicated in ELS development. In this regard, adult LTi cells 
are classed as group 3 innate lymphoid cells (ILC3s) and share many effector 
characteristics with Th17 cells, including RORγt expression, the chemokine receptor 
CCR6, secretion of IL-17, IL-22, and granulocyte-macrophage colony-stimulating factor 
(GM-CSF), and responsiveness to IL-23 and aryl hydrocarbon receptor (Ahr) ligands. 
Using Cxcr5-/- mice that lack Peyer’s patches (lymphoid follicles found within the small 
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intestine), adoptive transfer of adult CD4+CD3- LTi cells led to the development of 
intestinal lymphoid aggregates [150]. Additionally, overexpression of IL-7 led to an 
increase in intestinal lymphoid aggregates that was associated with an increase in the 
number of LTi cells [151]. Thus, multiple immune cells have been linked with the 
development of ELS during inflammation and their contribution to this process is likely to 
be complex and context dependent. 
While potential propagators of ELS are being identified in numerous disease settings, 
less is known about mediators that inhibit ELS development. Recently however, our 
group identified IL-27 as an inhibitor of ELS development in a model of inflammatory 
arthritis [146]. Here, Il27ra-/- mice developed exacerbated inflammatory arthritis 
characterised by an increase in leukocyte infiltration and synovial exudate. Additionally, 
in the absence of IL-27 receptor, mice developed synovial ELS that was associated with 
an increase in homeostatic chemokine expression [146]. In addition, in a mouse model 
of primary Sjögren’s syndrome, IL-27 gene therapy using a recombinant adeno-
associated virus vector reduced the size of lymphocyte aggregates in salivary glands 
[152]. Hence, IL-27 has emerged as a novel inhibitor of ELS development.  
A common feature in the development of SLOs and ELS is the production of homeostatic 
chemokines. However, during ELS development additional cell types, other than LTo 
cells, may acquire the ability to produce these chemokines. Here, stromal cells may play 
a role in shaping ELS development. For example, infection with Pseudomonas 
aeruginosa results in iBALT development associated with IL-17 driven CXCL12 
production from pulmonary stromal cells [144]. Similarly, IL-17 stimulation of synovial 
fibroblasts from patients with RA induces the expression of CXCL12 [153]. Other studies 
using an influenza infection model identified that stromal cells and peripheral node 
addressin (PNAd)-positive HEVs produced CXCL13, CCL19 and CCL21 required for 
iBALT formation [154]. Interestingly, iBALT still developed in Cxcl13-/- mice suggesting 
that other chemokines can direct the recruitment of B cells in this model [154]. Following 
adenovirus challenge in the salivary gland IL-22 induced the expression of CXCL13 from 
stromal cells and CXCL12 from epithelial cells that contributed to ELS development 
[145]. Hence, stromal cells contribute to ELS development through secreting 
homeostatic chemokines including CXCL13, CXCL12, CCL19 and CCL21, which may 
influence the composition and activity of ELS. 
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Thus, immune cells and stromal cells can adopt features of LTi cells and LTo cells 
respectively, in order to initiate the development of ELS in chronically inflamed tissue 
(Figure 1.4). 
1.4.3 The Function of ELS in disease 
For ELS to support B cell responses and antibody production they must recapitulate the 
function of SLOs. The expression of AID, which promotes somatic hypermutation and 
class-switch recombination, identifies the presence of active germinal centres. AID is 
expressed in lymphoid aggregates from the synovium of RA patients [155]. In trans-well 
co-culture studies, synovial fibroblasts from RA patients increased the expression of AID 
in B cells [156]. Class-switch recombination can also be detected using PCR directed 
against circular transcripts (e.g., Ig-Cµ for IgM-IgG class-switching) that are generated 
by the looping out of DNA during genomic recombination. These circular transcripts have 
been identified in ELS following cytomegalovirus challenge in the salivary gland and in a 
murine model of lupus [157, 158]. Furthermore, transfer of AID-positive lymphoid 
aggregates into severe combined immunodeficient (SCID) mice resulted in the release 
of human anti-citrullinated protein antibodies (ACPAs) into the circulation [155]. Similarly, 
the transfer of salivary gland biopsies featuring ELS from patients with Sjögren’s 
syndrome into SCID mice resulted in the release of human antibodies against 
ribonucleoproteins Ro (Sjögren’s syndrome antigen A; SSA) and La (Sjögren’s 
syndrome antigen B; SSB) [159]. Hence, ELS are sites of active class-switching and 
autoantibody production within inflamed tissues.  
In addition, a number of studies demonstrate that ELS can display functional 
anti-pathogen responses. For example, following influenza virus infection in mice, ELS 
formed in the lung that generated plasma cells specific for influenza virus nucleoprotein 
[160]. In this model, ELS were maintained through chemokine secretion by dendritic 
cells. Importantly, depletion of dendritic cells resulted in decreased levels of class-switch 
dependent IgA [160], indicating that ELS can generate antigen-specific responses and 
class-switching. Indeed, anti-pathogen responses have also been observed at ELS 
independently of SLO involvement. In spleen, lymph node and Peyer’s patches (SLP) 
mice, reconstitution with wild type bone marrow prior to influenza infection resulted in the 
development of ELS within the lung (iBALT) that were effective in clearing the virus [161]. 
Thus, it is proposed that the development of ELS in autoimmunity is detrimental, due to 
the perpetuation of the immune response, whereas ELS development in infection may 
be beneficial through the establishment of local anti-pathogen responses.  
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Figure 1.4 - Secondary lymphoid organogenesis and ectopic lymphoid-like 
structure development. (A) The development of secondary lymphoid organs (SLOs) 
occurs at pre-programmed sites during embryogenesis. It is mediated through the 
interaction of LTi cells, which secrete LTαβ, with LTo cells, that express the LTβ receptor. 
This interaction stimulates LTo cells to secrete homeostatic chemokines (CXCL13, 
CXCL12, CCL19 and CCL21) that recruit and spatially organise cells into lymphoid 
organs. The recruitment of cells is supported by the release of VEGF, FGF and HGF 
from LTo cells that promotes the formation of high endothelial venules (HEVs). LTo cells 
are also capable of differentiating into follicular dendritic cells (fDCs) that upregulate 
expression of adhesion molecules to further support leukocyte recruitment. SLOs are 
sites of T cell priming and antibody production. (B) At sites of chronic inflammation 
ectopic lymphoid-like structures (ELS) can form. Immune cells can substitute the role of 
LTi cells and the release of effector molecules can induce stromal cells to produce 
homeostatic chemokines involved in the recruitment and spatial organisation of cells into 
ELS. ELS are sites of T cell priming and plasticity of T cells may support the activities of 
B cells and antibody production. LTi, lymphoid tissue inducer; LTo, lymphoid tissue 
organiser; LT, lymphotoxin; VEGF, vascular endothelial growth factor; FGF, fibroblast 
growth factor; HGF, hepatocyte growth factor; ICAM, intracellular adhesion molecule; 
VCAM, vascular cell adhesion molecule.  
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1.5 Rheumatoid arthritis 
Rheumatoid arthritis (RA) affects approximately 0.5% to 1% of the global adult 
population making it the most common rheumatic autoimmune disease [162]. It is 
characterised by chronic inflammation of the joints, resulting in synovial inflammation 
and hyperplasia, autoantibody production and cartilage and bone erosion. As a 
consequence, RA is associated with musculoskeletal defects resulting in a decline in 
physical ability. It is also linked with an increased risk in developing comorbidities. The 
inflammatory environment in RA causes muscle and adipose tissue to become insulin 
resistant, effects cognitive function, alters cholesterol levels, and is associated with an 
increased risk of cardiovascular disease leading to premature death [34, 163, 164]. 
1.5.1 Risk factors associated with RA 
The mechanisms that lead to a breach of tolerance in RA are poorly understood. 
However, there are numerous genetic and environmental risk factors associated with its 
development. For example, smoking, which promotes the citrullination of proteins, is an 
environmental risk factor for the development of RA. Many of the genetic risk alleles 
identified overlap with immune regulatory genes. For example, alleles that contain the 
shared epitope (QKRAA) in the HLA-DRB1 locus are particularly susceptible to 
developing RA. These residues form part of the antigen presenting binding site, and it is 
thought that they allow the presentation of arthritogenic peptides [165]. Additionally, risk 
alleles have been found in PTPN22, a protein tyrosine phosphatase that downregulates 
T cell receptor responses [166], PADI4, a peptidylarginine deaminase able to citrullinate 
proteins and CTLA4, an immune checkpoint receptor expressed on activated T cells 
[165]. Interestingly, genetic variations in IL6ST (encoding gp130) and IL6R are common 
to patients with RA [167, 168] and a single nucleotide polymorphism in IL27 was linked 
to more advanced disease [169]. Hence, while the cause of RA remains unknown, it is 
generally thought that environmental and genetic predisposition contributes to the 
breach of immunological tolerance and autoantibody generation. 
1.5.2 Disease pathogenesis 
A hallmark of RA is the presence of autoantibodies such as rheumatoid factor (RF), 
directed against Fc fragments of IgG, and autoantibodies against citrullinated peptides 
(ACPAs) [162]. Whilst not all patients have circulating autoantibodies, their presence is 
associated with more severe joint damage and increased mortality [170-172]. 
Additionally, circulating ACPAs can be detected up to 10 years before diagnosis [173], 
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and over time their concentration and epitope diversity increases [162]. It is proposed 
that a subsequent trigger then promotes articular localisation and the onset of clinical 
disease.  
Joint swelling in RA is characterised by infiltration of leukocytes, synovial hyperplasia, 
thickening of the synovial lining and pannus formation. Inflammatory cells found within 
the synovium include, T and B cells, macrophages, dendritic cells, neutrophils, natural 
killer (NK) cells and monocytes [174]. The inflamed synovium invades cartilage and 
promotes bone destruction, which is facilitated by soluble mediators such as cytokines 
[54]. For example, RANKL (receptor activator of nuclear factor-kB ligand) is secreted by 
synovial fibroblasts and activated T cells in response to IL-1b, TNFa, IL-6 and IL-17, and 
is essential for the differentiation of osteoclasts and subsequent bone resorption. 
Additionally, pro-inflammatory cytokines induce chondrocytes to secrete matrix 
metalloproteases (MMPs) that cleave proteoglycans and collagens that form cartilage 
[54]. Furthermore, inflammatory cytokines can enter the circulation resulting in systemic 
inflammation, fatigue, depression and other associated comorbidities.  
1.5.3 Assessment of disease activity 
Assessment of a patient’s disease activity enables identification of the stage of disease 
and response to therapy. One such measure is the Disease Activity Score (DAS)28 index 
which provides a continuous measure of disease activity [175]. It considers the number 
of swollen and tender joints out of 28 examined, serum markers of inflammation (e.g. 
CRP) and personal assessment of health, in order to calculate an overall disease activity 
score. A DAS28 score greater than 5.1 indicates active disease, less than 3.2 low 
disease activity and a score below 2.6 indicates remission [176].  
Other measures include the American College of Rheumatology (ACR) score which 
allows judgment of improvement but not a measure of disease activity. An ACR20 score 
means that a patient has 20% fewer swollen or tender joints, a reduction in overall 
assessment of RA and reduction in serum markers of inflammation. An ACR50 and 
ACR70 response indicates a 50% and 70% improvement respectively [177]. Whilst the 
DAS28 is routinely used in the clinic, ACR scores are a standardised measure of 
response to therapy in clinical trials.  
1.5.4 Treatment of RA 
The treatment of RA aims to reduce systemic and local inflammation and prevent 
irreversible joint damage [178]. This is achieved through the use of disease modifying 
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anti-rheumatic drugs (DMARDs) and various biologic drugs and small molecule inhibitors 
directed against signalling pathways or inflammatory cytokines that contribute to the 
pathogenesis of RA (Figure 1.5). Early diagnosis and intervention, during a “therapeutic 
window of opportunity” increases the likelihood of therapy being effective and achieving 
disease remission [179]. In this context, a recent study showed that a single infusion of 
rituximab in patients with autoantibodies but no clinical symptoms delayed the onset of 
RA [180].  
Upon diagnosis DMARD therapy is recommended, and treatment generally begins with 
the use of methotrexate [175]. If disease activity does not reduce (determined using the 
DAS28 score) TNF inhibitors (e.g., etanercept, infliximab) can be used in conjunction 
with methotrexate. For patients with high disease activity, methotrexate combined with 
TNF inhibitors is typically used from diagnosis [181, 182]. In this context, studies have 
shown that the combination of methotrexate with TNF inhibitors has a synergistic effect 
[183]. However, not all patients respond equally well to any individual drug. For example, 
approximately 40% of patients show poor responses to anti-TNF therapy [184-186]. In a 
treat-to-target approach, other biologic agents can be used until disease activity is 
reduced. In this regard, patients display marked improvement in disease activity when 
switched to either a different TNF inhibitor [187] or to a different biologic [188-190]. These 
commonly include anti-IL6R (e.g. tocilizumab), anti-CD20 (e.g. rituximab), CTLA4-IgG 
(e.g. abatacept) and JAK inhibitors (e.g. tofacitinib). While the mode of action for these 
drugs differs quite considerably, they all combat inflammation through actions on target 
cells, cytokines and signalling cascades that drive disease progression (Figure 1.5). 
Tocilizumab – a human monoclonal antibody that acts as an IL-6 receptor antagonist. In 
this regard it recognises both membrane bound and soluble IL-6 receptor, as such it 
inhibits both classical and trans-signalling [191].  
Rituximab – a B cell targeting antibody that binds CD20 to deplete B cells. The 
mechanism by which rituximab depletes B cells is debated but could be due to 
cytotoxicity and inducing apoptosis [192].  
Abatacept – a CTLA4-IgG that blocks the co-stimulatory interaction between CD28 and 
CD80 or CD86 expressed on APCs that is required for T cell activation [178]. Thus, 
abatacept functions to suppress T cell activation and release of effector molecules. 
Tofacitinib – a small molecule inhibitor that inhibits the JAK-STAT pathway. It primarily 
targets JAK1 and JAK3 [178].        
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Figure 1.5 - Biologic agents for the treatment of Rheumatoid arthritis. Current 
biologics for the treatment of Rheumatoid arthritis reduce inflammation by targeting 
inflammatory cytokines and the activities of T and B cells. They target either (i) the 
cytokine (ii) the receptor or (iii) the intracellular signalling pathway. Different biologic 
targets are shown in the boxes and drug names indicated in brackets.   
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1.6 Ectopic lymphoid-like structures in Rheumatoid arthritis 
The development of minimally invasive ultrasound-guided synovial biopsy sampling has 
advanced our understanding of disease pathogenesis in RA [174]. It is now appreciated 
that RA is a highly heterogenous disease. Infiltrating immune cells can either be found 
randomly distributed throughout the synovial cavity or spatially organised into ELS. 
These patterns of synovial pathology have been termed ‘diffuse’ and ‘follicular’ synovitis 
respectively. While RA is typically characterised by the infiltration of immune cells a third 
pattern of synovial pathology termed ‘pauci-immune’, comprises few immune cells yet is 
still found in active disease (Figure 1.6) [155, 193-195]. These different forms of synovitis 
impact disease progression and severity, and the clinical response to mainstream 
therapies, including anti-TNF and anti-CD20 specific antibodies [195-197]. 
1.6.1 The role of IL-6 and IL-27 in RA 
The cytokines IL-6 and IL-27 play key roles in shaping synovial pathology. Despite 
signalling through the same co-receptor, gp130, IL-6 and IL-27 levels in RA correspond 
with differences in disease activity [47]. For example, IL-6 is highly expressed in the 
synovial fluid of RA patients [198] and blockade of IL-6 signalling is clinically beneficial 
highlighted by the use of tocilizumab. Equally, in animal models of inflammatory arthritis 
Il6-/- mice display a protected phenotype with reduced synovial leukocyte infiltration and 
erosive joint damage [69, 88, 89, 199].  
In contrast, in collagen-induced arthritis systemic administration of IL-27 resulted in 
reduced incidence of disease and histological paw score. This was associated with 
reduced collagen-specific antibody titres and decreased serum levels of IL-6 and IL-17 
[200]. Furthermore, the local injection of adenovirus expressing IL-27 into the ankles of 
mice following the induction of collagen-induced arthritis resulted in reduced joint 
inflammation and bone erosion, which was also associated with decreased expression 
of IL-6 and IL-17 in inflamed joints [201]. Thus, IL-27 can act both systemically and locally 
to improve synovitis and joint damage in inflammatory arthritis. Elevated levels of 
synovial and serum IL-27 observed in clinical RA may therefore reflect an effort to 
counteract persistent local and systemic inflammation. 
Consistent with the anti-inflammatory properties of IL-27 when administered during 
experimental inflammatory arthritis, recent studies using the antigen-induced arthritis 
(AIA) model in Il27ra-/- mice resulted in exacerbated disease. Here, synovitis was 
associated with elevated adaptive immune responses in Il27ra-/- mice, highlighted by 
 26 
increased T cell infiltrate and mBSA-specific antibody titres. Moreover, Il27ra-/- mice 
developed synovial ELS with 100% penetrance, characterised by the presence of CD21+ 
follicular dendritic cells, Bcl-6, a marker of germinal centre B cells, and increased 
expression of homeostatic chemokines [146]. Crucially, this is reflected in synovial 
biopsies from RA patients. Here, patients with follicular disease, characterised by the 
presence of synovial ELS, displayed decreased expression of IL27 compared to patients 
with diffuse synovitis [146]. Thus, IL-6 and IL-27 have opposing roles in shaping synovial 
pathology. 
1.6.2 ELS and disease severity 
ELS within the synovium of RA patients have been shown to express AID and generate 
autoantibodies [155] (see section 1.4.3). Subsequently the presence of ELS within the 
synovium of RA patients has been shown to correlate with disease severity and degree 
of inflammation. For example, levels of CXCL13 and CD20, that mark the presence of 
ELS, correlate with the degree of erosive bone damage [202, 203]. Additionally, the 
presence of lymphoid aggregates within the joints of RA patients correlated with elevated 
synovial autoantibodies, RF and ACPAs [204]. However, in other studies despite the 
presence of lymphoid aggregates correlating with an increase in serum levels of 
inflammatory markers, ESR and CRP, there was no difference in clinical measures, such 
as DAS28 scores, or autoantibody levels [205]. Thus, the effect of synovial ELS on 
disease severity in RA is debated. 
1.6.3 ELS and response to therapeutics 
Anti-TNF therapy is the frontline biologic used in RA [178]. However not all patients 
respond to treatment. In one study, the improvement in DAS28 scores was found to be 
significantly lower in patients with synovial lymphoid aggregates following the use of 
anti-TNF therapies [197]. Here, the presence of lymphoid aggregates within the 
synovium of RA patients was a negative predictor of the response to anti-TNF therapy, 
despite the elevated levels of TNFa within the synovium of patients with ‘follicular’ 
pathology [194, 206]. Comparable findings were also reported by Dennis et al., where 
CXCL13 serum levels were used as a predictive marker of lymphoid-rich synovitis [195]. 
Here, CXCL13high/sICAMlow patients displayed better clinical responses (ACR50) to 
anti-IL-6R (tocilizumab) as compared to anti-TNF (adalimumab) inhibitors. However, the 
relationship between the presence of synovial ELS and response to biological drugs 
remains a controversial topic, and synovial lymphoid aggregates have also been linked 
with improved clinical responses to anti-TNF treatment [207]. 
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Studies have also investigated the link between clinical response to rituximab, an 
anti-CD20 antibody, and the presence of lymphoid aggregates. Here, it is also evident 
that not all patients respond equally to treatment [196]. Following rituximab treatment, 
patients with lymphoid aggregates showed no reduction in autoantibody levels [204]. 
This may represent the lack of expression of CD20 by antibody secreting plasma cells 
[208]. Interestingly, while rituximab treatment has been shown to effectively deplete 
circulating B cells, little effect was observed in B cells residing within ELS with no 
difference in the number or area of lymphoid aggregates within the synovium [209]. Thus, 
ELS may provide an environment that supports B cell survival during anti-CD20 
treatment. Notably, 6 months after rituximab treatment, patients with higher circulating 
levels of CXCL13 displayed a significant increase in the number of circulating B cells 
compared to patients with low CXCL13 levels [210]. Hence, CXCL13 levels may indicate 
the extent of B cell replenishment following treatment and could potentially be used to 
inform of treatment strategies. 
Taken together, these studies suggest that ELS can affect the response to biologic 
therapy, however a greater understanding is needed in this area.
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Figure 1.6 - Joint pathology in Rheumatoid Arthritis. Normal (left of joint) and 
inflammation-associated erosion in rheumatoid arthritis (right of joint). 
Immunohistochemical staining for CD20 (B cells), CD3 (T cells), CD68 
(monocyte/macrophage) and CD138 (plasma cells) highlights differences in synovial 
pathology. Synovial inflammation can comprise diffuse leukocyte infiltrates (diffuse) also 
associated with being myeloid-rich, contain follicular aggregates of lymphocytes 
(follicular) or have low infiltration of immune cells (pauci immune). Adapted from Pitzalis 
et al. 2013.  
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1.7 Gastric cancer 
Gastric cancer is the second largest cause of cancer related deaths worldwide [211]. 
Most gastric cancers arise from gastric epithelium (adenocarcinomas), with other 
malignancies arising from connective tissue (sarcoma) and lymphatics (lymphoma) 
being less common. However, all are highly heterogenous with regards to growth, 
architecture and pathogenesis [212]. Gastric cancers can be further classified based on 
their histological appearance. Two subtypes exist - intestinal and diffuse carcinomas. 
Diffuse carcinomas are poorly differentiated and composed of solitary tumour cells. 
Intestinal-type carcinomas are well differentiated and form glandular structures 
reminiscent of colorectal carcinomas, hence the name [213]. Gastric cancer develops as 
a result of an inflammatory process that progresses from chronic gastritis to intestinal 
metaplasia. Factors associated with an increased risk of gastric cancer include diet, 
smoking, genetic predisposition (e.g. mutations in E-cadherin) and infection [211]. For 
the latter, chronic gastritis caused by infection with Helicobacter pylori is a major risk 
factor for gastric cancer. In this context, it is now estimated that over 20% of all human 
cancer cases are associated with chronic inflammation [214]. 
However, a question that remains unanswered is how chronic inflammation triggers 
tumourigenesis in the gastric epithelium. In this regard, it is thought that an inflammatory 
microenvironment consisting of inflammatory cells, cytokines, chemokines and growth 
factors act on epithelial cells to trigger intracellular signalling pathways and activation of 
transcription factors [215]. A key transcription factor associated with gastric 
tumourigenesis is STAT3. Activation of STAT3 induces the transcription of genes 
involved in cell progression and survival and angiogenesis [216]. In clinical gastric 
cancer, patients display increased STAT3 activation in response to heightened levels of 
the IL-6 family cytokine, IL-11 [217, 218]. Similarly, mice that have constitutive activation 
of STAT3 downstream of the IL-6 family signalling receptor, gp130, spontaneously 
develop gastric tumours. These mice, termed gp130Y757F:Y757F (gp130F/F) (Figure 1.7), 
have a ‘knock-in’ substitution of tyrosine 757 for a phenylalanine in the cytoplasmic 
domain of gp130, which disrupts the binding of SOCS3. Hence the negative feedback 
inhibition mediated by SOCS3 on gp130 signalling is inhibited, which leads to prolonged 
and hyperactivation of STAT3 and subsequent gastric tumourigenesis. This phenotype 
is driven by the IL-6 family cytokine, IL-11 (Figure 1.7) [219-221]. 
Another transcription factor implemented in gastric tumourigenesis is NF-kB. Here, 
pro-inflammatory cytokines (e.g. IL-1b, TNFa) and PRRs, that detect microbial 
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pathogens (e.g. TLR2), can activate the NF-kB pathway. This can lead to cell 
proliferation, survival, migration and angiogenesis as well as increasing transcription of 
pro-inflammatory cytokines that further perpetuates the inflammatory environment [215]. 
Importantly, there is also cross-regulation between these two pathways. For example, 
hyperactivation of STAT3 in gp130F/F mice resulted in the transcriptional induction of 
TLR2 on gastric epithelial cells and resultant activation of NF-kB [222]. 
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Figure 1.7 - Hyperactive STAT3 signalling in gp130Y757F:Y757F mice causes gastric 
tumourigenesis. The IL-6 family of cytokines signal through a co-receptor called 
gp130 to activate STATs. Gastric tumourigenesis in gp130Y757F:Y757F (gp130F/F) mice is 
driven by IL-11 binding to the IL-11 receptor. Binding results in association of JAKs 
which phosphorylate tyrosine residues on the intracellular domain of gp130. This 
promotes the binding of STAT3. Subsequent phosphorylation of STAT3 by receptor-
associated JAKs promotes STAT dimerization, and their translocation to the nucleus 
where they initiate transcription. In WT mice, this process is tightly regulated by 
suppressors of cytokine signalling 3 (SOCS3) which binds to phosphorylated tyrosine 
757 and acts through negative feedback to supress STAT3 activity. In gp130F/F mice, 
there is a substitution of tyrosine 757 for a phenylalanine in the intracellular domain of 
gp130. This disrupts the binding of SOCS3 and therefore leads to a loss of the 
negative feedback inhibition mediated by SOCS3 on STAT3 activity. Thus, gp130F/F 
mice have hyperactivation of STAT3 (indicated by the size of the arrow) leading to 
gastric tumourigenesis.  
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1.8 Ectopic lymphoid-like structures in cancer 
Chronic inflammation is a feature of many tumours and as such provides an environment 
for the development of ELS. However, one would assume that the highly 
immunosuppressive tumour environment might prevent the formation of ELS. 
Nonetheless, ELS have now been described in many cancers including colorectal [223-
225], breast [226, 227], melanoma [226, 228-230], ovarian [226, 231] and non-small cell 
lung cancer (NSCLC) [226, 232-234]. These range from simple lymphoid aggregates to 
highly organised structures more reminiscent of SLOs. Akin to the development of ELS 
in autoimmunity, tumour-associated ELS also share the same set of molecules as SLOs 
(see section 1.4). However, it is important to note that the permissiveness of the tumour 
microenvironment is likely to have an effect on tumour-associated ELS development. For 
example, metastases from melanoma, lung and colorectal cancers induce a higher 
density of lymphoid aggregates than metastases from breast cancer [235]. Thus, tumour-
associated ELS are likely to differ between different types of cancer, depending on the 
permissiveness of the tissue to ELS formation, as well as between patients.  
Since ELS are typically seen as sites of T cell priming and antibody generation, it raises 
the question whether tumour-associated ELS are capable of inducing anti-tumour 
responses. The first example of this came from using tumour-specific antibody-LTa 
fusion proteins in mouse tumour models. Here, administration of antibody-LTa fusion 
protein resulted in a decrease in pulmonary metastases and increased survival. This was 
attributed to an increased T cell response and the development of lymphoid aggregates 
at the tumour site [236]. In addition, by using LTa-/- mice that lack lymph nodes it was 
found that the generation of tumour-specific T cells occurred in lymphoid aggregates at 
the tumour site, rather than being primed at SLOs [237]. In ELS that developed in 
melanoma, sequencing of immunoglobulin heavy chains revealed that B cells had 
undergone somatic hypermutation, class-switching and affinity maturation [228]. 
However, it was not determined whether the antibodies generated were directed against 
tumour antigens. In this context, studies of ELS in NSCLC identified the presence of 
germinal centre B cells, characterised by the expression of AID, Bcl-6 and Ki-67, as well 
as the presence of plasma cells that secreted antibodies against tumour antigens (e.g. 
NY-ESO-1, TP53, LAGE-1) [233]. The density of germinal centre B cells correlated with 
the density of plasma cells suggesting that these responses were generated at tumour-
associated ELS, rather than in the periphery [233]. Furthermore, in patients with NSCLC, 
the immune cell populations found within ELS were identified using flow cytometry and 
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differential expression of cell surface markers. Whilst the main populations present were 
memory cells, naïve T and B cells were also detected [233, 234]. Hence the activation 
and differentiation of naïve T and B cells could occur in tumour-associated ELS, 
promoting anti-tumour immunity.  
In this regard, there are examples where the development of tumour-associated ELS is 
associated with a favourable clinical outcome. For example, the targeting of LIGHT, an 
alternative LTbR ligand produced by activated T cells, to tumours using a vascular 
targeting peptide (VTP) resulted in the formation of intratumoural ELS, characterised by 
segregated T and B cell zones and PNAd+ HEVs [238]. Here, the development of ELS 
resulted in increased tumour infiltration of CD4+ and CD8+ T cells, loss of tumour cells 
and increased survival [238]. In colorectal cancer a high density of ELS correlated with 
improved patient survival [239, 240]. In NSCLC, a higher number of cytotoxic 
IFNg-generating CD8+ T cells were observed in patients that developed ELS and were 
associated with the presence of mature dendritic cells. Whilst patients with high levels of 
CD8+ T cells had improved survival, a further increase in survival was seen when 
combining high levels of CD8+ T cells with the presence of ELS [241]. Hence, tumour-
associated ELS may provide a microenvironment that allows CD8+ T cells to develop 
enhanced effector functions to support anti-tumour immunity. 
However, the presence of ELS is not always associated with favourable outcomes. In 
line with a role for Tregs in suppressing self-reactive T cells in SLOs, the presence of 
Tregs in ELS also has immunosuppressive effects. In primary breast tumours, high 
numbers of FoxP3+ Treg cells within ELS was associated with an increased risk of death 
[242]. In a mouse model of lung adenocarcinoma, the presence of Tregs in ELS 
suppressed anti-tumour responses. Importantly, Treg depletion led to T cell proliferation 
within ELS and generation of anti-tumour responses leading to tumour regression [243]. 
The presence of ELS also correlated with a poor prognosis in hepatocellular carcinoma. 
Here, the development of ELS was linked with NF-kB activation. Mice overexpressing 
IKKb in hepatocytes developed ELS and aggressive hepatocellular carcinomas. It was 
shown that ELS functioned as microniches providing survival and growth factors to 
support tumour progenitor cells until they egressed to form tumours [244].   
Thus, ELS characterised in cancer often show similarities with those seen in autoimmune 
conditions. However, their contribution to disease processes often differs. Therefore, 
there is a need to understand how these structures arise and whether the inflammatory 
context has a bearing on their involvement.   
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1.9 Aims 
The development of ELS is characteristic of chronic inflammatory diseases. They can 
develop at sites of tumourigenesis and in the synovium of patients with RA. In this regard, 
previous studies in our group have demonstrated the opposing role that IL-6 and IL-27 
have on synovial pathology. Here, Il27ra-/- mice develop exacerbated disease and the 
presence of synovial ELS. The work presented in this thesis aims to- 
1. Establish RNA sequencing of the inflamed synovium 
In order to identify transcriptomic changes associated with the development of ELS in 
inflammatory arthritis, RNA extraction from the synovium and cDNA library preparation 
must be optimised for RNA sequencing.  
2. Identify gene changes associated with the development of ELS during 
inflammatory arthritis 
Adopting a transcriptomic approach, experiments will explore the major inflammatory 
pathways and gene expression changes associated with the development of synovial 
ELS in Il27ra-/- mice. 
3. Investigate cross-disease mechanisms that govern ELS in inflammation 
Studies will characterise the development of ELS in a mouse model of gastric cancer 
and identify whether there are common mechanisms governing ELS development and 
activity across inflammatory arthritis and inflammation-associated cancer. 
4.  Target pathways associated with ELS development 
Mediators of ELS development identified through RNA sequencing will be targeted 
using a genetic and therapeutic approach to determine the effect on ELS development 
in inflamed tissues.  
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Chapter 2.  Materials and Methods 
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2.1 Reagents 
All chemicals were purchased from Sigma-Aldrich unless stated otherwise. Cell culture 
media and supplements were sourced from Gibco (ThermoFisher Scientific). Cells were 
routinely cultured in RPMI 1640 supplemented with 10% (v/v) fetal calf serum (FCS), 
2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate 
and 50 µM 2-mercaptoethanol unless indicated otherwise. 
2.1.1 Antibodies for immunohistochemistry 
Primary and secondary antibodies for immunohistochemistry are listed in Table 2.1.  
2.1.2 Antibodies for flow cytometry 
Fluorochrome-conjugated antibodies for use in flow cytometry are listed in Table 2.2. 
Matched isotype control antibodies were purchased from BD Biosciences.  
 
Table 2.1 – Antibodies for immunohistochemistry 
 
  
Target Primary Antibody Clone Company Secondary Antibody Company
CD3 Rabbit anti-human Polyclonal Dako Biotinylated swine 
anti-rabbit
Dako
B220 Rat anti-mouse RA3-6B2 BD Biosciences Biotinylated rabbit 
anti-rat
Dako
CD21 Goat anti-mouse D-19 Santa Cruz Biotinylated donkey 
anti-goat
Santa Cruz
Bcl-6 Rabbit anti-mouse N-3 Santa Cruz Biotinylated swine 
anti-rabbit 
Dako
pY-STAT3 Rabbit anti-mouse D3A7 Cell Signalling Biotinylated goat 
anti-rabbit
Vector 
Laboratories
CXCL13 Goat anti-mouse Polyclonal R&D Systems Biotinylated rabbit 
anti-goat
Dako
HEVs Rat anti-mouse MECA-79 In house Biotinylated rabbit 
anti-rat 
Dako
Ki67 Rabbit anti-mouse Polyclonal Abcam Biotinylated goat 
anti-rabbit
Vector 
Laboratories
Podoplanin Biotinylated Hamster anti-mouse 8.1.1 BioLegend NA NA
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Table 2.2 – Antibodies for flow cytometry 
 
  
Target Species Conjugate Clone Isotype Company
CD3 Hamster anti-
mouse
PE Cy7 145-2C11 IgG BioLegend
CD4 Rat anti-mouse eFluor 450        
PerCP Cy 5.5
RM4-5 IgG2a eBioscience
CD25 Rat anti-mouse PE PC61.5 IgG1 eBioscience
CD44 Rat anti-human/ 
mouse
APC IM7 IgG2b eBioscience
CD62L Rat anti-mouse FITC MEL-14 IgG2a eBioscience
CD8a Rat anti-mouse PerCP Cy 5.5 53-6.7 IgG2a eBioscience
CD11b Rat anti-human/ 
mouse
APC M1/70 IgG2b BioLegend
δγTCR Hamster anti-
mouse
APC eBioGL3 IgG eBioscience
RORγT Rat anti-human/ mouse
APC                     
PE AFKJS-9 IgG2a
eBioscience
NK1.1 Mouse anti-mouse FITC PK136 IgG2a
eBioscience
IL17A Rat anti-mouse PE TC11-18H10.1 IgG1 BD Biosciences
IL17A Rat anti-mouse Alexa Fluor 647  Alexa Fluor 488 TC11-18H10.1 IgG1
BioLegend
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2.2 In vivo studies of inflammatory arthritis 
2.2.1 Mice 
Experiments were performed using C57BL/6 wild-type, Il27ra-/- and Il6ra-/- mice. Wild-
type mice were purchased from Charles River. Il27ra-/- mice have been described 
previously and were originally sourced from The Jackson Laboratory (line B6N.129P2-
Il27ratm1Mak/J) [96]. In brief, a targeting vector was used to replace an exon encoding part 
of the extracellular fibronectin type III domain of the IL-27 receptor with a neomycin 
resistance (neo) cassette. Il6ra-/- mice were generated at GlaxoSmithKline (Stevenage, 
UK) using a traditional replacement vector to disrupt IL-6 recognition of the receptor by 
deleting exons 4, 5 and 6 [63]. Mice were bred and housed under specific-pathogen-free 
(SPF) conditions at Cardiff University. All experiments were carried out in accordance 
with Home Office approved project licences 30/2928 (2015-2017) and PB3E4EE13 
(2017-2019), with consideration of the 3 R’s (Replace, Reduce, Refine) [245]. 
2.2.2 Murine antigen-induced arthritis 
Antigen-induced arthritis (AIA) was established in 8-12 week-old male mice as described 
previously (Figure 2.1) [246, 247]. A methylated-BSA (mBSA)-specific immune response 
was generated by subcutaneous injection of an emulsion of mBSA in Complete Freund’s 
Adjuvant (mBSA/CFA) into the right flank (100 µl using a 1 ml syringe and 25G needle). 
The mBSA/CFA emulsion was prepared by mixing equal volumes of 2 mg/ml mBSA and 
CFA, before repeatedly passing through an 18G needle to form a white, stable emulsion 
(Figure 2.1B). At the same time, mice were also administered Bordetella pertussis toxin 
(160 ng in 100 µl) by intraperitoneal injection (1 ml syringe, 25G needle). Seven days 
later, mice received an identical subcutaneous booster immunisation of mBSA/CFA into 
the left flank.  
Inflammatory arthritis was triggered 21 days after initial immune priming by an 
intraarticular injection of mBSA (10 µl of 10 mg/ml) into the knee using a 29G insulin 
syringe (Figure 2.1A and C). Local joint swelling was measured using a POCO 2T 
micrometer (Kroeplin) to temporally monitor clinical signs of inflammatory arthritis. At 
defined time points, mice were killed under terminal anaesthesia or using a schedule 1 
method (CO2 followed by cervical dislocation). 
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Figure 2.1 - Antigen-induced arthritis. (A) Timeline of joint swelling and disease stages 
of antigen-induced arthritis. The priming phase establishes an antigen-specific T cell and 
antibody response to mBSA in the absence of synovitis. The acute response is marked 
by an early T cell response and the infiltration of innate leukocyte populations including 
neutrophils and inflammatory macrophages. The chronic-like phase of AIA features a 
prominent effector T cell response within the joint and regions of B cell infiltration. Arrows 
mark the time and routes of mBSA/CFA and Bordetella pertussis toxin administrations 
to induce AIA. Joint swelling is measured on days 0, 1, 2, 3, 7 and 10 post arthritis 
induction. (B) A stable mBSA/CFA emulsion suitable for immunisations will remain intact 
when dropped onto water (bottom box) and does not disperse (top box). (C) Intraarticular 
injections can be practiced using a dye. A successful injection can be visualised as a 
symmetrical distribution of ink around the patellar ligament. Adapted from Jones et al., 
2018. s.c., subcutaneous; i.p., intraperitoneal; i.a., intraarticular.  
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2.2.3 Collection of blood serum 
Whole blood was collected by cardiac puncture (1 ml syringe, 25 G needle). To recover 
serum, blood was incubated at room temperature for 30 min to allow coagulation. 
Samples were centrifuged (2,000 xg, 10 min, 4°C) and the serum carefully transferred 
to a sterile tube before being stored at -80°C.  
2.2.4 Preparation of knee joints for histology 
Whole knee joints were recovered by cutting through the bones proximal (femur) and 
distal (tibia and fibula) to the knee. Following the removal of skin, knees were placed into 
histology cassettes and fixed in 10% (v/v) neutral buffered formal saline, pH 7.4 at 4˚C. 
After 3 days, joints were transferred into 0.5 M EDTA, pH 8, for decalcification and the 
solution changed twice a week. Complete decalcification was confirmed by X-ray using 
a Kodak FX-Pro imaging system (Figure 2.2). Fixed and decalcified joints were 
processed and embedded in paraffin using the HistoCore PEARL and Arcadia H 
instruments from Leica Biosystems. Parasagittal serial sections of 7 µm were prepared 
using a Leica RM2235 rotary microtome. 
2.2.5 Haematoxylin, fast green and safranin O staining of tissue 
Tissue sections were de-waxed in three changes of xylene and rehydrated in decreasing 
concentrations of absolute ethanol - 100%, 90% and 70% (3 min each) before placing 
in distilled water. Synovitis and bone and cartilage erosion were evaluated after staining 
in haematoxylin, fast green and safranin O. Briefly, sections were first placed in Harris 
Haematoxylin (VWR International Ltd) for 5 minutes. Excess stain was removed under 
running tap water, and the sections transferred to 0.01% (w/v) fast green for 5 minutes. 
Samples were dipped briefly in 1% (v/v) acetic acid and incubated in 0.2% (w/v) 
safranin O for 5 minutes. After staining, sections were dehydrated through 70%, 90% 
and 100% absolute ethanol and cleared by three changes of xylene. Coverslips were 
placed onto stained slides using DPX mountant. 
2.2.6 Histological assessment of joint pathology  
Histological sections were scored for joint damage and inflammation by two independent 
observers blinded to the experimental design [69, 146, 246]. Haematoxylin staining was 
used to identify regions of synovial cellular infiltration, while proteoglycan staining by 
safranin O was used to detect erosion of the articular cartilage (Figure 2.3). The arthritic 
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index is the aggregate score for the inflammatory infiltrate, synovial exudate, synovial 
hyperplasia and cartilage/bone erosion, as outlined in Table 2.3.  
 
Figure 2.2 - Decalcification of knee joints. X-ray images of formalin-fixed mouse knees 
from an AIA experiment. A whole leg showing the presence of calcified bone can be seen 
on the left. Images on the right show knees (in histology cassettes) following EDTA 
decalcification. Images captured using a Kodak FX-Pro imaging system (Settings: 
Exposure, 30s; f-stop, 4.96; FOV, 200; focal plane, platen. 
 
Table 2.3 – Scoring criteria for histological assessment of joint pathology 
  
Synovial Infiltrate
0 Normal
1 Focal inflammatory infiltrates, adposity hardly affected
2 Focal inflammatroy infiltrate equals adiposity
3 Inflammatory infiltrate dominates cellular histology
4 Substantial inflammatory infiltrate with severe loss of adiposity
5 Ablation of adiposity due to inflammatory infiltrate
Synovial Exudate
0 Normal
1 Evidence of inflammatory cells in space
2 Moderate numbers of inflammatroy cells in space, with evidence of fibrin deposits
3 Substantial number of inflammatory cells with large fibrin deposits
Synovial Hyperplasia & Pannus Formation
0 Normal (1-3 layers thick)
1 Over three layer thick synovial lining and evidence of thickening and/ or invasion of joint 
space
2 Over three layer thick synovial lining 'creeping' over cartilage surfaces and/or finger-like 
processes into joint space
3 Over three layer thick synovial lining showng substantial covering of cartialge surfaces with 
evident cartilage loss
Cartilage & Bone Erosion
0 Normal
1 Detectable loss of cartilage detected by Safranin O staining
2 Detectable erosion of underlying bone by pannus activity
3 Pannus has destroyed a significant part of the bone
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Figure 2.3 - Histological assessment of AIA. Haematoxylin, fast green and safranin 
O staining of knee joints at day 10. Boxes highlight areas of inflammatory infiltrate (top), 
cartilage erosion (seen by loss of red safranin O staining; middle) and exudate (bottom). 
Scale bars: 600 µm.  
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2.2.7 Extraction of synovial RNA 
Inflamed synovial tissue was recovered by dissection under a microscope and was 
adapted from a protocol designed for the isolation of rat synovial tissue [248]. Synovial 
tissue was immediately placed into RNAlater (Ambion) and stored at -80°C. For recovery 
of RNA, synovium was removed from RNAlater and weighed. Total RNA was extracted 
by homogenising in 600 µl of RLT buffer (Qiagen) supplemented with 1% (v/v) 
β-mercaptoethanol, per 20 mg of tissue using a D1000 handheld homogeniser 
(Benchmark scientific). High-quality RNA was purified using a RNeasy Mini kit with 
on-column DNaseI digestion (Qiagen) according to the manufacturer’s instructions. The 
quality and quantity of eluted RNA was determined using a Nanodrop 2000 
spectrophotometer (ThermoFisher scientific) by measuring A260/280 and A260/230 
ratios, using absorbance measurements at 230 nm, 260 nm and 280 nm, to detect 
contaminating proteins and phenols respectively.  
2.2.8 Analysis of mBSA-specific immune responses 
Antigen-specific responses to mBSA were determined by measuring mBSA-specific IgG 
titres in serum (see section 2.8.1) and cellular cytokine responses following ex vivo 
mBSA restimulation. For the latter, inguinal lymph nodes were recovered and gently 
homogenised through sterile 40 µm cell strainers (Greiner Bio-one) to obtain single cell 
suspensions. Cells were resuspended in supplemented RPMI 1640 media and seeded 
in 96-well flat bottom plates at 5x105 cells/well. Cells were re-stimulated with 20 µg/ml of 
mBSA and incubated at 37°C for 72 hours. Culture supernatants were collected for 
analysis of cytokine secretion by ELISA as outlined in section 2.8.2. 
2.2.9 Isolation of joint-infiltrating leukocytes 
The inflamed synovium was dissected as described previously [248] and placed into 
supplemented RPMI 1640 media on ice. An enzymatic digest was performed to recover 
synovial leukocytes, using 1 mg/ml Collagenase type 4 (Worthington Biochemicals) in 
supplemented RPMI 1640 media. Digestion was performed at 37°C for 1-2 hours, with a 
gentle vortex every 15 min. Cells were passed through a 40 µm cell strainer to remove 
tissue debris, centrifuged (350 xg, 5 min), and resuspended in supplemented RPMI 1640 
media before proceeding with flow cytometric analysis (section 2.5).  
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2.3 Inflammation-associated gastric cancer 
2.3.1 Animals 
Experiments were performed using age-matched 4-week, 3-month and 6-month old wild-
type control mice and gp130Y757F:Y757F (gp130F/F) mice that spontaneously develop 
inflammation-associated gastric antrum adenomas [219]. At the molecular level, these 
mice have a knock-in phenylalanine mutation that replaces tyrosine residue 757 in the 
cytoplasmic domain of gp130. This disrupts the negative feedback imposed on gp130 by 
SOCS3. Six-month old gp130F/F mutant derivatives, heterozygous for Stat3 
(gp130F/F:Stat3+/-) or Il17a deficient (gp130F/F:Il17a-/-) were also used to investigate the 
role of STAT3 and IL-17A in tumour-associated ELS development. Mice were generated 
as previously described [219, 221, 249], were on a mixed C57BL/6 X 129/Sv background 
and were maintained under SPF conditions at the Hudson Institute of Medical Research 
(Australia). Experiments were performed in accordance with, and approved by, the 
Monash Medical Centre ‘A’ Monash University Animal Ethics Committee.  
2.3.2 Haematoxylin and eosin staining of stomach tissue 
Stomachs were dissected and fixed in 10% (v/v) neutral buffered formalin, pH 7.4, and 
embedded in paraffin at the histology facility at the Hudson Institute of Medical Research, 
before being shipped to Cardiff University. For initial histological assessment of tumour-
associated ELS, slides were stained with haematoxylin and eosin (H&E). Briefly, 
sections were de-waxed in three changes of xylene and rehydrated in decreasing 
concentrations of absolute ethanol before placing in distilled water (see section 2.2.5). 
Sections were placed in Harris Haematoxylin (VWR International Ltd) for 5 minutes and 
excess stain was removed under running tap water. Sections were blued by placing in 
1% (w/v) sodium bicarbonate for 30 seconds before placing in eosin for 5 minutes. After 
staining, sections were dehydrated through increasing concentrations of absolute 
ethanol and cleared by three changes of xylene (see section 2.2.5). Coverslips were 
placed onto stained slides using DPX mountant. For a comprehensive characterisation 
of the composition, cellular organisation and activity of tumour-associated ELS, 
immunohistochemistry was performed as outlined in section 2.7.  
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2.4 In Vitro T cell cultures 
Spleens were recovered by dissection and a single cell suspension generated by gently 
homogenising through a sterile 40 µm cell strainer (Greiner Bio-one) in supplemented 
RPMI 1640. Recovered cells were collected by centrifugation (350 xg, 5 min) and 
contaminating red blood cells were lysed by resuspension in RBC lysis buffer 
(BioLegend). To enrich for CD4+ T cells (typically >90% purity), cells were again collected 
by centrifugation (350 xg, 5 min) and CD4+ T cells were recovered by negative selection 
using a MACS CD4+ T cell Isolation Kit (Miltenyi Biotec) according to manufacturer’s 
instructions. This kit uses a cocktail of biotinylated antibodies to select non-CD4+ T cells. 
These cells are magnetically labelled using Anti-Biotin MicroBeads and separated from 
target CD4+ T cells using a magnetic column.  
Enriched populations of naïve CD4+CD25-CD44loCD62Lhi T cells were obtained by flow 
cytometry cell sorting. Briefly, CD4+ T cells (2 x 107 cells/ml) were treated with Fc Block 
(4 µg/ml; BD Biosciences), before incubation with fluorochrome-conjugated antibodies 
to CD4, CD25, CD44, and CD62L used at a final dilution of 1/200 (Table 2.2). Cell sorting 
was performed using a BD FACS Aria III (BD Biosciences) using the gating strategy 
presented in Figure 2.4. 
CD4+ T cells (1 x 105 cells/well) were cultured in Nunclon delta surface 96-well U-shape 
bottom plates (ThermoFisher scientific) in supplemented RPMI 1640 [63, 146]. For 
activation, cells were co-stimulated with plate bound anti-CD3 (1 µg/ml anti-CD3; clone 
145-2C11, R&D systems) and soluble anti-CD28 (5 µg/ml; clone 37.51, eBioscience). 
Cytokines were included at the following concentrations to promote differentiation of 
naïve CD4+ T cells into defined T helper lineages: For Th1 differentiation, IL-12 (20 
ng/ml); for Th2 cells, IL-4 (40 ng/ml); for Treg cells, TGFβ (5 ng/ml); for Th17 cells, TGFβ 
(1 ng/ml) and IL-6 (20 ng/ml), as indicated in the relevant sections. Where indicated 
anti-IL-2 was added at 10 µg/ml. Cells were incubated for 4 days at 37°C before staining 
by flow cytometry (section 2.5). Alternatively, cells were resuspended in 250 µl RLT 
buffer before purifying RNA using a RNeasy Mini kit (Qiagen) according to the 
manufacturer’s instructions. Gene expression was determined as outlined in section 2.6. 
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Figure 2.4 - Gating strategy for sorting of naïve cells. Lymphocytes were first 
identified based on their forward scatter and side scatter profiles. Single events were 
then selected based on the forward scatter area and height profiles. A disproportionate 
ratio between the area and height indicates multiple cells being acquired at the same 
time. Naïve T cells were then identified as CD4+CD25-CD44loCD62Lhi. 
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2.5 Flow Cytometry  
Flow cytometry was performed on cells recovered from inflamed joint tissue (section 
2.2.9) and draining lymph nodes (section 2.2.8) during AIA, and from CD4+ T cells 
cultured in vitro (section 2.4). To quantify the number of cells recovered from inflamed 
joint tissues and draining lymph nodes, cell counting beads (Life Technologies) were 
used as instructed by the manufacturer. 
2.5.1 Cell surface staining 
Cells were centrifuged (520 xg, 3 min) and resuspended in Zombie Aqua live/dead stain 
(BioLegend) in PBS for 5 minutes in the dark. Cells were washed twice in FACS buffer 
(0.5 % BSA, 5 mM EDTA, 7.5 mM Sodium Azide in PBS) and non-specific staining was 
prevented by incubating cells in 4 µg/ml rat anti-mouse CD16/CD32 (Fc block; clone 
2.4G2, BD biosciences) for 15 minutes. Cells were incubated in FACS buffer containing 
fluorochrome-conjugated antibodies specific to cell surface receptors (Table 2.2) at a 
working dilution of 1/200. Cells were washed twice (520 xg, 3 min) before resuspending 
in CellFix (BD Biosciences) and acquiring on a BD FACS Canto II (BD Biosciences). 
Data was analysed using FlowJo Version 10.  
2.5.2 Intracellular flow cytometry 
Before intracellular cytokine staining, cells were first stimulated (4 hours at 37°C) with 
50 ng/ml PMA and 500 ng/ml ionomycin in the presence of the Golgi protein transport 
inhibitor, monensin (3 µM). Live/dead staining, Fc block and labelling of cell surface 
receptors was performed as described in section 2.5.1, before proceeding with 
intracellular cytokine or transcription factor staining.  
Cells were fixed and permeabilised using Cytofix/Cytoperm (BD Biosciences) and 
washed twice with permeabilization wash buffer (BD Biosciences) according to 
manufacturer’s recommendations. Intracellular IL-21 staining was carried out as 
previously described [250]. In brief, IL-21 was detected using a soluble IL-21 receptor Fc 
followed by a goat anti-human f(ab)’-PE. Cells were then washed twice with 
permeabilization wash buffer and all other cytokines and transcription factors were 
labelled using fluorochrome-conjugated antibodies (Table 2.2) at a working dilution of 
1/100 for 30 minutes. Cells were again washed twice as above and resuspended in 
CellFix (BD Biosciences). Cells were acquired on a BD FACS Canto II (BD Biosciences) 
and data analysis performed using FlowJo version 10. 
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2.6 RNA expression analysis 
Analysis of gene expression was performed on RNA recovered from synovial tissue 
(section 2.2.7), T cells cultured in vitro (section 2.4), and stomach antrum and tumour 
tissue (section 2.3). For the latter, RNA was isolated from snap-frozen antrum and 
tumour tissue using TRIzol reagent (ThermoFisher scientific) and performed at the 
Hudson Institute of Medical Research. 
2.6.1 cDNA synthesis 
Reverse transcription of total RNA to cDNA was performed using a nanoScript 2 Reverse 
Transcription kit (Primerdesign) using random oligonucleotide primers. For all reactions, 
1 µg of RNA was used. Resulting cDNA was diluted by adding an equal volume of 
RNase-free water to obtain a final cDNA concentration of 25 ng/µl. For stomach antrum 
and tumour tissue a Transcriptor High Fidelity cDNA Synthesis kit was used (Roche). 
2.6.2 Quantitative real-time PCR 
Gene expression was quantified using TaqMan Gene Expression Assays (Applied 
Biosystems) in a MicroAmp Optical 384-well reaction plate (Applied Biosystems). The 
reaction was performed using 5 µl TaqMan Fast Advance Master Mix, 0.5 µl TaqMan 
Primers and Probes with the FAM-MGB reporter, 3.5 µl nuclease-free water and 1 µl of 
cDNA (generated as outlined in section 2.6.1) and amplified and acquired using the 
QuantStudio 12K Flex Real-Time PCR system (Applied Biosystems). Data was analysed 
using a comparative threshold cycle (Ct) method. This is the PCR cycle number at which 
the signal of the reporter crosses a set threshold in the exponential phase of 
amplification. Ct values for genes of interest are then standardised against an internal 
housekeeping control, whose expression is known to remain unchanged in different 
conditions. For all experiments genes were normalised against Actb. 
For stomach antrum and tumour tissue, SYBR Green chemistry (Applied Biosystems) 
was used to quantify gene expression. Detection of gene expression was performed 
using the 7900 HT Fast RT-PCR system (Applied Biosystems) and analysed using the 
Sequence Detection system version 2.3 software (Applied Biosystems) using a 
comparative threshold cycle method as described above. 
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2.7 Immunohistochemistry 
Immunohistochemical staining was performed on parasagittal serial sections of formalin 
fixed paraffin embedded knee joints (section 2.2.4) and formalin fixed paraffin embedded 
mouse stomachs (section 2.3.2). Sections were de-waxed in three changes of xylene 
and rehydrated in decreasing concentrations of absolute ethanol - 100%, 90% and 70% 
(3 min each) before placing in distilled water. Antigen retrieval was performed by heating 
sections at 95°C for 40 minutes in 10mM sodium citrate buffer containing 0.05% (v/v) 
Tween 20. Slides were allowed to cool to room temperature for 20 minutes before 
endogenous peroxidase activity was blocked using 3% (v/v) H2O2. Non-specific antibody 
binding was blocked by incubating sections with 10% (v/v) serum (Table 2.4) of the same 
species from which the secondary antibody was raised. For CD21 detection, a serum 
free universal protein block (CAS block; Invitrogen) was used. Primary antibodies (Table 
2.4) were incubated overnight at 4°C, in TBS (0.05 M Tris Base, 0.9% (w/v) NaCl, 0.05% 
(v/v) Tween 20), unless stated otherwise. Antibody labelling was detected using 
biotinylated secondary antibodies (Table 2.4) specific to the primary antibody. 
Visualisation of antibody labelling was performed using the Vectastain ABC kit and the 
3,3’-diaminobenzidine (DAB) staining kit (both from Vector Laboratories) according to 
manufacturer’s protocols. This system combines an avidin-conjugated horseradish 
peroxidase with DAB chromagen that precipitates at the site of antibody binding to yield 
a localised brown colour. Slides were counterstained in Harris Haematoxylin (1 min; 
VWR International Ltd) before coverslipping in DPX mountant. Sections were visualised 
using a Leica DM 2000 microscope and Leica Application Suite v4.9 software. Positive 
staining was quantified using the Leica QWin microscope imaging software, which 
quantifies the area of staining based on the number of brown DAB-positive pixels.  
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Table 2.4 – Working concentration of antibodies for immunohistochemistry 
 
 
 
  
Target Primary Antibody Working Concentration Secondary Antibody
Working 
Dilution Serum Block
CD3 Rabbit anti-human 3 μg/ml Biotinylated swine 
anti-rabbit
1/200 Swine
B220 Rat anti-mouse 0.31 μg/ml Biotinylated rabbit 
anti-rat
1/200 Rabbit
CD21 Goat anti-mouse 1 μg/ml Biotinylated donkey 
anti-goat
1/200 CAS block
Bcl-6 Rabbit anti-mouse 4 μg/ml Biotinylated swine 
anti-rabbit
1/200 Swine
pY-STAT3 Rabbit anti-mouse 0.8 μg/ml Biotinylated goat 
anti-rabbit
1/200 Goat
CXCL13 Goat anti-mouse 15 μg/ml Biotinylated rabbit 
anti-goat
1/200 Rabbit
HEVs Rat anti-mouse 5 μg/ml Biotinylated rabbit 
anti-rat
1/200 Goat
Ki67 Rabbit anti-mouse 1 μg/ml Biotinylated goat 
anti-rabbit
1/200 Goat
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2.8 ELISA 
2.8.1 Direct ELISA to measure mBSA-specific antibody titres 
Antibodies specific to mBSA in serum were measured as described previously [69, 146]. 
Costar half-well 96-well plates (Corning Inc.) were coated overnight with 5 µg/ml mBSA 
in PBS at room temperature. After washing in PBS containing 0.05% (v/v) Tween 20, 
nonspecific binding was blocked using 5% (w/v) milk extract in PBS containing 0.05% 
(v/v) Tween 20 for 1 hour. Multi-well plates were washed as above. Serum was diluted 
1/100 - 1/10000 in 5% (w/v) milk extract in PBS and added to the microplates for 2 hours 
at room temperature. After washing, mBSA-specific antibodies were detected using a 
horseradish peroxidase conjugated goat anti-mouse IgG (0.5 mg/ml, 2 hours, Dako). The 
chromogenic peroxidase substrate 3,3’,5,5’-tetramethylbenzidine blue (TMB; KPL Inc.) 
was used to quantify serum IgG binding to mBSA, before measuring absorbance at 
450 nm using a FLUOstar Omega plate reader (BMG Labtech). 
2.8.2 Detection of inflammatory cytokines by ELISA 
Inflammatory cytokine secretion into cell culture supernatants were quantified using 
commercially available ELISA kits from R&D Systems. All ELISAs were carried out 
following the manufacturer’s instructions and utilised a sandwich ELISA approach 
combining capture antibodies, detection antibodies and a range of protein standards at 
specified concentrations.  
2.9 Transcriptomic profiling of synovium 
For RNA sequencing of mouse synovium, RNA was extracted as outlined in section 2.2.7 
and quality determined on a Nanodrop 2000 spectrophotometer (ThermoFisher 
scientific) as well as an Agilent bioanalyser using an RNA Nano kit (Agilent 
Technologies). Libraries were prepared with 0.5 – 1 µg of total RNA. A poly (A) capture 
method using a Dynabead mRNA Direct Kit (Ambion) was used to isolate mRNA. 
Libraries were then prepared using the TruSeq Stranded Total RNA Library Prep Kit 
(Illumina) following the manufacturer’s instructions before sequencing on a HiSeq 4000 
(Illumina). A detailed description of the optimisation and establishing the methodology of 
RNA sequencing for analysis of inflamed synovial tissue is provided in Chapter 3, 
section 3.2. 
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2.10 Statistics 
Where pilot data was available, the appropriate sample size for experimental groups was 
determined by statistical power analysis using G*Power (http://www.gpower.hhu.de/) 
[251]. For in vivo studies where no preliminary data was available, pilot experiments were 
performed using small group sizes calculated in accordance with the resource equation 
[252]: 
E = N - T 
Where N = total number of animals, T = number of treatments/groups 
and E must be between 10 and 20. 
Statistical analysis was performed using GraphPad Prism software. Where studies 
comprised two experimental groups and the data was normally distributed, a Student’s 
t-test was used to determine statistical significance. For data that was not normally 
distributed a Mann-Whitney U-test was performed. To identify statistical significance 
between multiple groups for normally distributed data a one-way ANOVA with Tukey’s 
multiple comparison test was used. Where experimental groups were compared across 
multiple time points, a two-way ANOVA was used with a Bonferroni post-test. A p < 0.05 
was considered statistically significant. Graphs are presented as mean ± standard error 
of the mean (SEM) unless indicated otherwise. 
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Chapter 3. Development and optimisation of RNA 
sequencing of mouse synovium   
 54 
3.1 Introduction 
The transcriptome is the complete set of RNA transcripts found within a cell or population 
of cells. For example, the transcriptome can be investigated at a single cell, tissue or 
whole organism level. Understanding how the expression of transcripts change during 
disease can provide insight into the mechanisms that underpin disease progression and 
has the potential to identify novel biomarkers and therapeutic targets that improve patient 
stratification and treatment.  
The development of next generation sequencing (NGS) technologies such as RNA 
sequencing (RNA-seq) are now replacing ‘first-generation’ Sanger sequencing and 
hybridisation approaches, such as microarray methods, for genome analysis [253]. 
RNA-seq provides cheaper, faster and more accurate transcript quantification than 
previous approaches [254]. As an active area of development, RNA-seq can now be 
used to identify small RNAs, splice variants, low expressed transcripts and map 
transcription start sites, all from a small amount of starting material [255]. In this regard, 
the limitations of RNA-seq are ever changing with single-cell RNA-seq analysis now 
becoming mainstream. Furthermore, since RNA-seq directly determines the sequence 
of cDNA it can be used to identify novel transcripts, thus overcoming a limitation of 
microarray approaches [255]. These advantages of RNA-seq make it an ideal tool for 
interpretation of gene regulation in a disease setting. 
RA patients present with distinct synovial pathotypes that may influence the course of 
disease and the clinical response to frontline biological therapy [193]. Understanding 
how RNA transcript expression changes between these pathotypes could aid in the 
identification of therapeutic targets and novel biomarkers for patient stratification. 
Importantly, the use of RNA-seq to investigate mechanisms that regulate synovial ELS 
may also provide insight into how ELS are regulated in other inflammatory settings. 
This chapter describes the optimisation of RNA-seq methodologies for the evaluation of 
inflamed synovial tissue from a mouse model of inflammatory arthritis. In this regard, 
genetically modified IL-27R-deficient mice that develop lymphoid-rich synovitis featuring 
ELS will be compared to control wild type mice that display a diffuse pattern of leukocyte 
infiltration [146]. Mice deficient in IL-6 are protected from developing chronic joint 
inflammation [69, 88, 199, 256]. Previously uncharacterised IL-6R-deficient mice, that I 
hypothesise will similarly display a ‘low inflammatory’ phenotype, will also be 
investigated.  
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3.2 Materials and Methods 
3.2.1 Optimisation of extraction of high-quality RNA from the synovium 
Since RNA-seq required high-quality RNA, a comparison of different extraction methods 
was performed. For TRIzol extraction, synovium was removed from RNAlater (Ambion) 
and placed in 1 mL of TRIzol (Ambion) before being passed through a 19-gauge followed 
by a 21-gauge needle to disrupt the tissue. Once homogenised, 200 µl of chloroform was 
added per 1 mL of TRIzol before centrifuging (12,000 xg, 15 min). Following 
centrifugation, the mixture separates into an organic phase, containing DNA and 
proteins, and an aqueous phase, containing RNA. The aqueous phase was carefully 
removed and an equal volume of 70% ethanol was added. RNA was purified using a 
RNeasy Mini kit with on-column DNaseI digestion (Qiagen) according to the 
manufacturer’s instructions. Extraction of synovial RNA by homogenisation in a 
commercial lysis buffer was performed as outlined in section 2.2.7.   
3.2.2 Input RNA quality control 
Synovial RNA was extracted as outlined in section 3.2.1. The quantity and integrity of 
the purified total RNA was assessed using a NanoDrop 2000 spectrophotometer 
(ThermoFisher Scientific) and an Agilent 2100 Bioanalyser using an RNA Nano kit 
(Agilent technologies) following the manufacturer’s instructions. Samples with an RNA 
Integrity Number (RIN) greater than 8 were required for library preparation. The RIN 
value is a ratio of the 18S and 28S ribosomal RNA (rRNA) and therefore serves as a 
measure of the quality of the RNA. For library preparation 0.5 – 1 µg of total RNA was 
used as input.  
3.2.3 Removal of ribosomal RNA  
Ribosomal RNA (rRNA) was removed from samples by poly (A) capture using a 
Dynabead mRNA Direct Kit (Ambion). This method uses an oligo d(T) probe to bind the 
polyadenylated tail of mRNA. The probes are bound to magnetic beads in order to 
positively select the mRNA from RNA species that are not polyadenylated such as rRNA. 
Efficient removal of rRNA was confirmed on an Agilent 2100 Bioanalyser using an RNA 
Pico kit (Agilent technologies) following the manufacturer’s instructions.  
3.2.4 Library Preparation 
Libraries were prepared using the TruSeq Stranded Total RNA Library Prep Kit (Illumina) 
following the manufacturer’s instructions. This contained all reagents required for the 
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multiple steps involved in library preparation as outlined in figure 3.1. Libraries were 
prepared for three biological replicates for each genotype and time point in line with 
ENCODE guidelines [257]. 
Fragmentation. Purified mRNA was fragmented by heating to 94°C for a given amount 
of time as stated in the relevant passage of text. 
Reverse transcription and adapter ligation. A reverse transcription reaction was utilised 
to generate cDNA using a SuperScript II reverse transcriptase (Invitrogen). This was 
followed by a purification step using Agencourt AMPure beads (Beckman Coulter). 
These are magnetic beads coated with carboxyl groups, that in the presence of salt, bind 
to DNA. Sequencing adapters were then annealed to the purified cDNA. These serve as 
barcodes to identify samples when pooled, as well as primers for amplification on the 
flow cell prior to sequencing (Figure 3.2). A further magnetic bead purification using 
AMPure beads was utilised to remove adapter dimers and smaller artefacts. Here, the 
volumetric ratio of salt to DNA was critical. Since larger DNA fragments have a higher 
charge, they will bind to the beads at lower salt concentrations. Hence a low bead to 
DNA ratio results in binding of larger fragments, allowing adapter dimers and smaller 
fragments to be separated. This ratio was optimised for binding the correct sized 
fragments for sequencing. 
PCR amplification and library quantification. Ligated cDNA libraries were then PCR 
amplified and purified with a final magnetic AMPure bead clean. Libraries were assessed 
on an Agilent 2100 Bioanalyser using a high sensitivity DNA kit (Agilent technologies) 
following the manufacturer’s instructions. Final cDNA libraries were quantified by qPCR 
using DNA of known concentrations as directed in the KAPA Library Quantification Kit 
(KAPA Biosystems). Libraries were diluted to a final concentration of 10 pM and 
combined into a single pool. The pooled libraries were sequenced across multiple lanes, 
in order to remove bias derived from sequencing on different lanes, using a HiSeq 4000 
(Illumina) and pair-end sequencing (Figure 3.2). To conform to ENCODE guidelines 
libraries were sequenced to have greater than 30 million mapped reads [257]. 
3.2.5 Read mapping strategy 
A workflow for the mapping strategy of RNA-seq data is outlined in figure 3.3. Firstly, raw 
sequencing files (fastq files) were trimmed in order to remove adapter sequences and 
low-quality reads, since these would affect mapping to the genome. A quality control was 
then performed using the fastQC software (Babraham Institute) in order to determine the 
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quality of the sequencing. The sequencing files were then mapped to a reference 
genome (mm10/ gb38.90) using STAR software. STAR is splice aware, hence reads are 
able to map over splice junctions. Duplicate reads were identified and marked using 
Picard (Broad Institute) and further analysis performed to assess the quality of the 
libraries (e.g. number of reads, percentage duplication). Reads per gene were 
determined using the featureCounts software.  
3.2.6 Differential gene expression analysis 
To identify differentially expressed genes between two samples, a differential gene 
expression analysis was performed using the DESeq2 package (Bioconductor). Firstly, 
normalised read counts were calculated, which accounts for different depth of 
sequencing of individual samples. The fragments per kilobase of transcript per million 
mapped reads (FPKM) was then calculated from the normalised counts, which considers 
the length of the gene. Since analysis was focused on identifying changes in the same 
gene in different conditions the normalised counts were used to calculate fold expression 
changes and statistical analysis. 
3.2.7 Evaluation of duplicated reads 
To determine whether duplicate reads could potentially bias gene expression analysis 
within the data set the dupRadar package (Bioconductor) was used [258]. This package 
plots the number of duplicates per gene, identified using Picard (see section 3.2.5) 
against its fold change, calculated using the DESeq2 package as described in 
section 3.2.5. 
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Figure 3.1 - Workflow of RNA-seq library preparation. Total RNA is extracted from 
the synovium. A poly(A) capture method isolates mRNA from rRNA. RNA is fragmented 
into suitable sizes for sequencing before a reverse transcription reaction is utilised to 
form cDNA. Unique adapters are then added which served as barcodes to enable 
multiplexing of samples, as well as primers for amplification on the flow cell. Finally, 
cDNA libraries are amplified, before being quantified and sequenced.   
  
 59 
 
Figure 3.2 - Illumina HiSeq 4000 sequencing chemistry. The cDNA sequence is 
determined by a strategy termed ‘reversible terminator sequencing’. The flow cell 
contains primers that are complimentary to the adapters ligated on the cDNA library (1). 
Each fragment is then copied by bridge amplification (2). Clusters formed of thousands 
of copies of each fragment are made by rounds of amplification (4). Fluorescently 
labelled ‘terminator’ dNTPs are added to determine the sequence. The 3’ end of the 
dNTPs is blocked to prevent extension, to allow imaging of the fluorescence. The 
sequencing proceeds by removing the blocked 3’ end and fluorescent label. The next 
dNTP can then be incorporated, and the cycle continues to obtain the full sequence.  
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Figure 3.3 - Workflow of RNA-Seq data mapping. The process begins with raw 
sequencing files from Illumina sequencing. The resulting file format from each process 
is shown in a blue box. Reference files used to trim, map and assign gene lengths are 
shown as orange circles. The processes carried out are shown at each stage in bold, 
and the software used is shown underneath in italics. 
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3.3 Results 
3.3.1 Investigating control of synovial pathology by IL-27 and IL-6 
The IL-6 family cytokines, IL-6 and IL-27 are key cytokines that shape innate and 
adaptive immune responses within the inflamed synovium, albeit often with opposing 
actions [47]. Whilst the induction of inflammatory arthritis in Il6-/- mice results in reduced 
synovial leukocyte infiltration and joint damage compared to control WT mice [69, 88, 
199, 256], Il27ra-/- mice display exacerbated disease and the presence of ELS within the 
synovium [146].  
Before proceeding with RNA-seq evaluation of synovial inflammation in WT, Il27ra-/- and 
Il6ra-/- mice, I first determined whether my technical proficiency in establishing AIA 
resulted in joint pathology that was consistent with my laboratory’s previous 
observations. This was also an opportunity to determine whether previously 
uncharacterised Il6ra-/- mice, first described by our group [63], were protected from 
developing AIA thus being consistent with the amelioration of inflammatory arthritis 
observed in Il6-/- mice [69, 199, 256].  
Indeed, histological analysis of joint pathology at day 10 post arthritis induction revealed 
the presence of infiltrating leukocytes in WT and Il27ra-/- mice that were notably reduced 
in Il6ra-/- mice (Figure 3.4A). Evaluation of disease severity based on joint histopathology 
(arthritic index; Figure 3.4B) confirmed that Il6ra-/- mice were protected from developing 
chronic joint inflammation, displaying a reduction in inflammatory infiltrate, exudate and 
cartilage and bone erosion (Figure 3.4A and B). Consistent with the development of 
synovial ELS in Il27ra-/- mice, dense accumulations of CD3+ T cells were observed in the 
inflamed synovium of these mice (Figure 3.5A and B). Synovial ELS were characterised 
by the induction of homeostatic chemokines (Figure 3.5C) the presence of CD21+ 
follicular dendritic cells and Bcl-6, a marker of germinal centre B cells (Figure 3.5D) [146]. 
Evaluation of knee joint swelling during the course of AIA correlated with disease 
severity. Here, Il27ra-/- mice displayed increased joint swelling and Il6ra-/- mice had 
decreased swelling compared to WT mice (Figure 3.5E). Interestingly, Il6ra-/- mice had 
decreased mBSA specific serum IgG titres (Figure 3.5F), suggesting an impaired 
adaptive immune response in these mice. Thus, induction of AIA in my studies was 
consistent with previously described roles for IL-27 and IL-6 in regulating synovial 
histopathology and provided rationale for a transcriptomic evaluation of the discrete 
synovial pathologies seen in these mice.   
 62 
 
 
Figure 3.4 - Induction of AIA in WT, Il27ra-/- and Il6ra-/- mice. (A) Representative 
images of Haematoxylin and safranin O staining at day 10 of AIA. Boxed areas highlight 
regions of inflammatory infiltrate (top) and cartilage erosion (bottom), identified by loss 
of safranin O staining. (B) Histopathology scoring of AIA at day 10. (A, B) WT, n = 4; 
Il27ra-/- and Il6ra-/-, n = 5. Scale bars: (A) 500 μm. Graphs represent mean ± SEM. 
* p < 0.05; ** p < 0.01. 
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Figure 3.5 - Assessment of AIA in WT, Il27ra-/- and Il6ra-/- mice. (A) Representative 
images of immunohistochemistry for CD3 at day 10 of AIA. (B) The number of synovial 
ELS were quantified in synovial sections. (C) qPCR of indicated genes in WT and Il27ra-/- 
mouse synovium at day 3 of AIA. (D) Serial sections from Il27ra-/- mice stained for CD3 
and Bcl-6 (top) and CD3 and CD21 (bottom). (E) Swelling of knee joints following intra-
articular injection of mBSA. (C) mBSA specific antibody titres at day 10 post arthritis 
induction. (A) WT, n = 4; Il27ra-/- and Il6ra-/-, n = 5. (B) n = 8 / group. (C) n = 6 / group. 
Scale bars: (A) 250 μm. Graphs represent mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 
0.001; **** p < 0.0001.  
Panels B-D adapted from previously published work (Jones et al. 2015).  
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3.3.2 Optimising the extraction of high-quality RNA for sequencing 
To evaluate gene signatures associated with the different synovial pathologies observed 
in WT, Il27ra-/- and Il6ra-/- mice, whole tissue RNA-seq was employed. For RNA-seq, 
extracting high-quality RNA is paramount as it influences the ability to map reads to the 
genome; low quality RNA leads to poor mapping [259]. Therefore, RIN values greater 
than 8 are required. As such, optimisation of RNA extraction from the synovium was 
required. Trizol extraction (see section 3.2.1) yielded low quality RNA with RIN values of 
approximately 6 (Figure 3.6A), whilst homogenisation of synovium in a commercial lysis 
buffer (see section 2.2.7) yielded high quality RNA with RIN values between 8 and 9 
(Figure 3.6B). Therefore, homogenisation of synovium was used to extract total RNA for 
library preparation and sequencing. 
 
 
 
 
 
Figure 3.6 - Optimisation of RNA extraction from mouse synovium. (A-B) 
Representative bioanalyser traces comparing total RNA extraction from mouse 
synovium. Total cellular RNA was extracted using Trizol (A) or after homogenisation 
using a benchtop homogeniser (B) before further purification using a Qiagen RNeasy 
Mini Kit with an on-column DNaseI digestion. (A) Trizol extraction; RIN = 6.10. (B) 
Homogenisation; RIN = 8.70. 
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3.3.3 Optimisation of RNA-seq of mouse synovium 
An initial step in RNA-seq is the fragmenting of RNA into suitable sizes for sequencing. 
For the HiSeq 4000 platform, fragment sizes of approximately 260 bp to 280 bp are 
recommended. Thus, fragmentation of RNA into suitable sizes was optimised by 
incubating the recovered RNA for between 2 and 8 minutes at 94°C (Figure 3.7). 
Bioanalyser traces confirmed that an optimal peak size was obtained when fragmenting 
synovial RNA for 6 minutes. 
Libraries were then prepared as outlined in section 3.2. Initially rRNA was removed using 
magnetically labelled oligos specific to rRNA sequences. When placed in a magnetic 
field this removes rRNA and leaves all other RNAs (e.g. mRNAs, microRNAs, lncRNAs 
etc.) for downstream sequencing steps. A TruSeq Stranded Total RNA Library Prep Kit 
was used to generate cDNA libraries of optimal size (Figure 3.8A). Reads were mapped 
to the reference genome as outlined in section 3.2.5 and assigned an RNA classification. 
Figure 3.8B shows that a high proportion of reads mapped to rRNA genes suggesting 
an ineffective removal of rRNA during depletion steps. Consequently, this resulted in a 
high number of duplicated reads as there were highly abundant and repetitive sequences 
(Figure 3.8C). 
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Figure 3.7 - Optimisation of fragmentation time for synovial RNA. Total RNA was 
fragmented for the indicated amount of time. Libraries were made with resulting 
fragmented RNA and the peak size determined by running on a bioanalyser. Peak size 
for each product is indicated in base pairs. Optimal peak size for library preparation for 
the Illumina platform is approximately 260 - 280 bp. 
 
 
 
Figure 3.8 - Ribosomal RNA contamination of libraries resulted in poor coverage. 
(A) Representative bioanalyser trace of cDNA product after library preparation. Arrow 
shows the peak fragmentation size. (B) Proportions of protein coding genes (green), 
ribosomal genes (blue) and other genes (composed of lncRNA, microRNA; yellow) as 
assigned by Ensembl. (C) Summary statistics from RNA sequencing showing the 
number of read pairs and the percentage of the total number of reads. A high number of 
duplicated read pairs is highlighted in red.  
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3.3.4 Contamination of cDNA libraries by ribosomal species 
Given the high proportion of contaminating rRNA reads observed following sequencing, 
samples were visualised using a bioanalyser to determine the efficiency of the rRNA 
depletion step. A comparison of two rRNA depletion kits from different manufacturers, 
and a poly(A) capture kit for isolation of mRNA was also investigated. Whilst both rRNA 
depletion kits left peaks that correlated with 18S and 28S peaks in the resulting total 
RNA (Figure 3.9A), the poly(A) capture kit was efficient in removing these peaks (Figure 
3.9A), with significantly reduced (4%) contaminating rRNA (Figure 3.9B). Therefore, 
based on these optimisation studies, a poly(A) capture method to positively select mRNA 
species was chosen as the most appropriate method of library preparation for RNA-seq. 
3.3.5 cDNA library preparation using poly(A) capture of mRNA 
Library preparation was performed as outlined in section 3.2 using a poly(A) capture 
method to purify mRNA, followed by a TruSeq Stranded Total RNA Library Prep Kit. 
Resulting libraries were visualised on a bioanalyser trace and had an optimal peak size 
of 280bp (Figure 3.10A). Reads were mapped to the reference genome as outlined in 
figure 3.3 and assigned an RNA classification as in figure 3.8B. After changing to a 
poly(A) capture method, resulting in a more efficient removal of rRNA, approximately 
80-90% of reads mapped to protein-coding genes and less than 5% mapped to rRNA 
(Figure 3.10B). The decrease in rRNA content was further highlighted by a reduction in 
the duplication of reads (Figure 3.10C). A high percentage (98%) of reads were mapped 
to the reference genome indicating the high quality of input RNA.  
Further to this, quality controls performed during the analysis pipeline also showed a 
high quality of sequencing with a high accuracy of base calling (Figure 3.11A). For high 
complexity random libraries, an equal proportion of each base is expected (Figure 
3.11B-C). The initial 10 base pairs of sequencing are disproportionate due to sequencing 
of primers and adapters which are synthetic and not random (Figure 3.11B). 
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Figure 3.9 - Comparison of methods to remove ribosomal species from mouse 
synovium. (A) Representative bioanalyser traces of total RNA (top), after ribosomal 
depletion using two different commercially available kits (middle) and following poly(A) 
capture of mRNA species (bottom). The red boxed area highlights the 18s and 28s 
ribosomal RNA peaks. (B) Quantification of the remaining ribosomal RNA as a 
percentage of total RNA. 
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Figure 3.10 - Complete removal of ribosomal RNA by polyadenylation capture. (A) 
Representative bioanalyser trace of cDNA product after library preparation. Arrow shows 
the peak fragmentation size. (B) Proportions of protein coding genes (green), ribosomal 
genes (blue) and other genes (composed of lncRNA, microRNA; yellow) as assigned by 
Ensembl. (C) Summary statistics from RNA sequencing showing the number of read 
pairs and the percentage of the total number of reads. 
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Figure 3.11 - Quality of Sequencing determined by FastQC report. (A-C) 
Representative traces from a FastQC report showing the quality of the sequencing. (A) 
Box and whisker plot of phred quality scores of each base called at each position within 
a read. The red line represents the median value and upper and lower lines represent 
the 90% and 10% values. The blue line is the mean quality score. A phred score of 30 
means there is 99.9% accuracy in the base called. A phred score of 40 gives 99.99% 
accuracy. (B) Trace showing the percentage of each base at a position in the read that 
has been called. For a random library an equal proportion of each base is expected. (C) 
Comparison of the GC content of a library (red), compared to a normal GC distribution 
(blue). 
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3.3.6 Gene expression is not affected by duplication 
Duplicated reads can arise from two sources. PCR duplicates (i.e. the read originates 
from the same cDNA molecule) or from biological replicates (i.e. reads with identical 
sequences but from different cDNA molecules). Convention in RNA-seq is to include 
duplicated reads in the analysis as it does not typically skew data [260]. Consistent with 
this, dupRadar analysis within the Bioconductor package confirmed that duplicated reads 
within the data set did not bias differential gene expression. Here, the number of 
duplicates per gene showed no correlation with fold change of the gene (Figure 3.12). 
Duplicated reads were consequently included in the bioinformatic analysis reported in 
Chapter 4. 
 
 
Figure 3.12 - Gene duplication does not affect the gene expression. Representative 
plot showing how duplication of a gene effects the fold change of the gene. Plots were 
generated using the dupRadar analysis, within the Bioconductor package. The red 
dotted line indicates a log2 fold change of 0. 
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3.4 Discussion 
This chapter outlines, for the first time, the establishment of RNA-seq methodologies for 
the evaluation of synovial inflammation in an experimental model of inflammatory 
arthritis. The extraction of high-quality synovial RNA, fragmentation of the purified RNA, 
removal of rRNA and the preparation of cDNA libraries were key steps that required 
significant optimisation to generate high quality sequencing reads. 
Before proceeding with RNA-seq of the synovium I showed that my induction of the AIA 
model was consistent with previous studies in these mice. The Il6ra-/- mice had not been 
characterised in this model previously. Consistent with the reduced development of AIA 
in Il6-/- mice, and with the use of the anti-IL-6R monoclonal antibody, tocilizumab, for the 
treatment of clinical RA, Il6ra-/- mice displayed ameliorated inflammatory arthritis. 
Similarly, in agreement with a role for IL-6 in directing the transition from an innate to an 
adaptive immune response [64], Il6ra-/- mice showed reduced mBSA-specific antibody 
titres reflecting that observed in AIA-challenged Il6-/- mice [199]. However, while I 
hypothesised that Il6ra-/- mice would display a similar phenotype to Il6-/- mice, there are 
examples of where the IL-6R-deficient mice display different phenotypes to IL-6 knockout 
mice. In this regard, Il6-/- and Il6ra-/- mice show a difference in skin wound healing [261] 
and recovery from dextran sodium sulphate (DSS)-induced colitis [262]. This may relate 
to the description of p28, p28:CLF and ciliary neurotrophic factor as low affinity ligands 
for the IL-6R that may allow the receptor to have distinct biological activities to IL-6 [263-
265]. Therefore, the initial evaluation of inflammatory arthritis that I have undertaken in 
Il6ra-/- mice suggests a similar protected phenotype to that observed in Il6-/- mice. Further 
comparative investigations throughout the full time course of AIA would provide 
additional insight into how the IL-6R and IL-6 influence inflammatory arthritis 
progression. 
During the early optimisation of library preparations for RNA-seq, an interesting finding 
that required significant optimisation to overcome was the persistent presence of rRNA 
following depletion steps, despite testing a number of commercial rRNA depletion kits. 
This may suggest an enrichment of rRNA in the synovium, where the commercial kits 
may have been saturated with rRNA during depletion resulting in a failure to efficiently 
remove all rRNA from samples. However, additional experiments using decreasing 
levels of input RNA showed no improvement in the ability to efficiently deplete rRNA 
content (data not shown). Similarly, technical support from an Illumina representative 
encountered the same difficulty, suggesting that this was a tissue specific problem rather 
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than an error in methodology. Hence positive selection using poly(A) capture was used 
to isolate mRNA for sequencing. While this resulted in a loss of RNA species that lack a 
poly(A) tail (e.g., microRNA, linc RNA etc), identification of protein-coding genes 
associated with the development of synovial ELS was deemed the priority. 
An advantage of RNA-seq over hybridisation techniques is that depth of sequencing can 
be varied. As samples are sequenced to a greater depth more transcripts are identified 
and quantification is more precise [266]. In order to identify genes that have low 
expression levels, as well as highly expressed genes, samples were sequenced to a 
high depth (> 60 million paired-end reads). However, increasing the depth of sequencing 
can also result in increased background and duplication levels [267]. Duplicated reads 
can arise from two sources: PCR duplicates (i.e. the read originates from the same cDNA 
molecule) or from biologically relevant replicates (i.e. reads with identical sequences but 
from different cDNA molecules). The question remains whether removing duplicates 
results in improved accuracy by reducing background noise from PCR duplicates, or 
whether it reduces accuracy by removing biologically relevant replicates. In line with 
previous studies [260, 268, 269], the levels of duplication had no effect on differential 
gene expression. Consequently, read duplicates were retained in the analysis.   
In summary, this chapter describes the optimisation of RNA-seq methodologies to study 
gene expression changes in the synovium during inflammatory arthritis. This approach 
has the potential to reveal new mechanisms that govern the development and 
progression of joint inflammation, including ELS-rich synovitis, and identify new 
therapeutic targets and biomarkers that may improve the treatment of patients with 
inflammatory arthritis. 
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Chapter 4. Transcriptomic analysis of joint 
inflammation featuring synovial ELS  
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4.1 Introduction 
The synovitis associated with RA is highly heterogenous. Histological assessment of 
joint pathology identifies 3 broad classifications of synovitis termed ‘pauci-immune’, 
‘diffuse’ and ‘follicular’, where the latter is characterised by lymphoid-rich aggregates 
called ectopic lymphoid-like structures (ELS) [155, 193-195]. Importantly, synovial ELS 
act as sites of T cell priming and autoantibody generation (e.g. RF, ACPA). While this 
remains a controversial topic, the presence of synovial ELS in RA has been linked with 
an inferior response to biological drug therapies (e.g. anti-TNF inhibitors) and are 
associated with severe local and systemic inflammation [195-197]. At present, 
biomarkers for RA are lacking. While disease-specific autoantibodies such as RF and 
ACPA correlate with disease severity, they unreliably predict underlying joint pathology 
[193]. Identifying cytokine-regulated mechanisms that determine the development of 
distinct synovial pathotypes has the potential to define biomarkers for patient 
stratification and to identify novel therapeutic targets for the treatment of RA patients with 
ELS-rich disease. 
Transcriptomic approaches are now being used to investigate differences in gene 
expression between RA patients with defined forms of pathology in an attempt to improve 
patient stratification and treatment decisions [195]. For example, microarray analysis has 
identified 4 synovial phenotypes termed ‘myeloid’, ‘lymphoid’, ‘fibroid’ and ‘low 
inflammatory’ that display differential responses to biological drugs [195]. These 
phenotypes are comparable to those identified through histological approaches used to 
assess joint pathology [146, 155, 193-195]. However, the synovitis associated with RA 
does not always fall neatly into these broad classifications, and patients often display 
pathologies that lie between these definitions. Therefore, the use of genetically modified 
mice that display defined patterns of synovial histopathology may offer advantages in 
identifying the cytokine-driven mechanisms that promote these discrete forms of joint 
inflammation. 
The experiments outlined in this chapter will use optimised RNA-seq methodologies (see 
Chapter 3) to investigate joint inflammation in AIA-challenged WT, Il27ra-/- and Il6ra-/- 
mice that display histological features of synovitis that resemble those seen in RA [146]. 
Studies aimed to identify IL-27-regulated genes and pathways associated with the 
development of lymphoid-rich synovitis featuring ELS. 
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4.2 Methods 
4.2.1 Heatmaps 
Heatmaps were generated using Morpheus software available from the Broad Institute 
(https://software.broadinstitute.org/morpheus/). Heatmap visualisations used log2 fold 
change (log2FC) compared to a healthy WT control joint or a WT inflamed joint at an 
equivalent time point, as indicated in the text and figure legend. Data sets were 
hierarchically clustered using one minus Pearson correlation coefficient.  
4.2.2 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis (IPA; Qiagen) was used to identify canonical pathways 
associated with differentially regulated genes identified between genotypes and across 
the time course of AIA. Relevant pathways were determined by their p-value. 
4.2.3 K-means clustering  
Genesis software was used to perform K-means clustering. The optimal number of 
clusters was determined using statistical tests (Silhouette statistic and Gap method) and 
was performed in collaboration with Dr. Barbara Szomolay. The Silhouette and gap 
method provide a statistical measure of how individual genes behave in response to 
inflammatory activation. A high value indicates that genes displaying a similar profile of 
expression are appropriately grouped into clusters that share common patterns of 
regulation [270, 271].  
4.2.4 Gene Set Enrichment Analysis 
Gene Set Enrichment Analysis (GSEA) was performed using software from the Broad 
Institute (http://www.broad.mit.edu/gsea). Gene sets for effector T helper cell subsets 
(Th1, Th2, Th17 and Treg cells) and pathogenic Th17 cells are publicly available (GEO, 
GSE45975 and GSE39820 respectively) [272, 273]. Data sets were pre-ranked using 
the log2FC prior to GSEA. 
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4.3 Results 
4.3.1 Transcriptomic profiles reflect synovial pathology 
IL-6 and IL-27 are key cytokines that shape the inflammatory environment within the 
synovium during AIA. Using histopathological approaches, Il6-/- mice have previously 
been reported to be protected from developing inflammatory arthritis, with mice having 
reduced synovial infiltration and joint damage [69, 199, 256]. In Chapter 3, histological 
evaluation of synovitis in Il6ra-/- mice with AIA showed a similarly reduced profile of 
disease. In contrast, Il27ra-/- mice displayed exacerbated disease and the presence of 
ELS within the synovium at day 10 [146]. RNA-seq of synovium from WT, Il27ra-/- and 
Il6ra-/- mice was performed to identify transcriptomic changes associated with differences 
in synovial pathology. Here, samples clustered into two distinct groups: (i) genes 
expressed in naïve synovium across all genotypes and (ii) genes expressed post arthritis 
induction (Figure 4.1A). An interesting exception to this was synovial RNA-seq data from 
Il6ra-/- mice at day 10 of AIA, which clustered with the naïve samples and was therefore 
consistent with the reduced synovial inflammation observed in Il6ra-/- mice (see Figure 
3.4).  
While the aim of this study was to understand the cytokine-regulated mechanisms that 
control joint inflammation in each of these genotypes, we first determined whether 
differences were observed from the synovium of non-challenged WT, Il27ra-/- and Il6ra-/- 
mice. Very few differences were observed between tissues derived from WT and Il6ra-/- 
mice (50 differentially expressed genes; DEGs). However, there were 1198 DEGs 
observed when comparing naïve synovium from Il27ra-/- with WT mice (Figure 4.1B). 
Since genes expressed in naïve synovium clustered separately from inflamed synovium 
(Figure 4.1A) it was hypothesised that differences in baseline were not associated with 
inflammatory pathways. To confirm this, IPA was performed on DEGs, and the top 5 
pathways were associated with bone remodelling (e.g. Spp1, Col2a1, Mmp9), cell cycle 
regulation (e.g. Cdc25b, Wee1) and synthesis of amino acids and ribonucleotides (e.g. 
Pak3, Map3k9) (Figure 4.1C). Importantly, whilst some of these pathways included 
inflammatory mediators, these were not predominantly differentially regulated. 
Interestingly however, expression of the homeostatic chemokine, Cxcl13, was 
significantly increased in naïve synovium from Il27ra-/- mice (Figure 4.1D). Thus, whilst 
there were differences between naïve synovium from WT, Il27ra-/- and Il6ra-/- mice, these 
were not principally linked with the control of inflammation.  
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Transcriptomic analysis of the inflamed synovium from AIA challenged WT, Il27ra-/- and 
Il6ra-/- mice hierarchically clustered genes into those differentially regulated early in 
disease (day 3) and once synovial pathology was established (day 10) (Figure 4.2). 
Whilst there were gene expression differences between all three genotypes at day 3, 
more prominent differences were observed at day 10. Here, clusters of IL-27 regulated 
genes that may be uniquely expressed during the development of synovial ELS were 
observed (Figure 4.2). Additionally, Il6ra-/- mice displayed lower expression of a large 
number of genes prominently expressed at day 10 in WT and Il27ra-/- mice. This is 
consistent with the protected phenotype observed in Il6ra-/- mice, where histopathology 
revealed a reduced local adaptive immune response in inflamed joints and lower mBSA-
specific antibody titres (see Chapter 3). Interestingly a cluster of genes highly 
upregulated in Il6ra-/- mice at day 10 was identified (Figure 4.2). Since IL-6 controls the 
switch from an innate to adaptive immune response [64], I asked whether genes 
upregulated in Il6ra-/- mice at day 10 (Figure 4.3A) were associated with an impairment 
in this transition. Indeed, IPA analysis revealed the top 5 pathways were associated with 
innate signalling, cell adhesion and bone and matrix remodelling (Figure 4.3B and C). 
Genes identified within these pathways included Dkk1, an IL-6 regulated inhibitor of new 
bone formation [274], and Mmp12, a macrophage-expressed matrix metalloproteinase 
associated with synovial thickening and cartilage destruction [275]. Thus, the heightened 
expression of genes associated with innate immunity in Il6ra-/- mice, combined with a 
diminished adaptive immune response, suggests that the transition from innate to 
adaptive immunity in IL6R-deficiency is dysregulated. Together, these data show that 
the distinct patterns of synovial histopathology observed in WT, Il27ra-/- and Il6ra-/- mice 
are also associated with different transcriptomic profiles.  
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Figure 4.1 - Naïve synovium from WT, Il27ra-/- and Il6ra-/- mice have different 
transcriptomic profiles. (A) Relative expression of differentially expressed protein-
coding genes in WT, Il27ra-/- and Il6ra-/- mice in naïve synovium and at day 3 and day 10 
post induction of AIA (p < 0.05, log2FC > 1.5). Coloured bars highlight clusters of genes 
expressed during inflammatory arthritis (red) and those expressed in naïve synovium 
(green). Heatmap was clustered using one minus Pearson correlation. (B) The number 
of differentially expressed genes in naïve synovium of Il27ra-/- and Il6ra-/- mice when 
compared to a healthy WT control joint (p < 0.05, log2FC > 1). (C) The top 5 canonical 
pathways associated with the differentially expressed genes from panel B as determined 
by IPA. Representative genes comprising the pathways are also shown with expression 
determined by comparing to a healthy WT control joint. (D) Expression of Cxcl13, 
depicted as normalised read counts, in naïve synovium from WT and Il27ra-/- mice. OA, 
osteoarthritis.  
 80 
 
 
Figure 4.2 - Different transcriptional profiles are observed in the inflamed 
synovium of WT, Il27ra-/- and Il6ra-/- mice. Relative expression of differentially 
expressed protein coding genes (p < 0.05, log2FC > 1.5) between genotypes at day 3 
and day 10 of AIA when compared to a healthy WT control joint. Coloured bars highlight 
clusters of genes regulated at day 3 (blue), day 10 (purple), in Il6ra-/- mice (red) and in 
Il27ra-/- mice (green). Heatmap was clustered using one minus Pearson correlation.   
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Figure 4.3 - A cluster of highly expressed genes in Il6ra-/- mice are associated with 
innate immune responses. (A) Relative expression of the cluster of genes highly 
expressed in Il6ra-/- mice at day 10 of AIA (p < 0.05, log2FC > 1.5) when compared to a 
healthy WT control joint. Heatmap was clustered using one minus Pearson correlation. 
(B) The top 5 canonical pathways associated with the differentially expressed genes from 
panel A as determined by IPA. (C) Relative expression of genes comprising the 
pathways shown in panel B as determined by IPA. OA, osteoarthritis.  
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4.3.2 ELS-rich synovitis is associated with an increase in DEGs 
At day 3 of AIA, which precedes the development of synovial ELS [146], there were 111 
DEGs (50 upregulated, 61 downregulated) between Il27ra-/- and WT. In line with the 
previously described exacerbation of inflammatory arthritis observed in Il27ra-/- mice 
[146], 363 genes were differentially regulated at day 10. Whilst the number of 
downregulated genes was comparable to day 3 (64 genes), there was a large increase 
in the number of upregulated genes (299 genes) (Figure 4.4A and B). Surprisingly, Il6ra-/- 
mice had a large number of DEGs at both day 3 and day 10 compared to WT (Figure 
4.4A and B). Interestingly however, inflammatory genes prominently expressed in 
Il27ra-/- mice (e.g., Il17a, Il17f, Il21) were often downregulated in Il6ra-/- mice (Figure 
4.4A), which may reflect the often opposing outcomes that IL-6 and IL-27 have in 
adaptive immunity [47, 93, 105]. Therefore, exacerbated synovitis featuring ELS in 
Il27ra-/- mice was associated with an increase in transcriptomic output.  
We next used IPA to identify canonical pathways associated with the DEGs in Il27ra-/- 
and Il6ra-/- mice. At day 3, the relatively small number of DEGs identified in Il27ra-/- mice 
(see Figure 4.4) were linked with few pathways, that were primarily associated with 
innate immune involvement (Figure 4.5A). In contrast, at day 10 Il27ra-/- mice were 
enriched for pathways involved in T cell activation, effector responses, signalling and 
differentiation. Mice deficient in IL-6R were strongly enriched for pathways associated 
with fibrosis, macrophage and fibroblast responses, and osteoblast and osteoclast 
responses (Figure 4.5B). Thus, our transcriptomic analysis of the inflamed synovium 
reflects key features of synovial inflammation in these mice [69, 146] and is identifying 
key pathways consistent with previously defined roles for IL-6 and IL-27 in regulating 
fibrosis, osteoclastogenesis, innate immune regulation, T cell differentiation and effector 
characteristics [47].  
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Figure 4.4 - Synovitis featuring ELS in Il27ra-/- mice is associated with an increase 
in gene expression. (A) Volcano plots of gene expression profiles in Il27ra-/- and Il6ra-/- 
mice compared to WT mice at day 3 and day 10 of AIA. Dotted lines identify significant 
genes (log2FC > 1, p < 0.05). At each time point the 10 most upregulated (red) and 
downregulated (blue) protein-coding genes are shown. (B) The number of differentially 
expressed genes (log2FC > 1, p < 0.05) either upregulated (red) or downregulated (blue) 
in Il27ra-/- and Il6ra-/- compared to WT at day 3 and day 10 of AIA.   
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Figure 4.5 - IPA identifies IL-6 and IL-27 regulated pathways associated with 
synovial inflammation. (A-B) Dot plot of canonical pathways identified by IPA when 
comparing Il27ra-/- and Il6ra-/- synovium to WT synovium at day 3 (A) and day 10 (B) of 
AIA. The statistical significance of the pathway is represented by the size and colour of 
the dot. The diagonal red dotted line represents an equal significance of the pathway in 
both genotypes.   
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4.3.3 K-means clustering to identify patterns of gene behaviour 
While the IPA analysis of RNA-seq datasets described in the previous sections provide 
some insight into the regulation of AIA in WT, Il27ra-/- and ll6ra-/- mice, the large number 
of DEGs observed made interpretation of the data very challenging. To resolve this, 
K-means clustering was used to identify groups of genes that displayed similar patterns 
of expression across the time course of AIA. To first gain insight into how genes behaved 
in WT mice, the optimal number of clusters was determined using statistical tests. The 
silhouette method identified 2 or 3 gene clusters as optimal, whereas the gap statistic 
method identified 4 or 5 clusters as optimal (Figure 4.6A). Using these values as a guide, 
5 gene clusters were selected as these separated broadly into genes that were (i) 
upregulated to different extents (clusters 2 and 5), (ii) downregulated to a different 
degree (clusters 1 and 3), and (iii) appeared to selectively increase at day 10 (cluster 4) 
(Figure 4.6B).  
Canonical pathways associated with each gene cluster were determined using IPA. 
Cluster 1, comprised of genes associated with metabolic pathways such as the TCA 
cycle (e.g. Idhg3, Sdh) and oxidative phosphorylation (e.g. Atp5c1, Sdha) (Figure 4.7). 
Clusters 2 and 5 comprised genes that were upregulated in AIA and were highly enriched 
for genes involved in T cell activation, differentiation and signalling. These genes 
included effector cytokines (e.g. Ifng, Il17a, Il21, Il22, Tgfb), transcriptional regulators 
(e.g. Stat1, Tbx21), cell surface receptors (e.g. Cd40l, Cd274, which encodes the 
immune checkpoint PD-L1) and mediators of cell trafficking (e.g. Cxcl3, Icam1, Glycam1) 
(Figure 4.7). Cluster 4 transcripts, that were predominantly increased at day 10 of AIA, 
were enriched for fibrosis, bone remodelling and matrix remodelling pathways, 
highlighted by an increase in the expression of collagens (e.g. Col1a1, Col1a2, Col6a4, 
Col23a1), bone morphogenic proteins (e.g. Bmp1, Bmp15) and matrix 
metalloproteinases (e.g. Mmp2, Mmp11, Mmp23b) (Figure 4.7). Thus K-means 
clustering has allowed the identification of gene expression behaviours associated with 
the development of synovitis during AIA. 
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Figure 4.6 - K-means clustering of the synovial transcriptome during the time 
course of AIA. (A) Mathematical determination of the optimal number of clusters to use 
for K-means clustering using the silhouette and gap statistic methods. (B) K-means 
clustering of differentially expressed genes (log2FC > 1.5, p < 0.05) in WT mice across 
the time course of AIA when compared to a healthy control joint. The number of genes 
in each cluster is identified in the top left corner.   
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Figure 4.7 - Individual gene clusters in WT mice are linked with different canonical 
pathways. The top canonical pathways, as determined by IPA, associated with each 
cluster of differentially expressed genes (log2FC > 1.5, p < 0.05) in WT mice across the 
time course of AIA when compared to a healthy control joint. Examples of differentially 
regulated genes from each pathway are shown on the right.   
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4.3.4 ELS-rich synovitis is prominently associated with T cell pathways 
Having identified patterns of gene behaviour in WT mice with AIA, we next wanted to 
uncover genes associated with the development of synovial ELS. For this, the number 
of DEGs in Il27ra-/- mice relative to WT control mice over the time course of AIA were 
identified for each cluster (Figure 4.8A). Cluster 2 and cluster 5, which were associated 
with inflammatory pathways and T cell signalling in WT mice (see Figure 4.7), had the 
largest number of DEGs, accounting for 63% of the total number (Figure 4.8A). DEGs 
from these clusters were mostly upregulated at day 10 when ELS-rich synovitis is 
established in Il27ra-/- mice (Figure 4.8A). Pathway analysis of cluster 2 and cluster 5 
DEGs revealed an upregulation of T helper cell activation and cytokine signalling (Figure 
4.8B). These genes included effector cytokines (e.g. Il17a, Ifng, Il17f), cell surface 
receptors (e.g. Cd3e, Icos, Cd274, Il27ra) and transcriptional regulators (e.g. Stat1, 
Gata3, Tbx21). Notably, cytokine signalling associated with IL-17 regulation was greatly 
enriched in DEGs from cluster 5 (Figure 4.8B). For other clusters, a smaller number of 
DEGs were observed. Therefore, pathway analysis with fewer genes may have 
contributed to the lower significance observed (Figure 4.8B). Hence, synovial ELS 
development is associated with local upregulation of T helper cell activation and cytokine 
signalling.  
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Figure 4.8 - Canonical pathways associated with differentially expressed genes in 
Il27ra-/- mice. (A) The number of differentially expressed genes (log2FC > 1, p < 0.05) 
for each cluster in Il27ra-/- mice compared to WT mice at the same time point of AIA. 
Upregulated genes are shown in red and downregulated genes in blue. The number of 
differentially regulated genes is indicated above each bar. (B) Canonical pathways 
associated with each cluster of differentially expressed genes in Il27ra-/- mice, as 
determined by IPA. Examples of differentially regulated genes from individual pathways 
are shown on the right.   
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4.3.5 Adhesion and matrix remodelling pathways are linked with synovial ELS 
Whilst autoantibodies such as RF and ACPA correlate with disease severity they 
unreliably predict underlying joint pathology [193]. As such, biomarkers that can inform 
of underlying synovial pathology are lacking. Such biomarkers would have the potential 
to stratify patients according to synovial pathotype and inform of treatment decisions. 
Since genes in cluster 4 were uniquely upregulated in established disease, when ELS 
were present (see Figure 4.6B), we questioned whether DEGs in Il27ra-/- mice from this 
cluster may identify pathways and gene signatures characteristic of ELS. The highest 
number of DEGs were identified at day 10, with some genes being highly expressed 
compared to WT mice and others downregulated (Figure 4.9A and B). Prominently 
downregulated genes in Il27ra-/- mice included Erdr1, a negative regulator of cell 
migration and proliferation, whose overexpression in inflammatory arthritis has been 
shown to have a therapeutic effect [276, 277]. Interestingly another downregulated gene, 
Cd5l, has recently been implicated in regulating Th17 cell pathogenicity [278]. This may 
reflect the important role IL-27 plays in suppressing Th17-type responses. In contrast, 
genes that were upregulated were associated with cell adhesion (e.g. Madcam1, Msln, 
Cdh3) and matrix remodelling (e.g. Col9a3, Ibsp, Matn3). Hence these genes link 
canonical pathways with ELS-rich synovitis and may provide gene signatures with the 
potential to support the stratification of RA patients with this form of inflammatory arthritis. 
4.3.6 T cell pathways are enriched in ELS-associated disease 
T helper cell activation and cytokine signalling pathways were upregulated in DEGs from 
cluster 5 in Il27ra-/- mice (see Figure 4.8B). Figure 4.10A shows the genes within 
pathways and their expression compared to WT mice. Whilst genes show comparable 
expression between WT and Il27ra-/- mice at day 3, they are highly upregulated in Il27ra-/- 
mice at day 10. Given the opposing roles often played by IL-27 and IL-6 in the control of 
T cell responses, pathway analysis also included data from Il6ra-/- mice. As expected, 
the majority of these genes were downregulated in Il6ra-/- mice that develop a low 
inflammatory phenotype (Figure 4.10A). Of particular interest are the Th17-associated 
genes, Il17a, Il17f, Il21 and Il22 as well as the Th1 signature cytokine Ifng (Figure 4.10B) 
which are all highly expressed in Il27ra-/- mice at day 10. In contrast, in Il6ra-/- mice that 
fail to mount Th17 responses [63], expression of Th2-assocaited genes, such as Il5 and 
Il13, were more prominent. Interestingly, genes encoding key mediators of lymphoid 
organogenesis (e.g., Lta and Cxcl13), were also increased in Il27ra-/- mice (Figure 4.10A 
and B).   
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Figure 4.9 - Increased expression of adhesion molecules and matrix remodelling 
genes in Il27ra-/- mice. (A) The number of differentially expressed genes (log2FC > 1, 
p < 0.05) for cluster 4 in Il27ra-/- mice compared to WT mice at the same time point of 
AIA. (B) Heatmap of differentially expressed genes in Il27ra-/- mice from cluster 4 
compared to WT mice at the same time point. (C) Selected genes associated with 
adhesion molecules and matrix remodelling are plotted for WT, Il27ra-/- and Il6ra-/- mice 
when compared to a healthy WT control joint.  
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Figure 4.10 - T cell pathways are increased in ELS-associated synovitis. (A) 
Heatmap of genes that comprise differentially regulated canonical pathways from 
cluster 5, as determined by IPA. Gene expression is shown relative to a healthy WT 
control joint at the same time point. (B) Selected genes are plotted for WT, Il27ra-/- and 
Il6ra-/- mice when compared to a healthy control joint.  
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4.3.7 Synovial ELS development is associated with increased Th17 gene profiles 
The anti-inflammatory effects of IL-27 in adaptive immunity include its ability to inhibit 
IL-2 production and certain T cell responses [47, 91], whilst supporting the development 
of CXCR3+ Treg populations [102]. For example, IL-27 has been shown to inhibit Th17 
[279] and Th2 [98] responses and promote IL-10 secretion from T cells [103]. In 
inflammatory arthritis, DEGs from cluster 5 in Il27ra-/- mice were associated with the 
regulation of T helper cell cytokine expression, particularly IL-17 (see Figure 4.8B and 
Figure 4.10). Since IL-27 has complex roles in regulating CD4+ T cell responses, GSEA 
was used to determine enrichment for particular T helper cell subsets in these DEGs, 
using previously reported gene sets for Th1, Th17, Th2 and Treg cells (GSE45975) [273]. 
Here, DEGs were enriched for markers of Th17 cells when compared to Th2 and Treg 
cells (Figure 4.11). However, an equal proportion of genes were associated with a Th17 
and a Th1 phenotype (Figure 4.11). 
To further evaluate the role of T helper cells in ELS development, the total number of 
DEGs were mapped onto gene expression profiles of canonical T helper cell subsets 
from GSE45975 (Figure 4.12A) [273]. Genes were only included if differentially 
expressed in the dataset. Hence, in line with figure 4.11, Th1 and Th17 genes had a 
greater number of DEGs in inflammatory arthritis (Figure 4.12A). Expression of Th1 gene 
profiles were similar between WT and Il27ra-/- across AIA. (Figure 4.12A). These genes 
were mostly increased at day 3 and reduced to lower levels by day 10 (Figure 4.12B). 
However, expression of the Th1 signature cytokine, Ifng, was decreased in Il27ra-/- mice 
at day 3 compared to WT, consistent with the original observation that IL-27 promotes 
the production of IFNg [94, 95, 97, 98, 280]. In contrast, Ifng expression was increased 
at day 10 in Il27ra-/- mice compared to WT (Figure 4.12B and see Figure 4.4A). Similarly, 
expression of Tbx21 (T-bet), the master transcriptional regulator of Th1 cells, was also 
elevated at day 10. At day 3, Th17 profiles were increased in both WT and Il27ra-/- mice. 
Consistent with the role of IL-27 as an inhibitor of the Th17 programme, whilst Th17-
associated genes returned to lower levels by day 10 in WT, their expression was 
maintained and increased in Il27ra-/- mice (Figure 4.12A and B). In contrast, Th2 
signature cytokines, such as Il4 and Il5, were increased in Il6ra-/- mice (Figure 4.12B), in 
line with previous findings (see Figure 4.10) [281]. Hence these data highlight an 
increased and maintained Th17-type gene signature is associated with ELS 
development in Il27ra-/- mice. 
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Figure 4.11 - Enrichment of Th17 and Th1 genes in ELS-associated synovitis. (A) 
Gene set enrichment of differentially expressed genes from cluster 5 in Il27ra-/- mice 
analysed against previously reported gene sets for Th17, Th1, Th2 and Treg cells (data 
from GEO, GSE45975). The area under the curve highlights how enriched the data set 
is for a particular phenotype. NES; Normalised Enrichment Score. FDR q; False 
Discovery Rate q-value.  
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Figure 4.12 - Th17 cells are maintained in ELS-associated synovitis. (A) Heatmap 
of differentially expressed genes (log2FC > 1.5, p < 0.05) when compared to a healthy 
control joint mapped to the top 200 genes of each T helper cell subset. Genes for T 
helper cell subsets are only included if they were also differentially regulated in AIA (data 
from GEO, GSE45975). (B) Expression across the time course of AIA in example genes 
from each T helper cell subset from panel A for WT, Il27ra-/- and Il6ra-/- mice.  
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4.3.8 STAT3 transcriptional regulation correlates with ELS development 
STAT3 is a key transcriptional regulator of Th17 cell development [20]. Similarly, STAT3 
control of leukocyte infiltration is key to determining disease severity in inflammatory 
arthritis [69]. Hence, the association of STAT3 in ELS development within the inflamed 
synovium was evaluated using GSEA and previously identified STAT3 regulated genes 
from GSE40918 [282]. In this context, if STAT3 promotes the development of ELS-rich 
synovitis it was predicted that STAT3-induced genes would be increased in Il27ra-/- mice 
while STAT3-repressed genes would be decreased. At day 3, prior to the development 
of synovial ELS, genes identified as being induced by STAT3 were expressed in both 
Il27ra-/- mice and WT mice. Notably, STAT3-repressed genes were significantly 
decreased in Il27ra-/- mice compared to WT mice (Figure 4.13A). In line with a role for 
IL-27 in inducing IFNg expression [94, 95, 97, 98, 280], the repressed genes contained 
many IFNg-inducible genes such as Gbp4, Ccl4, Ccl3 and Igtp (Figure 4.13B). At day 10, 
once ELS were established, genes identified as being induced by STAT3 were highly 
enriched in Il27ra-/- mice. However, in contrast to day 3, genes identified as being 
repressed by STAT3 were also enriched in Il27ra-/- mice at day 10 (Figure 4.13C). 
Consequently, DEGs at day 10 did not appear to correlate with STAT3 activity. 
Importantly, induced genes comprised Th17 cytokines including, Il22, Il17a, Il17f, Il23r 
and Rorc (Figure 4.13D).  
  
 97 
 
Figure 4.13 - A STAT3 signature precedes ELS development. (A-D) GSEA using a 
set of genes previously reported to be STAT3 regulated (either induced or repressed; 
data from GEO, GSE40918). (A) GSEA plots for STAT3 induced or repressed genes at 
day 3 of AIA. (B) The expression (log2FC) of representative STAT3 regulated genes 
identified in panel A between Il27ra-/- and WT mice at day 3 of AIA. (C) GSEA plots for 
STAT3 induced or repressed genes at day 10 of AIA. (D) The expression (log2FC) of 
representative STAT3 regulated genes identified in panel C between Il27ra-/- and WT 
mice at day 10 of AIA. The area under the curve highlights how enriched the data set is 
in a particular phenotype.  NES; Normalised Enrichment Score. FDR q; False Discovery 
Rate q-value.  
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4.3.9 Joint-infiltrating CD3+ CD4+ Th17 cells are the main source of IL-17A 
Since synovial ELS were associated with a maintained Th17-type response (see Figure 
4.11 and Figure 4.12), I characterised the IL-17A secreting cells within the inflamed 
synovium of mice with AIA. For this, the isolation of joint infiltrating cells was optimised. 
Use of a collagenase digestion isolated a clear and viable CD3+CD4+ population that 
was lost when using mechanical disruption of the tissue (Figure 4.14A). Hence 
enzymatic digestion of synovial tissue was the preferred method for isolating joint-
infiltrating cells.  
Using the pan T cell marker, CD3, and a myeloid cell marker, CD11b, the majority of 
IL-17A producing cells were found to be CD3+ (Figure 4.14B). To determine the CD3+ 
population that was producing IL-17A within the joint, antibodies for CD4, NK1.1, CD8 
and gdTCR were used to discriminate T helper, natural killer, cytotoxic and gd T cells 
respectively. Whilst all CD3+ populations produced varying levels of IL-17A, the largest 
population (approximately 90% of CD3+ IL-17A-producing cells) were CD4+ cells 
(Figure 4.14C). Interestingly, the proportion and cellular distribution of IL-17A producing 
cells were comparable for all populations between WT and Il27ra-/- mice (Figure 4.14D 
and E). However, Il27ra-/- mice develop increased synovitis and heightened synovial T 
cell infiltration [146]. Consequently, there was a significant increase observed in the 
number of CD3+CD4+ IL-17A-producing cells within the joint (Figure 4.14F). Although 
only accounting for approximately 5% of IL-17-producing cells within the joint, a 
comparable increase was also suggested for gd T cells, albeit not statistically significant 
at the group sizes investigated. This data highlights CD3+CD4+ T helper cells as the main 
source of IL-17A within the inflamed joint during AIA, the number of which are increased 
in the synovium of Il27ra-/- mice. 
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Figure 4.14 - Joint-infiltrating CD3+CD4+ cells are the main producers of synovial 
IL-17A. (A-E) Flow cytometry analysis of joint infiltrating cells at day 10 of AIA. (A) 
Inflamed synovium was either digested in 1 mg/mL collagenase IV or mechanically 
disrupted to isolate joint-infiltrating cells. Successful isolation was determined by flow 
cytometric analysis of CD3+CD4+ T cells. (B-C) Flow cytometric analysis of joint 
infiltrating cells at day 10 of AIA isolated by enzymatic digestion of the inflamed synovium 
in 1 mg/mL collagenase IV. (C) Representative flow cytometry plots gated on IL-17A+ 
cells shown in red box in panel B. (D) Cellular distribution of IL-17-producing cells within 
the inflamed joints of WT and Il27ra-/- mice shown as a percentage of total. (E) The 
percentage of IL-17A-producing T helper cells in WT and Il27ra-/- mice. (F) The total 
number of IL-17A-producing T helper cells and gd T cells in WT and Il27ra-/- mice. (D-E) 
WT, n = 4; Il27ra-/-, n = 3. * p < 0.05.  
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4.3.10 A pathogenic Th17 cell signature is linked with ELS development 
Th17 cells display functional plasticity. For example, intestinal Th17 cells have a 
homeostatic role and adopt regulatory characteristics including the secretion of IL-10 
[283]. Conversely, Th17 cells drive the pathogenesis of experimental autoimmune 
encephalomyelitis (EAE), a model of multiple sclerosis, through secretion of 
pro-inflammatory mediators [284]. This has led to the notion of pathogenic and 
non-pathogenic Th17 cells. To identify whether ELS-rich synovitis was enriched for 
pathogenic Th17 cells, which have been linked with the initiation of inflammatory 
diseases, GSEA was performed using gene sets for pathogenic and non-pathogenic 
Th17 cells [272]. In this context, Th17 cells, expanded in vitro in different conditions, 
were deemed pathogenic if they caused the onset of EAE when adoptively transferred 
into mice [272]. Genes upregulated in Il27ra-/- mice at day 10 were highly enriched in a 
pathogenic Th17 signature (Figure 4.15A). The pathogenic signature comprised genes 
such as Cxcl3, Il22 and Icos, which were all upregulated in Il27ra-/- mice (Figure 4.15B). 
Similarly, T-bet (Tbx21), the master transcriptional regulator of Th1 cells, was associated 
with a pathogenic Th17 signature and was highly upregulated in Il27ra-/- mice (Figure 
4.15B) potentially highlighting the plastic nature of Th17 cells through their ability to 
acquire Th1 effector characteristics. Hence, these data revealed a pathogenic Th17 
phenotype that was associated with ELS-rich synovitis in IL-27R-deficiency.  
4.3.11 Regulation of ELS-associated chemokine expression by Th17 cells 
The homeostatic chemokine, CXCL13, is associated with ELS development in a number 
of inflammatory diseases [138]. Importantly, expression of Cxcl13 was upregulated in 
Il27ra-/- mice that develop synovial ELS [146] (see Figure 4.10B). Interestingly, 
expression of the signature Th17 cytokines Il17a, Il21 and Il22 all positively correlated 
with the expression of Cxcl13 in AIA (Figure 4.16A). Since the development of ELS was 
associated with an upregulation of IL-17-producing cells (see Figure 4.12 and Figure 
4.14), we determined whether these cells directly produced CXCL13. Interestingly, naïve 
CD4+ T cells expanded in vitro under polarising conditions for Th1, Treg and Th17 cells 
revealed Th1 cells as the most prominent CXCL13-producing subset (Figure 4.16B). In 
contrast to in vivo correlations, cultures that produced high levels of Il17a had decreased 
expression of Cxcl13 (Figure 4.16A and B). Thus, under these culture conditions, Th17 
cells do not secrete the lymphoid chemokine CXCL13.  
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Figure 4.15 - A pathogenic Th17 signature is associated with ELS development. 
(A) GSEA plots using genes upregulated in Il27ra-/- mice at day 10 of AIA compared to 
WT (log2FC > 1, p < 0.05). Upregulated genes were mapped to data sets previously 
reported to be differentially expressed between pathogenic and non-pathogenic Th17 
cells (data from GEO, GSE39820). (B) The expression in Il27ra-/- mice of representative 
pathogenic (red) and non-pathogenic (blue) genes presented relative to WT at day 10 of 
AIA.  
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Figure 4.16 - In vitro generated Th17 cells do not secrete CXCL13. (A) Correlation 
analysis in WT and Il27ra-/- mice of the expression of Th17 signature cytokines (Il17a, 
Il21 and Il22) and Cxcl13 as determined by qPCR. (B) Relative expression of Cxcl13, 
Il17a and Ifng, determined by qPCR, following the activation of naïve T cells in the 
presence of the indicated T-cell polarising cytokines for 48 hours. Th1 (IL-12, 20 ng/ml), 
Treg (TGFb, 2 ng/ml), Th17 (TGFb, 1 ng/ml and IL-6, 20 ng/ml). Where indicated 
anti-IL-2 was added at 10 µg/ml to support a more robust differentiation of Th17 cells. 
The expression of all genes has been made relative to an internal housekeeping gene, 
Actb.  
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4.4 Discussion 
The activities associated with ELS contribute to local T cell priming and antibody 
generation within inflamed tissues. The presence of synovial ELS in RA has therefore 
been linked with severe local and systemic inflammation, as well as inferior responses 
to frontline biological drug therapies such as anti-TNF inhibitors [195-197]. Hence, 
understanding the mechanisms underlying ELS development and maintenance within 
the inflamed synovium could aid in identifying improved therapeutic targets for the 
treatment of patients with ELS-rich synovitis. In this chapter, a transcriptomic approach 
was used to identify synovial gene expression changes in a novel model of inflammatory 
arthritis featuring synovial ELS. Here, ELS-rich synovitis was associated with a 
heightened T cell response within the inflamed joints of Il27ra-/- mice. Using GSEA and 
previously published gene signatures for defined T helper cell subsets, analysis identified 
a central involvement of pathogenic Th17 cell response in synovitis displaying ELS. 
Based on observations presented in Chapter 3, I also hypothesised that a transcriptomic 
evaluation of synovitis in Il6ra-/- mice would support my histopathological analysis that 
showed that these mice are protected from developing chronic joint inflammation during 
AIA.  
The success of the IL-6 receptor targeted monoclonal antibody tocilizumab for the 
treatment of RA has highlighted the important role IL-6 plays in RA progression [36]. 
Although Il6-/- mice have been shown to be protected from developing inflammatory 
arthritis [69, 199, 256], the development of AIA in Il6ra-/- mice has not previously been 
investigated. Whilst histological analysis performed in Chapter 3 revealed reduced 
disease severity and synovial T cell infiltration in Il6ra-/- mice, this chapter characterised 
gene expression changes associated with establishing AIA in these mice. Differences in 
the transcriptomic output between Il6ra-/- and WT mice were observed throughout the 
time course of AIA. However, hierarchical clustering revealed the most apparent 
changes to be observed at day 10. Here, Il6ra-/- mice showed a significant reduction in 
gene expression, reflecting the amelioration of chronic joint inflammation seen in these 
mice. Whilst I expected the Il6ra-/- mice to show a downregulation of genes compared to 
WT, to reflect the protected phenotype seen in these mice, there were also a lot of 
upregulated genes. This may suggest a different form of pathology in these mice, where 
hyperactivity of stromal and tissue-resident cells feature following the resolution of 
leukocyte infiltration. Interestingly, pathway analysis found that a cluster of genes highly 
expressed at day 10 in Il6ra-/- mice was primarily associated with innate signalling 
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pathways, consistent with the known role for IL-6 in promoting resolution of innate 
immune responses and the transition towards adaptive immunity [64]. Consistent with a 
role for IL-6 in promoting adaptive immune responses and the progression of arthritis, 
the expression of pro-inflammatory cytokines linked with effector T cell responses (e.g. 
Il17a, Ifng, Il17f, Il21) were also decreased in Il6ra-/- mice. However, the expression of 
the Th2 signature cytokines Il4 and Il5 were elevated in Il6ra-/- mice. While IL-6 has long 
been implicated in directing Th1 and Th2 responses [81], this observation supports 
previous data from our group that showed enhanced Th2 cell differentiation in Il6ra-/- T 
cells. Here, conditioned media recovered from peritoneal leukocytes stimulated with a 
cell-free bacterial supernatant supported Th2 cell differentiation in Il6ra-/- CD4+ T cells, 
while WT cells developed into Th1 effector cells [281]. Similarly, IL-6 derived from 
antigen presenting cells has been shown to inhibit Th2 differentiation. Here, CD4+ T cells 
co-cultured with IL-6-deficient bone marrow derived dendritic cells produced increased 
levels of IL-4 compared to cultures with WT bone marrow derived dendritic cells [285]. 
Together, this transcriptomic analysis of synovial pathology in Il6ra-/- mice supports an 
important role for IL-6 in promoting and maintaining adaptive immune responses and 
regulating the recruitment and effector characteristics of joint-infiltrating T helper cells. 
Transcriptomic analysis of synovial inflammation has allowed the identification of 
pathways associated with the induction of AIA. While many of the highly upregulated 
pathways were associated with inflammatory pathways, such as adhesion and 
chemotaxis, innate signalling and activation, T and B cell signalling and differentiation 
(discussed below), other pathways such as bone remodelling and metabolism were also 
altered. Interestingly there is evidence for a role of metabolic dysfunction in RA. 
Glycolytic enzymes such as glucose-6-phosphate isomerase, enolase and aldolase have 
been identified as potential triggers for loss of self-tolerance. These factors induced pro-
inflammatory cytokines and autoantibodies leading to the development of autoimmunity 
[286]. Additionally, analysis of serum samples from RA patients by mass spectrometry 
identified decreased levels of amino acids and glucose and increased levels of fatty acids 
and cholesterol [287]. Furthermore, lactate, produced by immune cells in high energy 
demands, has been shown to be increased in RA patients, increases IL-17 expression 
by CD4+ T cells and has been linked with the development of ELS [288]. Here, 
expression of SLC5A12, a co-transporter for lactate expressed on CD4+ T cells, 
correlated with synovial tissue T cell score and the presence of ELS [288]. However, 
metabolic pathways identified through IPA and associated with the induction of AIA in 
WT mice were not prominently changed in Il27ra-/- mice. However, expression of Cd5l, a 
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novel regulator of Th17 pathogenicity [278], was differentially regulated in Il27ra-/- mice. 
Loss of CD5L in pathogenic Th17 cells leads to alterations in fatty acid and cholesterol 
metabolism resulting in altered RORgt activity [278]. This is consistent with the recent 
identification of cholesterol metabolites (e.g., oxysterols) as putative ligands for RORgt 
[289, 290].  
By using pathway analysis tools and mapping DEGs to markers of T helper cell subsets, 
this study identified an increased Th17 response during ELS-associated inflammatory 
arthritis in Il27ra-/- mice. Th17-associated genes upregulated during ELS-rich synovitis 
included Il17a, Il17f, Il21 and Il22. Interestingly, Th17 cells have been linked to initiation 
of ELS development in other inflammatory diseases. For example, the development of 
ELS in the lungs (called inducible bronchus-associated lymphoid tissue; iBALT) was 
dependent on IL-17 production by CD4+ T cells in response to challenge with 
lipopolysaccharide (LPS) and Pseudomonas aeruginosa [142, 144]. However, ELS 
development can also be IL-17 independent. In this regard, following challenge with a 
replication deficient modified vaccinia virus Ankara, iBALT development was 
independent of IL-17A and IL-17F [144]. Whilst IL-17A is the signature cytokine for the 
Th17 cell subset, these cells also produce IL-21 and IL-22, which have been linked with 
ELS development in a model of salivary gland inflammation with Sjögren’s syndrome-
like characteristics [145, 147]. In this model, despite the production of IL-17A within 
inflamed salivary glands, IL-22 was the key determinant of ELS development within 
inflamed salivary glands. Here, IL-22 was produced locally in the salivary gland, firstly 
by gd T cells and then later by T helper cells. In the absence of IL-22, lymphoid 
aggregates were significantly smaller and had decreased expression of the homeostatic 
chemokines CXCL13 and CXCL12 [145]. Thus, Th17 cells have been implicated as 
propagators of ELS development, and while IL-17A is the signature cytokine of these 
cells, other cytokines linked with the Th17 programme are also emerging as regulators 
of ELS. 
STAT3 activation in inflammatory arthritis drives leukocyte infiltration and influences 
disease severity [69]. Using GSEA and publicly available datasets that define STAT3-
reulgated genes, a robust STAT3 signature was associated with ELS-rich joint 
inflammation in Il27ra-/- mice. In this regard, gp130Y757F:Y757F mice, that display 
hyperactive STAT3 signalling, developed increased synovitis that was associated with 
an elevation in the number of IL-17A-secreting cells within the joint [69]. This is consistent 
with a previous study that links the presence of synovial ELS with enhanced STAT3 
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activity [291]. In previous studies from my laboratory, significant phosphorylated-STAT3 
staining detected by immunohistochemistry was found within the joint, but not exclusively 
restricted to synovial ELS [146]. Thus, while STAT3 activity is strongly linked with joint 
inflammation during inflammatory arthritis, STAT3 remains a poor marker for ELS 
activity, likely due to its broad roles in orchestrating inflammation. 
Although most predominantly described as anti-inflammatory, IL-27 was first identified 
as an inducer of an IFNg secretion in T helper cells [94, 95, 97, 98, 280]. Transcriptomic 
analysis of joint inflammation in Il27ra-/- mice revealed decreased expression of Ifng, as 
well as IFNg-regulated target genes at day 3 post arthritis induction. Thus, these data 
were in line with the original description of IL-27 as a Th1-supporting cytokine. However, 
interestingly, Ifng was increased in Il27ra-/- mice at day 10 post arthritis induction. This 
latter observation is more consistent with the more recent understanding of IL-27 as a 
potent suppressor of effector T cell responses, through its negative regulation of IL-2 
signalling [100-105]. Therefore, this study suggests temporal differences in how IL-27 
regulates Th1 responses. Therefore, IL-27 may support ‘early’ Th1 cell commitment, but 
then later act to inhibit effector Th1 responses and support resolution of inflammation. 
Another factor contributing to the elevated expression of Ifng at day 10 of AIA may be 
the highly plastic nature of Th17 cells (Figure 4.17). Through GSEA we identified a robust 
pathogenic Th17 phenotype in Il27ra-/- mice, consistent with the known role of IL-27 as a 
potent inhibitor of Th17-type responses [105]. In addition, we identified differential 
expression of a novel regulator of Th17 cell pathogenicity, Cd5l [278]. Whilst pathogenic 
Th17 cells maintain characteristics of Th17 cells, such as Il22 expression, they can also 
express Tbx21 (T-bet), the master transcriptional regulator of Th1 cells [272]. In this 
regard, the acquisition of Th1 effector characteristics by Th17 cells can be required for 
pathogenicity. For example, adoptive transfer of pathogenic Th17 cells into mice during 
EAE causes high disease incidence and disease severity [272]. Using Il17a fate-reporter 
mice, plasticity of Th17 cells can be tracked. In a model of EAE, Th17 cells were found 
to gain expression of IFNg that contributed to disease progression [292]. Here, the pro-
inflammatory cytokines produced in the CNS were derived through plasticity of Th17 
cells, with only a limited contribution from classic Th1 cells [292]. Similarly, IL-23 driven 
induction of IFNg in Th1-like cells that were derived from Th17 precursors was required 
for the development of colitis [293]. In addition, Th17 cells can also acquire the effector 
characteristics of other T helper subsets. In lymphoid aggregates in the small intestines 
(called Peyer’s patches) migrating Th17 cells adopt a Tfh-like phenotype by inducing 
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expression of Bcl-6, IL-21 and CXCR5 [294]. These plastic ‘Tfh-like’ ex-Th17 cells 
induced the expression of AID, required for class-switching and somatic hypermutation, 
and supported the development of IgA producing germinal centre B cells [294]. However, 
plasticity towards a Tfh-like phenotype was not observed in EAE, suggesting that the 
local environment is an important mediator of plasticity [294]. Importantly, ex-Th17 cells 
that a adopt a Th1-like phenotype have been isolated from joints of RA patients. Here, 
polyfunctional and pro-inflammatory ex-Th17 cells secreted increased levels of IFNg, 
GM-CSF and TNF [295]. Taken together, this demonstrates that the plasticity of Th17 
cells could contribute to the pro-inflammatory environment that supports ELS 
development and may account for the increase in Ifng expression observed during the 
later time point of AIA.  
Homeostatic chemokines are required for SLO development and are also associated 
with ELS development in numerous diseases [138]. Given the prominent Th17 response 
within the joint, I hypothesised that these cells produce CXCL13. Whilst levels of Cxcl13 
correlated with the expression of Th17-associated cytokines within the inflamed joint, in 
vitro T cell cultures revealed that expression of Il17a in Th17-polarised cells was not 
linked with Cxcl13 expression. Here, IFNg-producing Th1 cells expressed the highest 
level of Cxcl13. This is in contrast to in vitro cultures with human CD4+ T cells where 
TGFb, a cytokine required for the differentiation of Th17 cells, was required for CXCL13 
secretion [296, 297]. In these studies, T helper cells cultured in the presence of TGFb 
and IL-6 produced high levels of CXCL13, whereas those differentiated in response to 
IL-12 saw minimal induction. Also, addition of anti-IL-2 increased expression of CXCL13 
[297]. Thus, the studies using mouse T cell cultures herein are in contrast to previous 
experiments that suggest human IL-17-producing T helper cells directly produce 
CXCL13. However, Th17-associated cytokines may regulate the release of homeostatic 
chemokines from stromal cells. In mucosal tissues, IL-17 and IL-22 have been shown to 
induce homeostatic chemokines in stromal cells to support ELS development [144, 145]. 
Interestingly, transcriptomic analysis comparing synovium taken from naïve healthy mice 
revealed that expression of Cxcl13 was increased in Il27ra-/- mice compared to WT mice. 
Notably, genes linked with inflammatory pathways were not a prominent feature at 
baseline. This suggests that IL-27 may inhibit CXCL13 production within the joint, 
potentially predisposing Il27ra-/- mice to developing synovial ELS once leukocyte 
infiltration is initiated. However, the molecular basis underlying the elevated expression 
of Cxcl13 in Il27ra-/- synovium at baseline requires further investigation.  
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Through the use of transcriptomic approaches, the data presented in this chapter has 
identified canonical pathways and gene signatures linked with ELS-associated joint 
pathology in experimental inflammatory arthritis. Based on these transcriptomic studies 
and growing evidence of a role for T helper cells in promoting ELS development, analysis 
of joint-infiltrating leukocyte populations confirmed the presence of a prominent Th17 cell 
response in Il27ra-/- mice with ELS-rich synovitis. Thus, our cellular analysis of the biology 
associated with synovial ELS mirrors prominent inflammatory pathways identified 
through transcriptomic analysis of joint inflammation. Thus, immunomodulation of the 
Th17/IL-17 axis may provide a novel therapeutic opportunity for the treatment of 
diseases featuring ELS. In this context, the following two chapters will identify the 
significance of targeting the Th17/IL-17 axis on ELS development by (i) using genetic 
ablation of IL-17A in a novel model of ELS development in gastric cancer (Chapter 5) 
and (ii) drug targeting of the Th17 axis in a model of inflammatory arthritis featuring 
synovial ELS (Chapter 6).  
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Figure 4.17 - Potential role for Th17 cells and T helper cell plasticity in supporting 
synovial ELS development. Upon induction of inflammatory arthritis Th17 cells are 
recruited from the lymph node and enter the joint. Upon inflammatory cues, such as 
exposure to IL-23, Th17 cells form ‘pathogenic’ Th17 cells that may contribute to joint 
pathology. Th17 cells can exhibit a high degree of plasticity and can take on effector 
characteristics typically associated with Th1 cells, leading to the secretion of a milieu of 
cytokines including IFNɣ and the homeostatic chemokine CXCL13. Unknown 
inflammatory mediators may also direct the plasticity of Th17 cells to a Tfh-like 
phenotype that supports antibody responses. The secretion of IL-21 and induction of AID 
in B cells, required for class-switching and somatic hypermutation, may support the 
development, maintenance and activity of ELS. AID; activation induced cytidine 
deaminase.  
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Chapter 5. IL-17 control of tumour-associated 
ectopic lymphoid-like structures 
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5.1 Introduction 
ELS can potentially develop in any tissue where persistent inflammation is present. 
Consequently, ELS have been observed in inflamed tissues affected by infection, 
autoimmunity, cancer and transplant rejection [118]. The diversity of tissues and clinical 
conditions where ELS have been described suggest that common, cross-disease 
mechanisms may be involved in regulating the development, maintenance and function 
of these inducible lymphoid organ-like compartments. The presence of tumour-
associated ELS in certain cancers have been linked with improved patient survival and 
positive prognosis; possibly through the ability to promote local anti-tumour immune 
responses at ELS [137]. Hence, immunomodulation of ELS to support anti-tumour 
immunity may represent an attractive approach to cancer treatment [238, 298, 299].  
In clinical gastric cancer, patients display heightened levels of the IL-6 family cytokine, 
IL-11, and increased STAT3 activation [217, 218]. Genetically modified gp130F/F mice 
have previously been generated as a clinically relevant model of gastric cancer [219-
221]. Hyperactivation of STAT3 in response to IL-11 in these mice leads to the 
spontaneous development of gastric antrum adenomas. Previous studies in the gp130F/F 
mouse model of gastric cancer revealed accumulations of uncharacterised cellular 
aggregates within the gastric submucosa [219-221, 249]. Whilst the presence of tumour-
associated ELS have been identified in numerous cancers, their role and development 
in gastric cancer is yet to be determined. 
In this chapter, I discover that gastric tumourigenesis in gp130F/F mice is associated with 
the development of highly organised ELS. The transcriptomic approaches outlined in 
Chapter 4 identified a pathogenic Th17 signature linked with synovial ELS in 
experimental inflammatory arthritis. This chapter aims to investigate whether a 
Th17-type response is similarly associated with the formation of tumour-associated ELS 
in gp130F/F mice. Through genetic ablation of the Th17 signature cytokine IL-17A, studies 
will investigate the importance of the Th17 axis in the development, maintenance and 
function of tumour-associated ELS.  
 112 
5.2 Materials and Methods 
5.2.1 Dual Immunohistochemistry 
Two-step immunohistochemistry was used for the detection of segregated T and B cell 
zones at ELS within the same tissue section. Antigen retrieval, endogenous peroxidase 
blocking, and serum blocking was performed as described in section 2.7. The first 
antigen, CD3, was detected by incubating with the primary anti-CD3 antibody (Dako; see 
Table 2.1) overnight at 4°C. Antigen labelling was detected using a biotinylated 
secondary antibody (see Table 2.1), the Vectastain ABC kit and DAB chromagen as 
outlined in section 2.7. The tissue was then blocked with appropriate serum before 
detection of the second antigen, B220, by incubating with an anti-B220 antibody (BD 
Biosciences; see Table 2.1) for 2 hours at room temperature. Antigen labelling was 
detected as above except using VIP chromagen (Vector Laboratories) for visualisation. 
Slides were counterstained and mounted as detailed in section 2.7. 
5.2.2 Peanut agglutinin staining of germinal centres 
For detection of germinal centre reactions, sections were prepared as in section 2.7. 
Following incubation in CAS block, slides were treated with biotinylated peanut agglutinin 
(Vector Laboratories) for 1 hour at room temperature. Peanut agglutinin is a plant lectin 
that recognises a galactosyl (b-1,3) N-acetylgalactosamine structure present on the 
surface of germinal centre B cells. Staining was visualised using the Vectastain ABC kit 
and DAB chromagen (both from Vector Laboratories) as detailed in section 2.7. 
5.2.3 The Cancer Genome Atlas 
Clinical information and sequencing data for patients with stomach adenocarcinomas 
were downloaded from The Cancer Genome Atlas (TCGA) data portal (TCGA-STAD) 
using the data transfer tool. This cohort comprised of 398 patient tumour cases, of which 
173 were histologically classified as having intestinal-type gastric cancer. Sequencing 
data from matched tumour and non-tumour tissue was available for 33 gastric cancer 
patients. Expression levels are represented by fragments per kilobase of exon per million 
mapped reads (FPKM). 
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5.3 Results 
5.3.1 Submucosal cellular aggregates are ectopic lymphoid-like structures 
Hyperactive STAT3 signalling in gp130F/F mice leads to the spontaneous development 
of gastric antrum adenomas characterised by elongated pits and enlarged glandular 
structures that are absent in WT mice (Figure 5.1A and B) [219-221, 249, 300]. These 
previous studies also identified the presence of cellular aggregates within the inflamed 
gastric submucosa. Consistent with these observations, our histological evaluation of 
stomach sections revealed the presence of cellular aggregates in the gastric submucosa 
of gp130F/F mice, which were absent in age-matched WT mice (Figure 5.1C and D). 
Immunohistochemistry was employed to determine whether these cellular aggregates 
display characteristics consistent with the appearance of ELS. Indeed, the cellular 
aggregates comprised a rich co-localisation of CD3+ T cells and B220+ B cells, a pattern 
typical of lymphoid organisation (Figure 5.2A). Whilst B cells were largely restricted to 
ELS, T cells were also found as diffuse infiltrates throughout the gastric submucosa 
(Figure 5.2A). Further immunohistochemistry revealed that the lymphocytic aggregates 
also contained CD21+ follicular dendritic cell networks and podoplanin (pdpn)-expressing 
cells, suggesting the presence of stromal cells required for lymphoid organ development, 
structural organisation and antigen presentation (Figure 5.2B) [143, 301]. Also present 
were CXCL13-expressing cells, marking the presence of a homeostatic chemokine 
required for spatial cellular organisation within lymphoid organs. Further to this, 
peripheral node addressin (PNAd)-positive cells were present (Figure 5.2B). PNAd is a 
sulphated and fucosylated glycoprotein found on high endothelial venules (HEVs) and 
acts as the receptor for CD62L (L-selectin) to allow the tethering and rolling of naïve and 
central memory T cells into lymphoid tissues. Thus, tumour-associated cellular 
aggregates that develop in gp130F/F mice are lymphoid-rich and display a composition 
consistent with ELS. 
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Figure 5.1 – gp130F/F mice develop submucosal cellular aggregates. (A) 
Representative appearance of stomachs from 3 month old mice. Stomachs were opened 
and pinned with the lumen facing the viewer. Arrows indicate tumours. Fundic (f) and 
antral (a) regions are labelled. (B) Representative haematoxylin and eosin (H&E) 
staining of stomach sections from 6 week old mice showing elongated pits and enlarged 
glandular structures. The mucosa (m) and submucosa (sm) are labelled. (C-D) 
Representative H&E staining of cross sections through the gastric antral tissue of wild-
type (WT; gp130+/+) and gp130F/F (FF) mice at 6 months of age (n = 4 / group). Boxed 
area in (A) shows submucosal cellular aggregates in gp130F/F mice. Scale bars: (A) 0.5 
cm, (B) 500 µm.  
Panels A and B adapted from previously published work (Judd et al. 2004 and Ernst et 
al. 2008).  
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Figure 5.2 – Submucosal cellular aggregates in gp130F/F mice are ELS. (A) 
Representative immunohistochemistry of CD3 and B220 in sequential sections showing 
co-localisation in gp130F/F mice at 6 months of age (n = 4). (B) Representative 
immunohistochemistry of CD21, podoplanin (Pdpn), PNAd+ HEVs (boxed area shows 
high power image) and CXCL13 in 6-month-old gp130F/F mice (n = 3). Scale bars: (A) 
500 µm; (B) 125 µm. 
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5.3.2 Tumour-associated ELS display functional germinal centres 
Next, studies were performed to identify whether the submucosal ELS observed in 
gp130F/F mice displayed markers of functional germinal centres. Consistent with the 
presence of CD21+ follicular dendritic cell networks (see Figure 5.2B), ELS displayed 
reactive germinal centres as determined by the co-localisation of peanut agglutinin 
staining with Bcl-6-positive cells (Figure 5.3A). Peanut agglutinin binds to glycosylated 
proteins found on germinal centre B cells, and Bcl-6 is the master transcriptional 
regulator of Tfh cells and germinal centre B cells. Consistent with the appearance of 
functional germinal centres, staining for the cell cycle antigen Ki-67 also suggested the 
presence of proliferating germinal centre B cells (Figure 5.3B). As shown in figure 5.2A, 
ELS were comprised of dense accumulations of T and B cells. Interestingly, dual 
immunohistochemistry for CD3 and B220 revealed the presence of compartmentalised 
ELS featuring T and B cell segregation (Figure 5.3C). Here, the B cell zone co-localised 
with peanut agglutinin staining at germinal centres (Figure 5.3C). However, ELS lacking 
compartmentalised T and B cell zones also showed reactive germinal centres, 
suggesting that ELS displaying less cellular organisation were also functional. 
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Figure 5.3 – Submucosal tumour-associated ELS in gp130F/F mice have functional 
germinal centres and display cellular segregation. (A) Representative 
immunohistochemistry of Bcl-6 and peanut agglutinin in serial sections. (B) 
Representative immunohistochemistry of Ki-67+ cells. (C) Representative dual 
immunohistochemistry for CD3 (purple) and B220 (brown) showing segregation into 
distinct compartments and co-localisation of B cell zones with peanut agglutinin staining. 
(n = 3 A-B, n = 2 C). Scale bars: (A) 500 µm; (B) 125 µm; (C-D) 250 µm.  
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5.3.3 Gastric tumourigenesis and ELS development are tightly coupled 
Since hyperactive STAT3 signalling in gp130F/F mice leads to the spontaneous 
development of gastric adenomas and submucosal ELS, experiments aimed to identify 
whether ELS developed prior to, or as a result of gastric tumourigenesis. Gastric 
adenomas spontaneously develop in gp130F/F mice by 6 weeks of age and develop into 
advanced tumours by 6 months of age [219, 249]. Therefore, we monitored the 
development of ELS by immunohistochemistry in 4-week, 3-month and 6-month-old 
mice. Indeed, immunohistochemistry for CD3 and B220 in 4-week-old mice revealed that 
ELS were absent. In 3-month and 6-month-old mice, ELS were identified as dense 
accumulations of T cells and B cells (Figure 5.4A). Lymphoid aggregates were quantified 
based on B220 staining, since B cells were mostly restricted to ELS (see Figure 5.2A). 
The number, total area and average area of aggregates were all increased in 3-month 
and 6-month-old gp130F/F mice compared to WT control mice (Figure 5.4B-D).  
Homeostatic chemokines play a key role in the development of secondary lymphoid 
organs and ELS [138]. To determine whether the temporal development of ELS was also 
reflected in the pattern of homeostatic chemokine expression, qPCR was performed on 
gastric antrum tissue from WT and gp130F/F mice (FFA). At the later time points of 3 and 
6 months, tumours from gp130F/F mice (FFT) were also examined. At 4 weeks of age, 
which precedes the development of gastric adenomas and ELS in gp130F/F mice, the 
expression of Cxcl13, Ccl21 and Cxcl12 in the gastric antrum was comparable to control 
WT mice, while Ccl19 was not detected (Figure 5.5A). Similarly, no difference was 
observed in the expression of Bcl6, the master transcriptional regulator of T follicular 
helper cells and germinal centre B cells. In 3-month and 6-month-old gp130F/F mice, the 
development of ELS was associated with heightened expression of Cxcl13, Ccl19 and 
Ccl21 in gastric antrum tissue (FFA) when compared to WT mice or tumours from 
gp130F/F mice (Figure 5.5B and C). Consistent with the detection of Bcl-6 at tumour-
associated ELS (see Figure 5.3A), Bcl6 transcripts were also increased in gastric antrum 
and tumour tissue from gp130F/F mice (Figure 5.5B and C).  
In inflammatory arthritis, IL-27 has an inhibitory effect on the development of synovial 
ELS [146]. To determine whether IL-27 may similarly control the development of tumour-
associated ELS, Il27 expression (which encodes for the IL-27p28 subunit) was examined 
in 6-month-old WT and gp130F/F mice. Levels of the Il27 transcript were comparable 
between WT and gp130F/F gastric antrum as well as in tumour tissue, suggesting that 
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ELS development in the gastric submucosa of gp130F/F mice was not due to a loss of an 
inhibitory IL-27 signal (Figure 5.5D).  
Together, these data suggest that temporal induction of homeostatic chemokines, 
required for the recruitment of hematopoietic cells and the spatial organisation of 
lymphoid organs and ELS, coincides with the development of gastric adenomas. 
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Figure 5.4 – Lymphoid neogenesis is temporally coupled to gastric tumour 
development. (A) Representative immunohistochemistry of CD3 and B220 in sequential 
sections at time points corresponding to pre (4-week-old), early (3-month-old) and 
advanced (6-month-old) gastric tumour development in gp130F/F mice. (B-D) 
Quantification, following B220 immunohistochemical detection, of the number (B), total 
area (C) and average area (D) of ELS in wild-type (WT) and gp130F/F (FF) mice (A-D: 
n = 3/group at 4 weeks, n = 3/group at 3 months, n = 6-8/group at 6 months). G; 
genotype –indicates a significant increase in lymphoid neogenesis in gp130F/F mice 
compared to WT. T; timepoint – indicates a significant change in lymphoid neogenesis 
across time. Graphs represent mean ± SEM. * p <0.05; *** p <0.001.  
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Figure 5.5 – Temporal induction of lymphoid chemokines coincides with ELS 
development. qPCR analysis of ELS-associated genes in the gastric antrum of gp130+/+ 
(WT) and gp130F/F (FFA) mice at 4 weeks (A), 3 months (B) and 6 months (C) of age. In 
gp130F/F mice with gastric cancer (3- and 6-month-old mice) gene expression was also 
determined in the gastric tumour tissue (FFT). In 6-month-old WT and gp130F/F mice, the 
expression of the cytokine Il27 (D) was also determined. (n = 4 per group at 4 weeks, 
n = 7 per group at 3 months, n = 6-7 per group at 6 months). Graphs represent 
mean ± SEM. * p < 0.05; ** p < 0.01; *** p < 0.001. (qPCR performed by Louise McLeod). 
The expression of all genes has been made relative to an internal housekeeping gene, 
Actb.  
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5.3.4 Gastric tumourigenesis and ELS development is STAT3 dependent 
The activation of STAT3 is emerging as a common feature associated with ELS 
development. The cytokines IL-6, IL-21 and IL-22 all activate STAT3, have previously 
been linked with ELS development and maintenance [145, 147, 302, 303], and were 
highly expressed in the inflamed joints of Il27ra-/- mice with synovial ELS (see Chapter 
4). Additionally, in gp130F/F mice, IL-11 signals through the IL-11Ra/gp130 complex to 
hyperactivate STAT3 causing gastric tumourigenesis [219-221]. To identify whether 
STAT3 activation correlated with ELS development, data from 161 intestinal-type gastric 
cancer patients, including 33 patients with matched non-tumour tissue was analysed 
from TCGA. In non-tumour tissue the expression of SOCS3, a STAT3 target gene, did 
not correlate with homeostatic chemokine levels (Figure 5.6A). However, in intestinal-
type gastric cancer patients a positive correlation was found between SOCS3 and 
CCL19, CCL21 and CXCL13 (Figure 5.6B). Further to this, immunohistochemical 
analysis identified STAT3-positive cells within lymphoid-rich aggregates in 3-month-old 
(Figure 5.7A) and 6-month-old (Figure 5.7B) gp130F/F mice. Notably however, STAT3 
activity was not restricted to ELS and was also detected in areas of diffuse inflammatory 
infiltrates (Figure 5.7C). Together these results show that tumour-associated ELS in 
gastric cancer correlates with STAT3 activity. 
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Figure 5.6 – STAT3 target gene SOCS3 correlates with lymphoid chemokine 
expression in human gastric cancer. Spearman rank correlation coefficients of ELS-
associated genes with the STAT3 target gene SOCS3 in 33 matched non-tumour tissue 
(A) and 161 intestinal-type tumour tissue (B) taken from TCGA gastric cancer cohort. 
Data presented as log2FPKMs. 
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Figure 5.7 – p-Y705STAT3 activity is not restricted to tumour associated ELS. 
Representative immunohistochemistry of CD3, B220 and p-Y705STAT3 in sequential 
sections in 3-month-old (A) and 6-month-old (B-C) gp130F/F mice (n = 3/group). Staining 
shows p-Y705STAT3 positive cells in lymphoid aggregates (A-B) and in surrounding 
diffuse areas of leukocyte infiltration (C). Scale bars: (A-C) 125 µm. 
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5.3.5 An ELS-chemokine gene signature is linked with advanced gastric cancer 
T and B cell priming within ELS have the potential to support local anti-tumour responses 
[229, 236, 237]. In certain cancers, including colorectal and melanoma, gene signatures 
of ELS have shown prognostic value [224, 230]. To determine the clinical relevance of 
ELS in gastric cancer, the expression of homeostatic chemokines, CXCL13, CCL19 and 
CCL21, that correlate with the development of ELS (see Figures 5.5 and 5.6), was 
investigated in intestinal-type human gastric cancer data sets from TCGA. Expression of 
ELS-associated chemokines was increased in patients with more advanced gastric 
cancer (stages ii, iii and iv) (Figure 5.8A), which is consistent with the temporal 
development of ELS observed in gp130F/F mice (see Figure 5.4). Additionally, compared 
to patients where tumour growth was confined to the submucosa (T1), increased 
expression of ELS genes was found in patients where the tumour had spread to the 
subserosal layer, serosa and nearby tissues (T2, T3 and T4 respectively) (Figure 5.8B). 
Despite an association between ELS gene expression and tumour growth, no 
association was observed between expression of these lymphoid chemokines and the 
degree of lymph node involvement (N stage) (Figure 5.8C) or metastasis (M stage) 
(Figure 5.8D). Similarly, no statistical significance was found between the ELS-
associated genes and patient survival. Interestingly a 3-gene ELS signature based on 
single sample gene set enrichment of the homeostatic chemokines CXCL13, CCL21 and 
CCL19 also showed a similar trend [304]. Thus, an ELS gene signature was associated 
with advanced gastric cancer in patients but was not predictive of a favourable outcome 
as has been observed in some forms of cancer.  
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Figure 5.8 – An ELS gene signature is associated with advanced gastric cancer in 
patients. Analysis of ELS-associated genes with tumour stage (A), tumour growth (B), 
N stage (C) and M stage (D) in 174 intestinal-type gastric cancer patients from TCGA. 
(E) Association between homeostatic chemokine expression and patient survival (n = 87 
per group). Data presented as log2FPKM. * p <0.05; ** p <0.01. 
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5.3.6 A Th17 gene signature correlates with ELS development 
In Chapter 4, a Th17 signature was found to be linked with synovial ELS development in 
an inflammatory arthritis model. Since hyperactivation of STAT3 was associated with 
ELS development in the gastric submucosa, (see Figure 5.6 and Figure 5.7) and that 
STAT3 activity is required for the differentiation of Th17 cells [20], we questioned the role 
of this effector T cell subset in ELS regulation. Given that the Th17-associated markers 
Il17a, Il23 and Rorc have previously been shown to be elevated in response to STAT3-
driven gastric tumourigenesis [249], and that gastric tumourigenesis and ELS 
development are tightly coupled (see Figure 5.4A), we investigated whether a Th17 
signature is associated with ELS in clinical disease. For this, using intestinal-type human 
gastric cancer datasets from TCGA, Th17-associated genes were correlated against the 
ELS-associated genes CXCL13, CCL21 and CCL19. Since the development of ELS in 
gastric cancer is observed in the submucosa and not intra-tumourally [304, 305], 
matched non-tumour tissue was used. The expression of the ELS-associated genes 
CXCL13 and CCL19 positively correlated with the expression of IL17A (Figure 5.9A), 
IL17F (Figure 5.9B) and CCR6 (Figure 5.9C), but little correlation was found between 
Th17 signature genes and CCL21 (Figure 5.9). Similarly, a 3-gene ELS signature was 
found to positively correlate with IL17A levels in TCGA datasets [304]. Thus, the 
development of ELS in gastric cancer is associated with the expression of Th17 signature 
genes. 
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Figure 5.9 – Markers of Th17 cell effector responses correlate with lymphoid 
chemokine expression in human gastric cancer. Spearman rank correlation 
coefficients of ELS-associated chemokine expression with the signature Th17 genes, 
IL17A (A), IL17F (B) and CCR6 (C) in 33 matched non-tumour tissue taken from TCGA 
gastric cancer cohort. Data presented as log2FPKMs. 
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5.3.7 Development of submucosal lymphoid aggregates is independent of IL-17A 
To determine whether IL-17A is required for ELS development, we looked for the 
presence of ELS by immunohistochemistry in gp130F/F mice that had been crossed with 
IL-17A deficient mice (gp130F/F:Il17a-/- ; FF:Il17; provided by Professor Brendan Jenkins, 
Hudson Institute, Melbourne). In the absence of IL-17A, lymphoid aggregates still 
developed in the submucosa and were comprised of dense accumulations of T and B 
cells (Figure 5.10A). Although not statistically significant, we did however note that 
gp130F/F:Il17a-/- mice appeared to develop fewer and smaller aggregates 
(Figure 5.10B-D) than those observed in gp130F/F mice. Since tumour-associated ELS 
development was shown to be STAT3 dependent (see Figures 5.6 and 5.7), gp130F/F 
mice were crossed with Stat3 heterozygous mice. By removing a single Stat3 allele, 
these mice have a reduced cellular pool of STAT3 available for phosphorylation [306]. 
As expected, this ‘normalisation’ of STAT3 activation in gp130F/F:Stat3+/- mice prevented  
gastric tumourigenesis and the associated development of ELS (Figure 5.10A-D), further 
suggesting a prominent role for STAT3 signalling in ELS development.  
Lymphoid aggregates in gp130F/F:Il17a-/- mice were further characterised to determine 
whether they showed features typical of ELS. Immunohistochemical analysis identified 
the presence of pY705-STAT3-positive cells and CXCL13-expressing cells. Also present 
were stromal cells expressing Pdpn, and PNAd-positive HEVs (Figure 5.11A). Hence 
lymphoid aggregates in gp130F/F:Il17a-/- mice displayed characteristics consistent with 
the formation of ELS.  
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Figure 5.10 – Formation of submucosal lymphoid aggregates is STAT3 dependent 
but independent of IL-17A. (A) Representative H&E and immunohistochemistry of CD3 
and B220 in sequential sections from WT, gp130F/F (FF), gp130F/F:Stat3+/- (FF:St3) and 
gp130F/F:Il17a-/- (FF:Il17) mice at 6 months of age. (B-D) The number (B), total area (C) 
and average size (D) of lymphoid aggregates were quantified in each strain (n = 6 WT, 
n = 5 gp130F/F, n = 4 gp130F/F:Stat3+/- , n = 4 gp130F/F:Il17a-/-). Scale bars: (A) 500 µm. 
Graphs represent mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.  
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Figure 5.11 – Characterisation of tumour associated lymphoid aggregates in 
gp130F/F:Il17a-/- mice. (A) Representative immunohistochemical staining of 
p-Y705STAT3, CXCL13, Pdpn and PNAd+ HEVs (boxed area shows high power image) 
in gp130F/F:Il17a-/- mice at 6-months of age (n = 3). Scale bars (A) 500 µm. 
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5.3.8 IL-17A is required for the development of functional ELS 
Reactive germinal centres that mark active B cell proliferation, differentiation and 
maturation of the antibody response through somatic hypermutation and class-switching, 
are key features of functional ELS [137]. For example, ELS in non-small cell lung 
carcinoma were comprised of germinal centre B cells that expressed AID, the enzyme 
required for class-switching and somatic hypermutation of antibodies, as well as plasma 
cells that produced tumour-specific antibodies. These were linked with improved patient 
survival [233]. Similarly, ELS in the synovium of rheumatoid arthritis patients have been 
shown to express AID, and its expression correlates with the production of 
autoantibodies such as ACPA [155]. To identify whether the lymphoid aggregates in 
gp130F/F:Il17a-/- mice represent bona fide functional ELS, immunohistochemistry was 
performed to detect CD21+ follicular dendritic cell networks and germinal centre B cells 
using peanut agglutinin. Whilst tumour-associated ELS in gp130F/F mice displayed 
reactive germinal centres (Figure 5.12A), loss of IL-17A resulted in lymphoid-rich 
aggregates that lacked CD21+ follicular dendritic cell networks and peanut agglutinin-
stained germinal centres (Figure 5.12A-C). Thus, despite the development of 
submucosal lymphoid aggregates in gp130F/F:Il17a-/- mice, these lack reactive germinal 
centres that mark mature and functional ELS.  
  
 133 
 
 
Figure 5.12 – Il17a is required for functional tumour-associated ELS. (A) 
Representative immunohistochemistry staining of peanut agglutinin and CD21 in 
gp130F/F (FF) and gp130F/F:Il17a-/- (FF:Il17) mice at 6 months of age. (B-C) Quantification 
of peanut agglutinin (B) and CD21 (C) staining in 6-month-old gp130F/F (FF) and 
gp130F/F:Il17a-/- (FF:Il17) mice (n = 3/group). Scale bars: (A) 500 µm. Graphs shown as 
mean ± SEM. ** p <0.01; **** p <0.0001. 
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5.3.9 Expression of IL-17A is not predictive of patient outcomes or stage of 
gastric cancer in clinical disease 
Our studies above suggest that IL-17A is important for the development of functional 
tumour-associated ELS, which may be important in establishing local anti-tumour 
responses. Using TCGA datasets for intestinal-type gastric cancer, we questioned 
whether IL17A expression was associated with patient survival or the stage of the 
disease. Despite IL-17A being necessary for germinal centre activity in gp130F/F mice 
(see Figure 5.12), IL17A expression showed no correlation with the stage of gastric 
cancer, or the degree of lymph node involvement and metastasis (Figure 5.13A). 
Similarly, no difference in survival was found between patients with high and low 
expression of IL17A (Figure 5.13B). Thus, the expression of IL17A was not associated 
with clinical disease progression, nor does it have prognostic significance.  
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Figure 5.13 – IL17A expression has no prognostic significance in gastric cancer 
patients. (A) Evaluation of IL17A expression with tumour stage and indicated TNM stage 
in 174 intestinal-type gastric cancer patients from TCGA. (B) Association between IL17A 
gene expression and patient survival (n = 87 per group). Data presented as log2FPKM.    
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5.4 Discussion 
Tumour-associated ELS have recently been identified in numerous cancers. In many 
cases the number of ELS positively correlates with patient survival, and it has been 
proposed that tumour-associated ELS represent immune privileged areas that can limit 
cancer progression [137, 138]. Hence, there is renewed interest in understanding the 
immune mechanisms underlying their development in order to enhance anti-tumour 
immunity [238, 298, 299]. 
In this chapter, a clinically relevant mouse model of gastric cancer was used to show that 
the temporal development of gastric tumourigenesis coincided with ELS development. 
Through immunohistochemical analysis, these immune cell aggregates were shown to 
be functional ELS displaying T and B cell segregation, with peanut agglutinin- and Ki-67-
positive germinal centres. In addition, the temporal development of ELS was associated 
with the induction of homeostatic chemokines (Cxcl13, Ccl19 and Ccl21). Hence, 
tumour-associated lymphoid aggregates that develop in the gastric submucosa of 
gp130F/F mice display characteristics consistent with those of functional ELS.  
During the course of this work another group also highlighted the presence of ELS in 
tumour biopsies from gastric cancer patients [305]. Here, ELS were characterised as 
having segregated T and B cell zones, Ki-67+ proliferating B cells, typically found in 
germinal centres, and PNAd+ HEVs, required for the recruitment of lymphocytes into 
lymphoid tissue. The histological presence of CD20+ immune aggregates, high tumour 
infiltration of T-bet+ Th1 cells and low infiltration of FoxP3+ Treg cells correlated with 
improved relapse-free survival [305]. Thus, the progression of gastric cancer was 
influenced by the presence of ELS.  
Recently, in melanoma [230] and colorectal cancer [224], gene signatures of ELS were 
discovered as prognostic indicators of increased patient survival. In this chapter, 
expression of homeostatic chemokines linked with the development of ELS were 
increased in advanced gastric cancer patients but showed no prognostic significance. A 
more comprehensive evaluation of tumour-associated ELS, for example utilising 
RNA-seq to identify transcriptomic signatures that include markers of ELS activity, may 
offer an opportunity to develop more robust markers with prognostic value. In this regard, 
in a recent study of gastric cancer patients, a B cell metagene signature was only linked 
with improved survival when combined with a marker of Th1 cell activity (e.g., TBX21 
encoding Tbet) [305]. In the same study, the histological presence of tumour-associated 
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CD20+ aggregates correlated with improved relapse-free survival [305]. This highlights 
the potential of using ELS as histological markers of disease progression and prognosis.  
Cytokines that activate STAT3 have been linked with ELS development in multiple 
diseases that feature chronic inflammation. For example, IL-6 signalling through the 
IL-6R/gp130 complex results in STAT3 activation and the development of ELS in the 
lung [302]. While IL-27 can activate both STAT3 and STAT1, in adaptive immunity IL-27 
is predominantly associated with the activation of STAT1 to exert anti-inflammatory 
outcomes [91]. For example, IL-27 through STAT1 signalling can counteract IL-6/STAT3 
driven responses [91] and can suppress the development of Th17 cells [279] and ELS 
[146]. In gp130F/F mice, gastric tumourigenesis and submucosal ELS development in 
gp130F/F mice is triggered by IL-11 signalling through the IL-11Ra/gp130 complex to 
activate STAT3 [219-221]. Importantly, ‘normalisation’ of STAT3 activation in 
gp130F/F:Stat3+/- mice prevented both gastric tumourigenesis and ELS development. 
Whilst phosphorylated STAT3 was detected in lymphoid aggregates, STAT3 activity was 
also found in areas of diffuse lymphocyte infiltration. Therefore, despite finding a 
correlation between the expression of ELS-associated genes and the prototypical STAT3 
target gene, SOCS3, localised activation of STAT3 by immunohistochemistry remains a 
poor indicator of mature or active ELS.  
In Chapter 4, studies identified a Th17 signature that was linked with the presence of 
synovial ELS during inflammatory arthritis. Also, in other autoimmune and infection 
models, effector Th17 responses have been implicated in ectopic lymphoneogenesis. In 
EAE, podoplanin-expressing Th17 cells and the signature cytokine IL-17 contributed to 
lymphoid neogenesis [143]. However, the role of Th17 cells in the development of ELS 
in the lungs (iBALT) appears controversial and context dependent. In response to 
challenge with LPS [142] and Pseudomonas aeruginosa [144] the development of ELS 
is IL-17 dependent. However, following infection with a modified vaccinia virus Ankara 
the development of iBALT was unaffected in the absence of IL-17 [144]. While IL-17 was 
also expressed within inflamed salivary glands following adenovirus challenge, another 
Th17-associated cytokine, IL-22, was the key mediator required for lymphoid neogenesis 
[145]. Consistent with the increased expression of the Th17 markers Il17a, Il23 and Rorc 
observed during gastric tumourigenesis in gp130F/F mice [249], expression of IL17A in 
clinical disease also correlated with the ELS-associated genes, CXCL13 and CCL19. 
Despite this, the genetic ablation of IL-17A in gp130F/F mice had little impact on gastric 
tumourigenesis [249] or the development of submucosal lymphoid aggregates. While not 
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statistically significant, we noted slightly fewer and smaller lymphoid aggregates in 
gp130F/F:Il17a-/- mice as compared to those in gp130F/F mice. We therefore questioned 
whether IL-17A may be important for the development of mature ELS. Consistent with 
this hypothesis, whilst lymphoid aggregates in gp130F/F:Il17a-/- mice displayed many of 
the characteristics of ELS (e.g. Pdpn, Cxcl13, PNAd), they lacked follicular dendritic cell 
networks and the formation of germinal centres. Interestingly, despite a lack of active 
germinal centres in gp130F/F:Il17a-/- there was no difference in tumour burden between 
gp130F/F and gp130F/F:Il17a-/- mice [249]. Likewise, IL17A expression in human gastric 
cancer patients showed no prognostic significance. However, it could be possible that a 
more robust Th17 signature composed of markers identified in Chapter 4 may have more 
prognostic value. Taken together, the above studies highlight a role for IL-17 and Th17 
cell axis in ELS development, although this is likely to be disease and context dependent. 
While ELS have been proposed as local sites for establishing anti-tumour immunity, it is 
also possible that ELS may contribute to persistent tissue inflammation and the 
associated formation of tumours. Thus, a time course was used to try and establish 
whether ELS developed before, or as a consequence of, gastric tumourigenesis in 
gp130F/F mice. However, by combining immunohistochemistry with the transcriptional 
evaluation of homeostatic chemokine expression we were unable to uncouple ELS 
development and gastric tumourigenesis. Interestingly, using a model of Helicobacter-
induced gastritis we found that ELS could develop in the absence of gastric tumours 
[304]. Here, infection of WT mice with H. felis led to the development of submucosal 
ELS. This was also associated with increased expression of the homeostatic 
chemokines Cxcl13 and Ccl19, as well as the signature Th17 cytokine, Il17a [304], 
suggesting another role for this effector T cell response in ELS development during 
H. felis infection. Therefore, it is likely that the local inflammatory response within the 
tissue, rather than the process of tumourigenesis, provides the cues required for ELS 
development.  
Using TCGA datasets no association was found between gene signatures of ELS 
development and improved patient survival. Interestingly, in both gp130F/F mice and 
biopsies from gastric cancer patients, tumour-associated ELS were found extra-
tumourally in the gastric submucosa rather than intra-tumourally [304, 305]. Similarly, in 
colorectal cancer the presence of extra-tumoural ELS correlated with advanced disease 
but not with a positive prognosis [307]. In contrast, the presence of intra-tumoural 
lymphoid aggregates in breast cancer patients was linked to improved patient survival 
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[227]. This raises the question as to whether the ability of ELS to improve outcomes in 
cancer is linked with their location. It is possible that intra-tumoural ELS are linked with 
improved prognosis due to their exposure to tumour antigens within the tumour stroma, 
which supports the development of local antigen-specific responses to tumours and 
enhanced anti-tumour immunity. 
In summary, this chapter characterises tumour-associated lymphoid aggregates that 
develop in the gastric submucosa as bona fide ELS. These ELS featured T and B cell 
compartmentalisation, reactive germinal centres and their development was linked with 
the temporal expression of homeostatic chemokines. However, the presence of ELS did 
not provide prognostic benefit. Through genetic ablation of IL-17A in the gp130F/F mouse 
model of gastric cancer, this work identifies a novel role for IL-17A in promoting ELS 
activity. Thus, immunomodulation of the Th17/IL-17 axis in certain cancers may provide 
an opportunity to promote anti-tumour responses at tumour-associated ELS. 
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Chapter 6.  Therapeutic targeting of the Th17 
master regulator RORgt in inflammatory arthritis 
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6.1 Introduction 
The Rorc gene encodes two isoforms - RORg1 and RORg2 (RORgt). They differ in the 
first 21 amino acids through alternative promoter usage. RORg1 is ubiquitously 
expressed and its functions are incompletely understood [308]. RORgt however is 
probably best known as a transcription factor that is essential for driving the 
differentiation and effector function of Th17 cells [20, 309]. However, RORgt is also 
expressed by ILC3 populations including adult LTi cells, and IL-17-producing gd T cells 
[310]. Therefore, drug targeting of RORgt is seen as a potential therapeutic approach for 
the treatment of diseases associated with innate and adaptive Th17-type effector 
responses. In this regard, the treatment of mice with RORgt inhibitors has been shown 
to delay the onset and severity of EAE [311] and collagen-induced arthritis [312]. To 
date, drug targeting of RORgt has not been tested in murine AIA, nor has this approach 
been explored to prevent the formation of ELS. However, the safety of targeting RORgt 
must be carefully considered given its important homeostatic roles. RORgt is essential 
for the survival and proliferation of immature CD4+CD8+ thymocytes through regulation 
of anti-apoptotic factors such as Bcl-xL [313, 314]. Additionally, RORgt is required for the 
development of LTi cells which are essential for SLO development during ontogeny 
[314]. It follows that Rorc-/- mice lack lymph nodes, LTi cells, have impaired Th17 cell 
development and also display thymic aberrations leading to metastatic T cell lymphoma 
and premature death [140, 309, 315]. 
In Chapter 4, a prominent Th17 signature was associated with the development of 
synovial ELS. Similarly, I identified altered expression of a novel regulator of Th17 
effector responses, CD5L, which has been shown to regulate the formation of cholesterol 
metabolites that have recently been identified as natural ligands for RORgt [289, 290]. 
While IL-17A/IL-17RA directed antibodies have limited efficacy in clinical trials of RA, 
inhibitors that more broadly target the effector characteristics of this T helper cell subset 
may be more effective. In this context, future studies will test a small molecule inhibitor 
of RORgt on the development and maintenance of synovial ELS, where I hypothesise 
that its inhibition would impair ELS formation. In this chapter, I present my initial proof-
of-concept studies evaluating a small molecule inhibitor of RORgt in WT mice during AIA.  
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6.2 Materials and Methods 
6.2.1 RORgt inhibitor 
The small molecule RORgt inhibitor was provided by Novartis. Previous studies had 
determined the efficacy and affinity of the inhibitor in vitro and during in vivo delayed-
type hypersensitivity reactions in rats [316].  
6.2.2 Inhibition of in vitro T cell cultures 
Naïve CD4+ T cells were recovered and activated under Th1, Th2 or Th17 polarising 
conditions as previously described in section 2.4. To identify the effect of RORgt inhibition 
on in vitro T cell differentiation, cultures included 1 µM RORgt inhibitor or vehicle control, 
DMSO. Intracellular staining for IL-17A, IFNg and IL-4 was carried out as described in 
section 2.5.2.  
6.2.3 Administration of a small molecule RORgt inhibitor during AIA 
Murine AIA was induced as previously described in section 2.2.2. Mice were 
administered with either 5 mg/kg of RORgt inhibitor or vehicle control (100 mM sodium 
citrate buffer, pH2). Mice were treated twice a day by oral gavage starting just prior to 
the induction of arthritis at day 0 and continuing for 10 days. Draining lymph nodes, 
synovium, joint-infiltrating T cells and knee joints were recovered and processed as 
previously outlined in section 2.2.  
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6.3 Results 
6.3.1 Inhibition of RORgt selectively prevents differentiation of Th17 cells 
Previous studies with the small molecule inhibitor had confirmed its ability to target 
RORgt. Treatment with the inhibitor impaired Th17 differentiation in in vitro human CD4+ 
T cell cultures, and reduced ear swelling in a mBSA-induced delayed-type 
hypersensitivity model in rats [316]. Initial experiments therefore tested the ability of the 
RORgt inhibitor to prevent Th17 cell differentiation in in vitro murine T cell cultures. Here, 
RORgt inhibition suppressed the differentiation of Th17 cells, but not that of 
IFNg-secreting Th1 cells and IL-4-producing Th2 cells (Figure 6.1A and B).  
6.3.2 RORgt inhibition decreases Th17 responses during AIA 
To evaluate whether RORgt inhibition reduced Th17 responses in vivo, WT mice were 
treated with 5 mg/kg of RORgt inhibitor for 10 days starting just prior to arthritis induction 
by intra-articular injection of mBSA on day 0. Treatment significantly reduced levels of 
IL-17A and IL-21 in CD4+ T cells isolated from draining lymph nodes (Figure 6.2A). To 
verify these findings, cells isolated from the draining lymph nodes were re-stimulated ex 
vivo with mBSA. When compared to mice treated with the vehicle control, levels of 
mBSA-specific IL-17A in the culture medium was significantly reduced in mice treated 
with the RORgt inhibitor. A similar trend was also observed for mBSA-specific IFNg 
responses, although not statistically significantly (Figure 6.2B).  
The effect of RORgt inhibition on synovial Th17 responses was then determined. 
Expression of Ccr6, a chemokine receptor expressed on Th17 cells, and the Th17-
associated effector cytokine, Il22, were significantly reduced in the synovium of mice 
treated with the RORgt inhibitor compared to vehicle. For the expression of the signature 
Th17 effector cytokines, Il17a and Il17f, a decreasing trend was observed albeit not 
statistically significant at the group sizes investigated (Figure 6.3A). Infiltrating synovial 
CD4+ T cells were also extracted from the inflamed synovium. Interestingly, the number 
of CD4+ T cells from vehicle and RORgt treatment groups were comparable (Figure 
6.3B). However, the proportion of CD4+ T cells secreting IL-17A was reduced following 
blockade of RORgt (Figure 6.3C and D). Thus, the inhibitor may affect T cell 
differentiation rather than proliferation. Taken together, this data highlights that RORgt 
inhibition during AIA inhibits the Th17 effector response.  
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Figure 6.1 - RORgt inhibition specifically blocks Th17 cell differentiation. (A-B) 
Naïve CD4+ T cells cultured in vitro under polarizing conditions for Th17, Th1 and Th2 
cells in the presence or absence of 1 µM RORgt inhibitor. (A) Representative flow 
cytometry plots and (B) percentage of cytokine-producing effector CD4+ T cells. (A-B) 
n = 3/group. Representative of two independent experiments. RORgti; RORgt inhibitor.
 145 
 
 
Figure 6.2 - Systemic effect of a RORgt inhibitor in AIA. (A-B) AIA was established in 
WT mice. Mice were treated with either vehicle (100 mM citrate buffer, pH2) or a RORgt 
inhibitor (5 mg/Kg) by oral gavage for 10 days, starting just prior to arthritis induction. (A) 
Flow cytometry of CD4+ T cells in inguinal lymph nodes at day 10 of AIA. (B) Ex vivo 
re-stimulation of inguinal lymph nodes with 20 µg/ml mBSA for 72 hours. Levels of IL-17A 
and IFN𝛾 were detected in culture supernatants by ELISA. (A-B) n = 6/group. RORgti; 
RORgt inhibitor.  
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Figure 6.3 - The effect of a RORgt inhibitor on synovial T cell responses. (A-D) AIA 
was established in WT mice. Mice were treated with either vehicle (100 mM citrate buffer, 
pH2) or a RORgt inhibitor (5 mg/Kg) by oral gavage for 10 days, starting just prior to 
arthritis induction. (A) Relative expression of indicated genes in the synovium of vehicle 
and RORgt inhibitor treated mice at day 10 of AIA. (B-D) Synovium was digested in 
1 mg/mL collagenase IV for 1 hour before staining for flow cytometry. (B) Number of 
CD4+ T cells extracted from the synovium as determined by flow cytometry. The 
percentage (C) and representative flow cytometry plots (D) of CD4+RORgt+ cells, 
CD4+IL-17A+ and CD4+RORgt+IL-17A+ cells extracted from the synovium at day 10 of 
AIA. (A) n = 6/group. (B-D) n = 3/group. (A) The expression of all genes has been made 
relative to an internal housekeeping control, Actb, and the expression of the vehicle set 
as 1. RORgti; RORgt inhibitor.  
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6.3.3 RORgt inhibition decreases arthritis severity 
Th17 cells play a role in the pathogenesis of inflammatory arthritis. For example, IL-17A 
promotes expression of inflammatory cytokines (e.g. TNFa, IL-6), matrix 
metalloproteinases that contribute to cartilage degradation, and RANKL that is essential 
for the differentiation of osteoclasts and subsequent bone resorption [54, 317]. Thus, the 
effect of a reduced Th17 effector response, through RORgt inhibition, on the severity of 
arthritis was evaluated. Knee joints were scored for inflammatory infiltrate, exudate, 
pannus formation and cartilage and bone erosion (Figure 6.4A and B). In these pilot 
studies, treatment with the RORgt inhibitor resulted in a reduction in inflammatory 
infiltrate, exudate and cartilage and bone erosion. Concomitantly, there was also a 
reduction in the overall arthritic index (Figure 6.4B). However, at the group size 
investigated these decreases were not significant but provide rationale for a more 
comprehensive analysis of RORgt inhibition in AIA and particularly in the regulation of 
ELS in Il27ra-/- mice. 
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Figure 6.4 - The effect of RORgt inhibition during AIA. (A-B) AIA was established in 
WT mice. Mice were treated with either vehicle (100 mM citrate buffer, pH2) or a RORgt 
inhibitor (5 mg/Kg) by oral gavage for 10 days, starting just prior to arthritis induction. (A) 
Representative images of haematoxylin, fast green and safranin O staining of knee 
joints. Boxes highlight areas of synovial infiltrate (top) and cartilage and bone erosion 
(bottom), seen as the loss of safranin O staining, in vehicle and RORgt inhibitor treated 
mice. (B) Histopathology scoring of AIA in vehicle and RORgt inhibitor treated mice. 
Scale bars: (A; top) 500 µm, (A; bottom) 200 µm. (A) n = 6/group. (B-C) n = 3/group. 
RORgti; RORgt inhibitor.   
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6.4 Discussion 
In this chapter, I present proof-of-concept studies using a RORgt inhibitor in WT mice 
during AIA. Consistent with the specific blockade of Th17 cell differentiation observed in 
vitro, treatment led to reduced expression of Th17 effector cytokines in both the draining 
lymph nodes and locally within the inflamed joint. This effect on Th17-associated 
cytokine production was associated with a reduction in arthritic index in mice treated with 
the RORgt inhibitor. These effects were seen in the small group sizes used and despite 
only starting administration just prior to arthritis induction, and thus at a point where the 
peripheral immune response to mBSA was established. Future experiments will 
determine the effect of RORgt inhibition on synovial ELS development in Il27ra-/- mice. 
For a comprehensive evaluation of the role of Th17 cells in the development of ELS, 
inhibitor dosing will be tested (i) during the priming phase of AIA in order to prevent the 
early formation of the Th17 cell response, and (ii) just prior to induction of local joint 
inflammation as performed herein. These studies will build on experiments performed in 
Chapter 5 where a role for Th17/IL-17A was revealed in promoting tumour-associated 
ELS activity in a model of gastric cancer. 
Since RORgt also controls thymocyte development and is required for LTi development 
and consequently SLO development, there is potential that blockade of RORgt could 
affect these important homeostatic functions. While short term inhibition of RORgt has 
been effective in the blockade of Th17-associated intestinal inflammation [318], in long 
term use the development of T cell lymphoma has emerged as a significant risk [316]. 
Here, 13-week treatment in rats was associated with thymic alterations that mirrored the 
phenotype observed in Rorc deficient mice [316]. Thus, the development of RORgt 
inhibitors therapeutically carries significant risk. However, the inhibitor used herein 
provides a useful mechanistic tool to explore the potential therapeutic effect of targeting 
the Th17 axis more broadly than typically explored through blockade of IL-17A and 
IL-17RA (e.g. secukinumab and brodalumab respectively). 
Interestingly however, Rorc-/- mice still develop ELS, despite the lack of LTi cells and 
impairment of Th17 cell differentiation. Exposure to dextran sulphate sodium induced the 
formation of ELS in the colon of Rorc-/- mice [141]. Despite having defects in lymphatic 
vessel expansion, Rorc-/- mice developed normal ELS in a model of salivary gland 
inflammation with Sjögren’s syndrome-like features [319]. Additionally, in response to 
influenza A virus infection, Rorc-/- mice developed iBALT, characterised by segregated 
T and B cell zones and CD21+ follicular dendritic cell networks [142]. However, the 
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development of iBALT was also found to be dependent on IL-17A production from gd- 
and ab T cells [142]. This may relate to the identification of another retinoic acid receptor 
related orphan receptor, RORa, that can drive the differentiation of Th17 cells [320]. 
Induction of EAE in Rora deficient mice resulted in decreased IL-17A production and 
severity of disease. Importantly, whilst Rorc-/- mice displayed a larger impairment in Th17 
differentiation, it was only in mice with a double deficiency in RORgt and RORa that a 
complete abrogation of Th17 development was observed [320]. 
Recently, the homeostatic and pro-inflammatory roles of RORgt have been delineated. 
Two crucial amino acids were essential for determining the function of RORgt [321]. Mice 
that lacked RORgt but expressed a mutant form, lacking the two crucial amino acids, had 
normal thymic development but did not generate Th17 responses. In this regard, the 
mutant form of RORgt did not lead to the expression of genes for Th17 development (e.g. 
Il17a, Il17f, Il23ra) but did express genes required for thymic development (e.g. Bcl2, 
Bcl2l1). This altered mechanism of action was attributed to inhibition of ubiquitination of 
the mutant RORgt. Interestingly, mice expressing the mutant form of RORgt developed 
lymph nodes, associated with the development of LTi cells. However, they did not 
develop Peyer’s patches [321]. This may highlight the different mechanisms required for 
SLO development and ELS development. Taken together, this may underline the 
potential to develop a therapy that exploits the inflammatory side of RORgt but not the 
homeostatic roles. 
In summary, this chapter presents proof-of-concept studies of targeting RORgt in 
inflammatory arthritis. RORgt inhibition resulted in reduced levels of Th17 effector 
cytokines in the periphery and within the joint, and these early studies suggest a potential 
therapeutic effect when evaluating arthritis severity during AIA. Thus, future studies will 
more fully determine the effect of blocking RORgt during inflammatory arthritis, and 
extend to investigating the regulation of synovial ELS in Il27ra-/- mice that are associated 
with exacerbated Th17 responses.  
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Chapter 7.  General Discussion 
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7.1 Discussion 
ELS are a common feature of inflamed tissues affected by autoimmunity, infection, tissue 
rejection and cancer. The mechanisms controlling ELS development and activity are 
likely to be highly disease and context dependent; our understanding of how ELS are 
controlled in different inflammatory settings remain poorly defined. Research presented 
in this thesis investigated the major inflammatory pathways linked with synovial ELS 
development during experimental inflammatory arthritis. The significance of these 
pathways in ELS regulation were further investigated in inflammation-associated gastric 
cancer, where tumourigenesis and ectopic lymphoid neogenesis were temporally 
coupled. In summary, the data presented in this thesis propose common mechanisms 
that govern ELS development across inflammatory arthritis and gastric cancer.  
- Through the use of transcriptomics, a prominent Th17 gene signature was 
associated with the development of synovial ELS in a mouse model of 
inflammatory arthritis. 
- The characterisation of ELS in a model of STAT3-driven gastric cancer provides 
a novel system for the mechanistic evaluation of tumour-associated ELS. 
- The genetic ablation of IL-17A in gp130F/F mice revealed an important role for 
IL-17A in supporting the development of active ELS. 
Thus, this work provides new insights into the role of the Th17/IL-17A axis in ELS 
development and maintenance in models of inflammatory arthritis and gastric cancer.  
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7.2 Cross-disease mechanisms governing ELS  
The work presented in this thesis has used mouse models of inflammatory arthritis and 
gastric cancer where ELS feature. Interestingly, tumour-associated ELS in gp130F/F mice 
were larger in size and displayed increased levels of organisation, such as T and B cell 
segregation, than those present in the synovium of Il27ra-/- mice. This may relate to 
development of ELS in gp130F/F mice at mucosal surfaces, whereas the synovium is 
devoid of epithelial surfaces. Consistent with this, ELS that form in the joints of patients 
with RA range from disorganised aggregates to highly-segregated lymphoid follicles 
[193]. Nonetheless, the work presented here has allowed the identification of cross-
disease mechanisms that regulate ELS.  
7.2.1 The Th17/IL-17A axis and ELS 
In Chapter 4, transcriptomic profiling of the inflamed synovium identified a strong Th17 
signature that was linked with the development of synovial ELS during inflammatory 
arthritis. Interestingly, effector Th17 responses have been linked with ELS development 
in other chronic inflammatory models. For example, in EAE, podoplanin-expressing Th17 
cells contributed to ELS development. This was dependent on the Th17 signature 
cytokine, IL-17, but not IL-21 [143]. Additionally, IL-17 has been implicated in the 
development of iBALT. In response to challenge with LPS, iBALT development was 
dependent on IL-17, with Il17ra-/- mice displaying reduced expression of CXCL13 and 
CCL19 [142]. Interestingly, despite the requirement for IL-17, ELS still developed in 
Rorc-/- mice [142]. Whilst gd T cells were detected in iBALT, the majority of IL-17 secreting 
cells were T helper cells [142]. In this regard, my analysis of joint-infiltrating cells during 
AIA similarly revealed that CD4+ T cells were the main IL-17-producing population. In 
other models of iBALT development the role of IL-17 is less clear. Following infection 
with a modified vaccinia virus Ankara the development of iBALT was unaffected in the 
absence of IL-17 [144]. However, in response to challenge with Pseudomonas 
aeruginosa the development of iBALT was impaired in the absence of IL-17. Here, IL-17 
was required to induce CXCL12 expression in pulmonary stromal cells [144]. In our 
studies, Il17a expression was also increased in a model of Helicobacter infection-
induced gastritis that was associated with the development of ELS. Here, the presence 
of ELS and Il17a expression was associated with heightened expression of the 
homeostatic chemokines Cxcl13 and Ccl19 [304]. In gp130F/F mice, gastric 
tumourigenesis was similarly associated with an increase in the Th17 markers, Il17a, 
Il23 and Rorc [249], and expression of IL17A in clinical disease correlated with the 
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homeostatic chemokines, CXCL13 and CCL19. Despite this, the genetic ablation of 
IL-17A in gp130F/F mice had little impact on gastric tumourigenesis, with no difference in 
tumour burden between gp130F/F and gp130F/F:Il17a-/- mice [249], or the development of 
submucosal lymphoid aggregates. These aggregates contained typical features of ELS 
including CXCL13-expressing cells, PNAd+ HEVs and podoplanin-expressing stromal 
cells. While not statistically significant, we noted slightly fewer and smaller lymphoid 
aggregates in gp130F/F:Il17a-/- mice as compared to those in gp130F/F mice. We therefore 
questioned whether IL-17A may be important for ELS maturation. Consistent with this 
hypothesis, lymphoid aggregates in gp130F/F:Il17a-/- mice lacked CD21+ follicular 
dendritic cell networks and germinal centres. Thus, this suggests that IL-17A is not 
required for the early formation of lymphoid aggregates, but promotes the maturation of 
functional ELS displaying germinal centre reactivity.  
While IL-17A is the signature cytokine for Th17 cells, these cells can also produce IL-21 
and IL-22, which have been linked with ELS development in a model of virus-induced 
sialadenitis with Sjögren’s syndrome-like characteristics [145, 147]. Here, IL-22 induced 
the expression of Cxcl13 and Cxcl12 from stromal and epithelial cells respectively. In the 
absence of IL-22, lymphoid aggregates were significantly smaller and had decreased 
expression of Cxcl13 and Cxcl12 [145]. Similar to the development of iBALT and synovial 
ELS, both gd T cells and T helper cells contributed to IL-22 production. Initially, the 
majority of IL-22 expression in the salivary gland was from gd T cells, however this was 
later replaced by T helper cells [145]. Thus, effector cytokines often linked with Th17-
type responses have been implicated in regulating ELS development and maintenance 
in models of autoimmunity, cancer and infection (Figure 7.1). 
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7.2.2 STAT3 regulation of ELS 
Cytokines that activate STAT3 have been linked with ELS development in multiple 
diseases that feature chronic inflammation [145, 147, 302, 303]. For example, IL-6 
signalling through the IL-6R/gp130 complex results in STAT3 activation and the 
development of ELS in the lung [302]. While IL-27 can activate both STAT3 and STAT1, 
it uniquely activates a group of STAT1 target genes to exert anti-inflammatory outcomes 
in adaptive immunity [93]. For example, IL-27 through STAT1 signalling can counteract 
IL-6/STAT3 driven responses [91] and can suppress the development of Th17 cells [279] 
and ELS [146, 152]. In inflammatory arthritis, STAT3 activation controls the recruitment 
and maintenance of activated leukocytes within the inflamed synovium and leads to 
increased disease severity. Here, the induction of AIA in gp130F/F mice, that display 
hyperactive STAT3 signalling, resulted in increased synovitis that was associated with 
an elevation in the number of IL-17A-secreting cells within the joint [69]. Similarly, 
hyperactive STAT3 signalling in gp130Y759F/Y759F mice results in the spontaneous 
development of arthritis [71, 322]. Using GSEA and publicly available datasets that 
defined STAT3-regulated genes, a robust STAT3 signature was associated with ELS-
rich joint inflammation in Il27ra-/- mice. This is consistent with a previous study that linked 
the presence of synovial ELS with enhanced STAT3 activity [291]. In gp130F/F mice, 
gastric tumourigenesis and submucosal ELS development is triggered by IL-11 signalling 
through the IL-11Ra/gp130 complex to activate STAT3 [219-221]. Here, expression of 
the prototypical STAT3 target gene, SOCS3, also correlated with the expression of ELS-
associated genes. Importantly, ‘normalisation’ of STAT3 activation in gp130F/F:Stat3+/- 
mice prevented both gastric tumourigenesis and ELS development. Indeed, 
phosphorylated STAT3 was detected in lymphoid aggregates in gp130F/F mice, however 
STAT3 activity was also found in areas of diffuse lymphocyte infiltration. Similarly, in 
previous studies from my laboratory, significant phosphorylated-STAT3 staining was 
found within the joint, but not exclusively restricted to synovial ELS [146]. More recently, 
a study in mice showed that a haploinsufficiency of the Ptpn2 gene was associated with 
the pathogenic conversion of Treg cells into Th17 cells during inflammatory arthritis, 
where exacerbated synovitis was also linked with heightened STAT3 activity and the 
development of ELS [323]. Therefore, while STAT3 activity is strongly linked with 
shaping a microenvironment within inflamed tissues that is conducive to ELS 
development, localised STAT3 activity is not specifically restricted to ELS, likely due to 
its broad roles in orchestrating inflammation. 
  
 156 
7.2.3 An inhibitory role for IL-27 in ELS regulation 
While studies presented within this thesis propose common mechanisms that influence 
ELS development, it is likely that there are disease-specific mechanisms that govern the 
control of ELS that are not shared. In this regard, my research in inflammatory arthritis 
and inflammation-associated gastric cancer potentially outline a context dependent role 
for IL-27 in ELS regulation. For example, ELS development in the inflamed synovium 
was associated with a loss of IL-27/IL-27R signalling [146]. However, the development 
of tumour-associated ELS in gastric cancer was not linked to a loss of Il27 expression. 
Here, Il27 expression in the gastric antrum was comparable between 6-month-old WT 
and gp130F/F mice. However, early expression of IL-27 may control ELS development in 
gp130F/F mice. As such, further investigations are required to understand the precise role 
of IL-27 in tumour-associated ELS formation. This would establish whether IL-27 
administration can inhibit tumour-associated ELS formation, or if IL-27 blockade has 
potential to support the development and activity of ELS. However, divergent roles have 
been described for IL-27 in cancer. For example, IL-27 has been linked with promoting 
anti-tumour immunity through supporting CD8+ and natural killer cell activity [324-327]. 
Paradoxically, IL-27 promotes an immunoregulatory phenotype in T cells through 
inducing the expression of co-inhibitory receptors (e.g. PD-1, PD-L1, TIM-3, LAG-3, 
TIGIT) that suppress anti-tumour immunity [115, 328]. Thus, a better appreciation of the 
role of IL-27 in cancer has potential to inform of its therapeutic credentials.  
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Figure 7.1 - The role of Th17 cells in ELS development, maintenance and activity. 
Th17 cells and effector cytokines have been implicated in ELS development, 
maintenance or activity in models of autoimmunity and chronic inflammation (green), 
infection (orange) and cancer (blue). The cytokines implicated in each inflammatory 
model are shown. AIA, antigen-induced arthritis; EAE, experimental autoimmune 
encephalomyelitis; iBALT, inducible bronchus associated lymphoid tissue.  
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7.3 Tumour-associated ELS and anti-tumour immunity 
In Chapter 5, I characterised the development of tumour-associated ELS in gp130F/F 
mice that spontaneously develop gastric tumours. ELS were defined as having T and B 
cell segregation, PNAd+ HEVs, CD21+ follicular dendritic cell networks, germinal centre 
reactions and increased expression of homeostatic chemokines. In our study of ELS in 
gastric cancer, an ELS gene signature composed of CXCL13, CCL21 and CCL19 did 
not predict a favourable prognosis.  However, an important question remains: Do ELS in 
gastric cancer support anti-tumour immune responses? In this context, in NSCLC, 
tumour-associated ELS were surrounded by CD138-positive plasma cells that secreted 
antibodies against tumour antigens (e.g. NY-ESO-1, TP53, LAGE-1). Furthermore, a 
high density of follicular B cells correlated with improved patient survival [233]. 
Additionally, patients with NSCLC that developed ELS had a higher number of cytotoxic 
IFNg-generating CD8+ T cells. Interestingly, patients with a combination of high levels of 
CD8+ T cells with the presence of ELS displayed significantly improved survival 
compared to patients with high levels of CD8+ T cells in the absence of ELS [241]. 
Together, these studies suggest that tumour-associated ELS can play an active role in 
supporting anti-tumour immunity. Consistent with this, targeted delivery of the cytokine 
LIGHT (TNFSF14), a LTbR ligand, to tumours using a vascular targeting peptide (VTP) 
promoted the formation of ELS, increased tumour infiltration by T cells and improved 
survival. However, administration of blocking antibodies to CD8 abolished the survival 
benefit of LIGHT-VTP treatment [238]. Thus, these studies suggest that ELS can serve 
as local sites for the generation of antibodies against tumour antigens and can re-model 
T cell responses to enhance anti-tumour immunity.  
Interestingly, gp130F/F mice that lacked expression of IL-17A developed lymphoid 
aggregates, but did not form germinal centres. Despite this defect in ELS activity, 
gp130F/F:Il17a-/- mice display a similar tumour burden to gp130F/F mice [249] and 
expression of IL17A had no prognostic significance when evaluating intestinal-type 
gastric cancer datasets in TCGA. In this regard and as previously discussed, a more 
comprehensive Th17 signature may have more prognostic value (see Chapter 5 
discussion). However, due to the reciprocal relationship between Th17 and Treg 
development it would be interesting to determine whether tumour-associated ELS in the 
gastric submucosa are enriched in Tregs that may suppress anti-tumour immunity. In 
this regard, a better understanding of the cellular composition and effector characteristics 
associated with tumour-associated ELS may provide opportunities to modulate ELS 
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activity through targeting defined T cell effector characteristics. In other studies of clinical 
gastric cancer, the presence of CD20+ aggregates, a high infiltration of T-bet+ Th1 cells 
and a low infiltration of FoxP3+ Treg cells correlated with improved survival [305]. In 
patients with primary breast tumours, high numbers of FoxP3+ Treg cells within ELS were 
associated with an increased risk of death [242]. Additionally, in a mouse model of lung 
adenocarcinoma, Tregs localised to tumour-associated ELS to suppress anti-tumour 
responses. In the same study, Treg depletion resulted in T cell proliferation within ELS 
and the generation of anti-tumour responses leading to tumour regression [243]. 
Furthermore, Treg depletion in a methylcholanthrene (MCA) carcinogen-induced 
fibrosarcoma mouse model resulted in HEV neogenesis and increased tumour-infiltrating 
T cells, resulting in a reduction in tumour growth rate [298]. The role of Tregs in regulating 
ELS is not restricted to cancer. For example, in a model of LPS-induced iBALT, Treg 
depletion resulted in increased incidence and number of iBALT [149]. Furthermore, mice 
deficient in CCR7 had reduced Treg cell numbers and spontaneously developed iBALT, 
characterised by segregated T and B cell zones and HEVs [329]. Additionally, GSEA in 
Chapter 4 identified an enriched Th17 signature compared to Treg signature in synovial 
inflammation featuring ELS. Thus, analysis of Treg cells and T cell effector 
characteristics in gp130F/F mice may elucidate the role that ELS play in anti-tumour 
immunity in these mice.  
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7.4 Potential for therapeutically targeting ELS 
The results presented in this thesis provide rationale for targeting the Th17/IL-17A axis 
in ELS-associated diseases. For example, inhibiting this pathway may be beneficial in 
chronic autoimmune diseases (Figure 7.2), whereas propagating Th17 cell responses 
may drive ELS function and germinal centre formation in cancer that could re-model T 
cell responses and promote anti-tumour immunity.   
In this regard, IL-17 blockade using anti-IL-17A and anti-IL-17RA monoclonal antibodies 
(e.g., secukinumab and brodalumab respectively) has already been trialled in RA. For 
example, a phase II clinical trial of 237 patients displaying inadequate responses to 
methotrexate, showed that a monthly subcutaneous injection of secukinumab failed to 
improve clinical outcome and the study did not reach its primary endpoint - the proportion 
of patients achieving ACR20 versus placebo at 16 weeks [330]. Long term, 52-week 
studies showed that IL-17 blockade was well tolerated and gave improved ACR and 
DAS28 responses and decreased CRP levels. However, non-responders at 16 weeks 
still did not respond with longer treatment [331]. Similar results were obtained in clinical 
trials with brodalumab. Here, a total of 252 patients with active RA and inadequate 
responses to methotrexate failed to reach significant differences in ACR20 responses 
compared to placebo [332]. Thus, anti-IL-17A/IL-17RA therapy has already been trialled 
in RA with limited success. However, these trials were not conducted in patients stratified 
according to histological presentation of disease. In this context, results presented in 
Chapter 4 highlighted an enriched Th17 signature in synovial inflammation featuring 
ELS. Similarly, RA patients stratified for the presence of ELS had increased levels of 
IL-17A compared to those without ELS [146]. Therefore, targeting of IL-17A may be more 
effective in ELS-positive patients.  
However, other Th17 effector cytokines are also associated with ELS formation. In RA 
cohorts stratified for the presence of ELS, featuring T and B cell segregation and CD21L 
expression, the Th17 effector cytokines IL17F, IL21 and IL22 were increased in ELS-
positive patients and correlated with CD21L expression [333]. However, no relationship 
was observed between the expression of IL17A and the presence of ELS [333]. Similarly, 
synovial IL-23 expression and levels of the Th17-associated chemoattractant, CCL20, 
were linked with the clinical presence of ELS in psoriatic arthritis [334]. This provides 
rationale for testing the neutralisation of other cytokines linked with the Th17 effector 
response in ELS-rich synovitis. In this regard, clinical trials in RA patients with 
guselkumab, a monoclonal antibody against the p19 subunit of IL-23, failed to reach 
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significant differences in ACR20 responses compared to placebo [335]. Importantly, 
these trials were also not conducted in patients stratified according to histological 
presentation of disease. As discussed above, targeting of the Th17 axis may be more 
beneficial in ELS-positive patients. It may also be interesting to investigate the broader 
inhibition of the Th17 programme in ELS-rich synovitis. For example, targeting of Th17 
cells with small molecule RORgt inhibitors may prove beneficial, although a long-term 
safety evaluation of this approach is required given the link to potential adverse side 
effects, including T cell lymphoma [316].  
Other inhibitors that may prove effective in targeting Th17 responses are JAK inhibitors. 
For example, tofacitinib, that predominantly targets JAK1 and JAK3 to disrupt JAK-STAT 
signalling in response to interferons, g-chain family cytokines (e.g. IL-2, IL-7, IL-15, IL-21) 
and gp130 family cytokines (e.g. IL-6, IL-11). Other JAK inhibitors licensed for the 
treatment of RA include ruxolitinib and baracitinib that target JAK1 and JAK2 [178, 336]. 
The development of Th17 cells is dependent on IL-6 signalling through STAT3, and 
STAT3 deficiency in T cells prevents the induction of Th17 cells [20, 337]. Additionally, 
hyperactivation of STAT3 in gp130F/F mice results in exacerbated synovitis that was 
associated with an increase in the number of IL-17A-secreting cells within the joint [69]. 
The activation of STAT3 is also emerging as a common feature of ELS development. 
The cytokines, IL-6, IL-21 and IL-22, that activate STAT3 have all been linked with ELS 
development and maintenance in inflammatory models [145, 147, 302, 303] and in RA 
synovial tissue, the presence of ELS was linked to enhanced STAT3 activation [291]. 
Furthermore, the data presented in this thesis identified a STAT3 signature in ELS-rich 
synovitis and IL-11 activation of STAT3 in gp130F/F mice resulted in gastric 
tumourigenesis and tumour-associated ELS development. Importantly, ‘normalisation’ of 
STAT3 in gp130F/F:Stat3+/- mice prevented both gastric tumourigenesis and ELS 
development. Thus, the use of JAK inhibitors to disrupt JAK-STAT signalling could be 
an attractive approach to targeting ELS. However, JAK inhibitors may also have the 
potential to block IL-27 signalling, thus promoting the development of ELS. 
An important point to consider is that clinically patients will likely have developed ELS 
before treatment begins. Therefore, is there any benefit in targeting mechanisms of ELS 
development? For example, in a model of LPS-induced iBALT, Il17a-/- mice failed to 
develop iBALT. It follows that mice failed to develop iBALT in this model when treated 
with an antibody to IL-17A at the same time as the final challenge with LPS. However, 
when administered 1 week later, once iBALT had developed, anti-IL-17A had little effect 
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on iBALT [142]. In this regard, IL-17A was involved in the initiation but not the 
maintenance of iBALT and highlights that anti-IL-17A therapy once iBALT had developed 
was ineffective. However, the role of IL-17A in ELS development is likely to be disease 
and context dependent. For example, in Chapter 5, IL-17A was shown to be important 
for the maintenance of germinal centres in tumour-associated ELS rather than their 
development. Thus, targeting IL-17A may still affect the function of ELS. 
Whilst IL-17A is required for the development of mature tumour-associated ELS, as 
evidenced by a lack of germinal centres in the lymphoid aggregates that form in 
gp130F/F:Il17a-/- mice, other Th17 effector cytokines such as IL-21 and IL-22 have also 
been linked with ELS development [145, 147]. In this regard, it would be interesting to 
evaluate the role of other cytokines within the Th17 programme in ELS development 
during gastric tumourigenesis. Here, the assessment of ELS in gp130F/F:Il6-/- mice may 
be beneficial, where the loss of IL-6 signalling is associated with reduced expression of 
Il17a, Il23, and Rorc in gastric tumours [249]. Interestingly gp130F/F:Il6-/- mice still develop 
gastric tumours comparable to those in gp130F/F mice and immune cell infiltrates within 
the gastric submucosa [220]. However, it remains to be determined whether bona fide 
ELS featuring germinal centres can form in the absence of IL-6.  
Since it is proposed that tumour-associated ELS are able to act as local sites for 
establishing anti-tumour immunity, propagating their activity may provide therapeutic 
benefit. In this context, propagating Th17 cell responses may drive ELS function and 
germinal centre formation promoting local anti-tumour immunity. However, the role of 
Th17 cells in tumourigenesis is complex [338]. For example, IL-17A can induce 
angiogenesis in tumour tissue and the production of IL-17 by Th17 cells in a mouse 
model of lung cancer promoted tumour growth [339]. In contrast, the adoptive transfer of 
Th17 cells reduced tumour growth in a mouse melanoma model, which was associated 
with the activation of CD8+ T cells required for anti-tumour immunity [340]. Thus, Th17 
effector responses have both pro- and anti-tumour effects. Therefore, given the inhibitory 
role of IL-27 on ELS development in arthritis [146], blockade of IL-27 may offer an 
interesting opportunity to promote ELS development in cancer. 
Additionally, enhancing the development of tumour-associated ELS may also offer 
therapeutic opportunities in cancer. For example, administration of LIGHT-VTP to 
tumours resulted in intra-tumoural ELS formation, enhanced T cell tumour infiltration and 
improved survival [238]. In addition, in a lung cancer transplantation model that was 
unresponsive to checkpoint inhibitor therapy with anti-CTLA4 and anti-PD-1, treatment 
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with LIGHT-VTP in combination with checkpoint inhibitor therapy resulted in prolonged 
survival [238]. Thus, ELS immunomodulation may represent attractive therapeutic 
targets in autoimmunity and cancer. 
 
 
 
 
 
 
 
Figure 7.2 - Mechanisms for targeting Th17 cell involvement in ELS development, 
maintenance or activity in autoimmunity. Th17 cells and their effector cytokines are 
implicated in ELS development, maintenance and activity. Potential inhibition of Th17 
cells could be through targeting RORgt, the master transcriptional regulator of Th17 cells, 
the use of JAK inhibitors, that disrupt the JAK-STAT signalling pathway or administration 
of interleukin-27. The targeting of IL-17A, may disrupt the development of ELS or 
germinal centre function. Blockade of IL-17 receptor (IL-17RA) will inhibit both IL-17A 
and IL-17F and therefore may have broader action.  
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7.5 Future perspectives 
7.5.1 Th17 cell plasticity and ELS 
Th17 effector cells are highly susceptible to functional plasticity. As previously discussed, 
Th17 cells can adopt Th1-like characteristics that have been shown to contribute to 
disease severity in EAE, as well as a Tfh-like phenotype that supports germinal centre 
B cells in Peyer’s patches (see Chapter 4 discussion). Indeed, polyfunctional ex-Th17 
cells (also called nonclassical Th1 cells) that no longer secrete IL-17 but produce other 
proinflammatory cytokines have now been isolated from the synovium of RA patients 
[295]. Furthermore, GSEA identified a pathogenic Th17 phenotype in ELS-rich synovitis. 
Given that IFNg-secreting Th1 cells produced Cxcl13, it would be interesting to identify 
whether pathogenic Th17 cells, that adopt Th1-like characteristics (e.g., Tbx21) also 
produce CXCL13 contributing to ELS development. Whilst these examples highlight the 
plasticity of Th17 cells in driving inflammation, Th17 cells have also been shown to adopt 
anti-inflammatory phenotypes [283]. Using IL-17A fate reporter mice, Th17 cells in the 
intestine were found to adopt a T regulatory type 1 (Tr1)-like phenotype and secrete 
IL-10. Furthermore, the adoptive transfer of Tr1-like exTh17 cells prevented the 
development of colitis in a Th17 cell mediated colitis model [283]. Thus, understanding 
the mechanisms of Th17 plasticity may allow their immunomodulation into 
anti-inflammatory phenotypes to provide therapeutic benefit.  
7.5.2 ELS composition and single-cell RNA-seq 
As discussed in section 7.3, a better understanding of the cellular composition and 
effector characteristics associated with ELS may provide opportunities to modulate their 
activity through targeting defined T cell effector characteristics. While a whole-tissue 
RNA-seq approach was taken here, advances in sequencing technologies such as 
single-cell RNA-seq could provide more information regarding ELS composition and 
regulation. In this regard, single-cell transcriptome profiling of synovial tissue has been 
used to identify cellular subpopulations present in RA [341]. Thus, single-cell RNA-seq 
could allow analysis of the cellular composition of ELS as well as the effector 
characteristics of those cells that reside within ELS. In this regard, use of single-cell 
RNA-seq to compare ELS across different diseases has the potential of identifying 
differences in the composition and effector characteristics linked with ELS in 
autoimmunity and cancer.  
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7.5.3 Identifying the antigen required to promote ELS 
The work presented here has focussed on the modulation of inflammation with regards 
to ELS development. However, other groups are investigating the antigen required to 
promote ELS. In this regard, studies of tumour-associated ELS have identified 
CD138-positive plasma cells that secreted antibodies against tumour antigens (e.g. 
NY-ESO-1, TP53, LAGE-1) [233]. Additionally, single cell cloning and the generation of 
recombinant antibodies from synovial B cells recovered from ELS+ RA patients has 
uncovered autoantibody specificity to citrullinated histones, mainly H2A and H2B as well 
as citrullinated vimentin, fibrinogen and calreticulin [342, 343]. Therefore, while targeting 
inflammatory pathways associated with ELS development is an attractive approach 
being investigated for the modulation of ELS, knowing more about how antigens shape 
the inflammatory response and the development of ELS is similarly important. Key 
questions that remain unanswered include: do ELS persist when antigen is present, but 
then resolve when the antigen is cleared? In this regard, mBSA antigen-induced arthritis 
and many other inflammatory models featuring ELS are resolving models, where the 
regression of ELS coincides with the resolution of inflammation. 
7.5.4 Immunometabolism and ELS 
Whilst there is currently a limited understanding in how immunometabolism regulates 
ELS, it is an emerging area of interest. As previously discussed, expression of SLC5A12, 
a co-transporter for lactate expressed on CD4+ T cells correlated with synovial tissue T 
cell score and the presence of ELS [288, 344] (see Chapter 4 discussion). In my 
RNA-seq dataset, Cd5l, which is a novel regulator of cholesterol and fatty acid 
metabolism that alters RORgt activity and Th17 pathogenicity [278], was differentially 
regulated in ELS-rich synovitis. Recently, studies have also linked 
N-myristoyltransferase (NMT) activity with altering Th17 responses in arthritis through 
regulating AMP kinase activity [345]. Here, T cells from RA patients had decreased levels 
of NMT compared to healthy controls. Interestingly, overexpression of NMT in RA T cells 
reduced expression of RORC and IL17A [345]. Thus, modulation of metabolic pathways 
has the potential to effect Th17 responses and ELS activity.  
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